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ABSTRACT 
  
iii 
 
Advances in culture independent technologies over the last decade have highlighted 
the pivotal role which the gut microbiota plays in maintaining human health. 
Conversely, perturbations to the composition or actions of the ‘normal/functioning’ 
microbiota have been frequently associated with the pathogenesis of several disease 
states. Therefore the selective modulation of enteric microbial communities 
represents a viable target for the development of novel treatments for such diseases. 
Notably, while bovine whey proteins and exercise have been shown to positively 
influence several physiological processes, such as energy balance, their effect on the 
composition or functionality of the gut microbiota remains largely unknown. In this 
thesis, a variety of ex vivo, murine and human models are used in conjunction with 
high-throughput DNA sequencing-based analysis to provide valuable and novel 
insights into the impact of both whey proteins and exercise on enteric microbial 
communities. Overall the results presented in this thesis highlight that the 
consumption both whey protein isolate (WPI), and individual component proteins of 
whey such as bovine serum albumin (BSA) and lactoferrin, reduce high fat diet 
associated body weight gain and are associated with beneficial alterations within the 
murine gut microbiota. Although the impact of exercise on enteric microbial 
communities remains less clear, it may be that longer term investigations are 
required for the true effect of exercise on the gut microbiota to be fully elucidated.   
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Chapter 1 
Bovine whey proteins: Agents to beneficially modulate the gut 
microbiota?  
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1.1 ABSTRACT 
The significant advances in culture independent technologies over the past decade 
have allowed for a meteoric rise in our understanding of the structure, composition 
and function of the 100 trillion microbial cells which inhabit the human gut. The gut 
microbiota is now understood to play a pivotal role in maintaining human health by 
influencing several physiological processes, such as modulation of the host immune 
system, regulation of fat storage as well as conferring protection against 
opportunistic pathogens. Conversely, perturbations to the composition of the normal 
gut microbiota have been frequently associated in the pathogenesis of several 
gastrointestinal (GI) diseases such as obesity and inflammatory bowel disease. 
Therefore it is a reasonable supposition that selective modulation of the gut 
microbiota has the potential to deliver novel treatments for such disease states. Diet 
is a major driving force in determining gut microbiota composition with the balance 
of macronutrients within the diet differentially effecting gut microbiota composition. 
To date, efforts using diet to beneficially modulate gut microbial communities have 
mainly focused on non-digestible carbohydrates (prebiotics), whose fermentation 
results in the production of short chain fatty acids (SCFAs), while dietary protein 
sources have traditionally been associated with the formation of putrefactive 
metabolites which may be detrimental to gut health. With respect to protein, whey is 
the milk serum which remains after the casein curd has been removed during the 
cheese making process and contains ~20% of the total protein content in milk. Whey 
is comprised of several component proteins, -lactoglobulin, -lactalbumin, serum 
albumin, lactoperoxidase, and lactoferrin, whose properties have been shown to 
beneficially influence several physiological processes such as energy balance and 
glucose metabolism. However, their effect on the composition of the gut microbiota 
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remains unclear. Here we review the role of the gut microbiota in GI diseases, the 
impact of diet on the gut microbiota and discuss properties of whey proteins which 
may represent novel agents by which enteric microbial populations may be 
modulated.   
4 
 
1.2 Introduction 
Humans may be thought of as ‘superorganisms’ owing to the genetic potential 
encoded not only within our own genomes but also that encoded within the genomes 
of our resident microbial populations. It is estimated that over 1000 bacterial species 
are contained within the human microbiota, each of which possesses a genome 
encoding an average of ~5,000 genes (Consortium 2012). The human microbiota and 
associated metagenome therefore carries with it a genetic repertoire which far 
outweighs that of the human host (~23,000 genes) and is capable of carrying out 
metabolic functions not encoded by the human genome. The vast majority of these 
microbial inhabitants (1.5 kg or 100 trillion cells) reside within the gut (Lander et al. 
2001, Eckburg et al. 2005, Consortium 2012). It has also been noted that while there 
are considerable inter-individual variations in the composition of the gut microbiota, 
there is a conserved set of metabolic functions shared between individuals known as 
the ‘core gut microbiome’ (Turnbaugh and Gordon 2009) suggesting that the overall 
functionality of the gut microbiota is of more importance to the host than its 
composition. The functions encoded within in the core gut microbiome are likely 
essential for optimum functionality of the gut. Studies have shown that the core gut 
microbiota confers several health benefits to the host which include protection 
against potential pathogens, regulation of fat storage and modulation of the host 
immune system (Sekirov et al. 2010).  
The composition of the gut microbiota goes through considerable changes 
throughout the life cycle of the host. Bacterial colonization of the GI tract occurs 
immediately following birth, where strict anaerobes such as Bacteroides spp., 
Clostridium and Bifidobacterium are amongst the initial colonizers upon depletion of 
the initial oxygen supply, although factors such as formula versus breastfeeding and 
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delivery method can have significant impacts on initial enteric bacterial populations 
(Palmer et al. 2007, Adlerberth and Wold 2009, Isolauri 2012). The formation of the 
‘healthy’ adult gut microbiota begins from ~2 years of age and it is thought to 
remain relatively stable until undergoing a final shift upon entering the elderly phase 
of life. The stable adult gut microbiota is primarily comprised of bacterial species 
which are members of the Firmicutes and Bacteroidetes phyla, with the remaining 
species being members of the Actinobacteria, Verrucomicrobia, Proteobacteria, 
Fusobacteria and/or Cyanobacteria phyla (Qin et al. 2010). Upon entering old age, 
the gut microbiota undergoes a final shift which is associated with an increased 
abundance of Bacteroides spp. and distinct shifts within the Clostridium genus 
(Claesson et al. 2011). These age associated phylogenetic shifts are thought to result 
from changes in host physiology such as chronic low-grade inflammation and 
changes in dietary habits (Franceschi 2007). 
Advances in culture independent, high throughput sequencing technologies and 
subsequent data analysis tools over the last decade have allowed for a dramatic rise 
in our understanding of the gut microbiota. Indeed, a PubMed search, using the term 
“gut microbiota”, for articles published between 2005 and 2015 returns 5240 related 
articles, whereas the same search yields just 144 related articles from the proceeding 
decade. On the basis of this new knowledge, the gut microbiota has been termed the 
body’s ‘forgotten’ organ (O'Hara and Shanahan 2006). In addition to contributing to 
health, perturbations of normal/healthy gut microbiota and functionality have also 
been shown to play a significant role in the pathogenesis of several GI diseases.  
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1.3 The role of the gut microbiota in gastrointestinal diseases 
There is an ever growing appreciation that perturbations in the composition of the 
normal gut microbiota contributes to the aetiology or severity of a substantial 
number of disease states ranging from Alzheimer’s diseases to obesity and type 2 
diabetes (T2D), reviewed comprehensively elsewhere (Clemente et al. 2012, de Vos 
and de Vos 2012, Carding et al. 2015). Indeed, such is the frequency that 
associations between disease states and the gut microbiota have been reported, this 
review will focus briefly on those between the gut microbiota and chronic GI 
diseases, including inflammatory bowel disease (IBD), irritable bowel syndrome 
(IBS), obesity, T2D and colorectal cancer (CRC), only. (Figure 1). 
1.3.1 Inflammatory bowel disease 
Ulcerative colitis (UC) and Crohn’s disease (CD) are forms of inflammatory bowel 
disease (IBD) and are characterised by chronic relapsing inflammation of the GI 
tract (Podolsky 1991).  While the aetiology of UC and CD are not fully understood, 
evidence suggests that both genetic and environmental factors play important roles 
in their development. Spehlmann et al. reported that while monozygotic twins were 
significantly more likely to be concordant for IBD than dizygotic twins, the genetic 
influence observed in the monozygotic twin cohort was relatively low (16% for UC 
and 35% for CD), highlighting the importance of environmental factors in disease 
pathogenesis (Spehlmann et al. 2008).   
There is increasing evidence that a perturbations to the normal intestinal microbiota 
has a role in the pathogenesis of IBD, where IBD patients harbour an altered gut 
microbiota (Frank et al. 2007, Sokol and Seksik 2010). Patients with IBD typically 
display a reduced bacterial diversity (Elson and Cong 2012). Ott et al. demonstrated 
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that alterations to the gut microbiota may be more dramatic in UC than CD, where 
overall bacterial diversity was 50% lower in CD patients and 70% lower in patients 
with UC than in healthy controls. This reduced diversity was associated with a loss 
of commensal anaerobic bacteria such as Bacteroides species (Ott et al. 2004). 
Notably, metagenomic and metaproteomic studies have revealed that the 
microbiome of patients with IBD possess 25% fewer genes and are depleted in 
functional pathways and proteins when compared to healthy individuals (Qin et al. 
2010, Erickson et al. 2012) 
In terms of compositional alterations to the gut microbiota, patients with IBD have 
consistently been shown to have reduced diversity within the Firmicutes phylum, 
with fewer of its constituent bacterial species detected when compared to healthy 
individuals (Ott et al. 2004, Manichanh et al. 2006, Frank et al. 2007). Among the 
decreases within the Firmicutes phylum is a reduced abundance of the butyrate 
producing bacteria Faecalibacterium prausnitzii in both UC and CD patients (Sokol 
et al. 2008, Willing et al. 2009, Machiels et al. 2013). Indeed, Sokol et al. showed 
that oral administration of F. prausnitzii markedly reduced the severity of 2,4,6 
trinitrobenzenesulphonic acid (TNBS) induced colitis and tended to correct the 
colitis induced microbial dysbiosis in mice (Sokol et al. 2008). It should, however, 
be noted that Hansen et al. have reported greater proportions of F. prausnitzii in a 
paediatric cohort of CD patients (Hansen et al. 2012) and so the role of F. prausnitzii 
in IBD among different age groups requires further attention. 
IBD patients have been shown to harbour greater Proteobacteria concentrations 
when compared to healthy individuals and so it has been suggested that species 
belonging to this phylum, particularly pathogenic strains Escherichia coli, play an 
aggressor role in IBD (Gophna et al. 2006, Baumgart et al. 2007, Carvalho et al. 
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2009, Mukhopadhya et al. 2012). Indeed, increases in facultative anaerobes (such as 
the Proteobacteria) and decreases in obligate anaerobes (including many Firmicutes) 
reported in IBD patients have given rise to the so called “oxygen” hypothesis, which 
suggests that individuals with IBD have a disruption in the anaerobiosis of the GI 
tract resulting in the aforementioned alterations to the gut microbiota (Rigottier-Gois 
2013). 
Ultimately, it remains unclear whether the microbial dysbiosis observed in 
individuals with IBD is a cause of IBD or a consequence of the disturbed gut 
environment as a result of chronic inflammation. A recent study by Gevers et al. 
assessed the intestinal microbiota of a large cohort (n=447) of newly diagnosed 
paediatric CD patients. The authors reported that CD patients had increases in the 
abundance of Enterobacteriaceae, Pasteurellaceae, Veillonellaceae and 
Fusobacteriaceae with concomitant decreases in abundances of Erysipelotrichales, 
Bacteroidales and Clostridiales when compared to a cohort (n=221) of healthy 
individuals implicating alterations to the gut microbiota in the development of CD. 
Notably, microbial differences between healthy controls and CD patients were only 
observed in mucosal samples (rather than fecal) suggesting alterations in bacteria 
which are reside in the mucosal layer play an important role in the aetiology of the 
disease (Gevers et al. 2014). 
1.3.2 Irritable bowel syndrome 
Irritable bowel syndrome (IBS) is a chronic function disorder of the GI system 
which is characterised by abdominal pain and altered bowel habits, wherein patients 
primarily experience  diarrhoea, constipation or both (Canavan et al. 2014).  While 
the underlying pathogenesis of this multifactorial syndrome is poorly understood 
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(Marshall et al. 2006), perturbations in the normal gut microbiota are thought to play 
a role in the low-grade inflammation associated with IBS (Öhman and Simrén 
2013). Several studies have reported a microbial dysbiosis in patients with IBS when 
compared to healthy controls. Rajilic-Stojanovic et al. reported paediatric patients 
with IBS had increased populations of members of the Firmicutes phylum, namely 
Ruminococcus, Clostridium and Dorea, coupled with decreased populations of 
Bifiobacterium and Faecalibacterium spp (Rajilić–Stojanović et al. 2011). Similar 
results were also reported by Saulnier et al. who also reported an increase in 
Proteobacteria populations in a paediatric cohort with IBS (Saulnier et al. 2011). 
Small intestinal bacterial overgrowth (SIBO) is defined as the presence of bacteria in 
excess of 10
5
 CFU/ml of intestinal fluid (Posserud et al. 2007) and has been 
associated with the aetiology of IBS. SIBO results in the bacterial fermentation of 
dietary carbohydrates within the small intestine which increases gas production, 
contributing to the symptoms of IBS (Ghoshal et al. 2006). Furthermore, the 
production of SCFAs by bacteria associated with SIBO reduces intestinal motility by 
triggering the release of peptides such as peptide YY thus altering normal intestinal 
transit (Dumoulin et al. 1998).  
A recent study which examined the fecal metabolite profiles using proton nuclear 
magnetic resonance concluded that samples from IBS patients and healthy controls 
could be distinguished based on their metabolite profile, with the intestinal 
environment of IBS patients being characterised by increased proteolysis, 
incomplete anaerobic fermentation and alterations in methane production. This study 
suggests that fecal metabolite and microbiota profiles are altered in IBS and may 
serve as biomarkers of human intestinal diseases (Shankar et al. 2015).  
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Both probiotic and antibiotic interventions have been observed to reduce the 
symptoms of IBS, further suggesting a role for bacteria in IBS pathogenesis (Collins 
2014). The administration of the antibiotic rifaximin markedly reduced IBS 
symptoms bloating, abdominal pain and loose or watery stools compared with a 
placebo group in one such study (Pimentel et al. 2011). A probiotic study by 
Tsuchiya et al. demonstrated that IBS patients in receipt of a probiotic cocktail 
(SCM-III) containing Lactobacillus helveticus (1.3 x 10
9
/100ml), Lactobacillus 
acidophilus (1.25 x 10
9
/100ml) and Bifidobacterium (4.95 x 10
9
/100ml) was either 
“effective” or “very effective” in more than 80% of patients. These patients 
displayed significant improvements in abdominal pain and bloating, which was 
concomitant with significantly increased abundances of intestinal Lactobacillus, 
Eubacterium and Bifidobacterium compared to a control cohort in receipt of a 
placebo (Tsuchiya et al. 2004). In a double-blind probiotic study, Kim et al. showed 
that administration of a the probiotic cocktail (Medilac DS) to IBS patients 
significantly reduced the frequency and severity of abdominal pain (Kim et al. 
2006). These results indicate a bacterial role in IBS onset and thus therapeutic 
modulation of the gut microbiota as a viable target for IBS treatment.  
1.3.3 Obesity 
According to the most recent WHO estimates, 1.9 billion adults (over 18) worldwide 
were overweight, of which nearly 600 million were obese (WHO 2015). Obesity is a 
multifactorial condition which primarily arises as a result of a long-term positive 
energy balance and is associated with a wide range of metabolic diseases such as 
type 2 diabetes (T2D), hypertension and cardiovascular disease (Eckel et al. 2005). 
While the dramatic increase in the incidence of obesity over the last 20-25 years to 
its current epidemic status is largely due to modern eating habits and an increasingly 
11 
 
sedentary lifestyle, increasing evidence has shown that the composition, diversity 
and function of the gut microbiota can play important roles in the aetiology of 
obesity. The relationships between the gut microbiota and obesity have been the 
focus of several comprehensive review articles (Flint 2011, Clarke et al. 2012, Cani 
2013, Moran and Shanahan 2014).  
Obesity is associated with an alteration in gut microbiota composition with a 
concurrent reduction in overall diversity (Turnbaugh et al. 2008, Turnbaugh et al. 
2009). Several studies have reported that obese mice (Ley et al. 2005, Turnbaugh et 
al. 2006) and, to a lesser extent, humans (Ley et al. 2006) harbour increased 
proportions of the Firmicutes phylum with concurrent decreases within the 
Bacteroidetes phylum compared to their normal weight counterparts, leading to an 
increased Firmicutes : Bacteroidetes (F:B) ratio being proposed as a potential 
biomarker of obesity. However, findings to the contrary have also been published 
(Murphy et al. 2010, Schwiertz et al. 2010), including data from the Human 
Microbiome Project which indicated no association between the F:B ratio and 
obesity or body mass index (BMI) (Finucane et al. 2014) and, thus, the accuracy of 
the F:B ratio as a biomarker of obesity remains in question.  
While the precise alterations in microbial composition that contribute to obesity 
remains the subject of debate, several important studies in gnotobiotic mice have 
highlighted the importance of the gut microbiota in the pathogenesis of obesity. 
Firstly, Backhed et al. demonstrated that the enteric microbiota is essential for the 
development of obesity in that the authors reported that germ free C57BL/6J mice 
were protected from diet induced obesity (DIO) whereas their conventionalised 
counterparts were not, despite no significant differences in energy (food) intake 
between the two groups (Bäckhed et al. 2007). Furthermore, Turnbaugh et al. 
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suggested that the obese-associated microbiota contributes to obesity through 
increased dietary harvest following observations that germ free mice 
conventionalised with a microbiota from genetically obese (ob/ob) mice had 
significantly higher amounts of body fat than mice conventionalised with a 
microbiota from lean animals (Turnbaugh et al. 2006). This theory was supported by 
a later study by Ridaura et al. who examined the effect of conventionalising germ 
free mice with the microbiota of twins discordant for obesity. The results of the 
study indicated that conventionalisation of germ free mice with a microbiota from 
obese twins (Ob) resulted in significant increases in body weight and adiposity when 
compared with mice conventionalised with a microbiota from lean twins (Ln). 
Moreover, co-housing of the Ob and Ln associated animals transformed the 
metabolic profile of the Ob associated animals to a Ln like state and prevented the 
development of increased body mass and adiposity (Ridaura et al. 2013).   
More recent studies have identified specific bacterial members of the gut microbiota 
which may play important roles in obesity determination. Fei et al. demonstrated 
that the mono-association of germ free C57BL/6J mice with an endotoxin producing 
Enterobacter strain, namely Enterobacter cloacae B29, isolated from the gut of a 
morbidly obese human, induced fully developed obesity and insulin resistance 
whereas germ free mice consuming the same high fat diet did not display the same 
disease phenotype. Enterobacter-associated mice displayed aggravated 
inflammatory conditions and increased serum endotoxin load suggesting a causative 
role for the Enterobacter strain in the onset of obesity (Fei and Zhao 2013). Another 
study, by Woting et al., revealed that Clostridium ramosum may also contribute to 
the aetiology of obesity. In this study, germ free mice were associated with a 
simplified human intestinal microbiota (SIHUMI) with or without C. ramosum 
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(SIHUMI+Cra or SIHUMI-Cra) or with just C. ramosum (Cra) and were provided 
with a high fat or low fat diet. After four weeks of high fat feeding, both 
SIHUMI+Cra and Cra mice displayed significantly higher body weight, body fat and 
higher food efficiency when compared to the SIHUMI-Cra animals. The authors of 
the study concluded that the presence of C. ramosum within the gut ecosystem 
intensifies diet induced obesity, possibly through the up regulation of small intestinal 
glucose and fat transporters (Woting et al. 2014). Conversely, other strains of 
commensal enteric bacteria such as Enterococcus faecalis FK-23 and Lactobacillus 
gasseri SBT2055 have been shown to exert anti-obesity and anti-adiposity effects in 
both rodent and human studies (Motonaga et al. 2009, Kadooka et al. 2010). The 
mucin degrading bacteria Akkermansia muciniphila has also received attention in 
this regard (Derrien et al. 2004). A study of note by Everard et al. demonstrated that, 
compared to their lean littermates, ob/ob mice had significantly lower abundances 
(3,300 fold) of A. muciniphila, which were normalised upon prebiotic 
(oligofructose) treatment, which in turn correlated with an improvement in the 
animal’s metabolic profile. Furthermore, the same study showed that orally 
administered A. muciniphila reversed high fat associated metabolic disorders 
including fat mass gain and insulin resistance in these mice (Everard et al. 2013). 
Another study noted an increase in the abundance of A. muciniphila in a cohort of 
overweight/obese humans following a period of calorie restriction which coupled 
with an improvement in several clinical parameters such as insulin resistance (Dao et 
al. 2015). While data from these studies suggest a protective role for A. muciniphila 
in obesity, contrasting results were observed by Qin et al. who in a large 
metagenome wide association study of 345 Chinese individuals reported that A. 
muciniphilia was enriched in patients with type 2 diabetes (Qin et al. 2012).  
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These results provide evidence that the gut microbiota plays an important role in the 
onset and severity of obesity and related conditions. These observations are 
particularly important in light of the fact that strategies to prevent/reduce the 
growing trend of worldwide obesity have been largely unsuccessful (Roberto et al. 
2015), and suggest that the gut microbiota represents a viable alternate target in the 
treatment of obesity 
1.3.4 Type 2 diabetes 
 T2D, which is primarily linked with obesity-related insulin resistance, has become a 
major health concern throughout the developed world (Chen et al. 2012). Obesity-
related T2D is associated with the presence of low-grade inflammation in bodily 
sites involved in metabolism regulation such as the liver, adipose tissue and muscles 
(Pickup and Crook 1998). This low-grade inflammation results from the moderate 
excess in the production of cytokines such as interleukin (IL)-6 and tumour necrosis 
factor alpha (TNF-), resulting in alterations in insulin signalling and subsequent 
development of insulin resistance (Hotamisligil 2006, Shoelson et al. 2006). 
Although obesity and associated inflammation are the primary cause of T2D, other 
factors such as host genetics (see review by Barroso (Barroso 2005)) and other 
environmental factors influence the condition. As with the aforementioned 
conditions, alterations to the gut microbiota in patients with T2D compared to 
healthy individuals have been reported in several studies (Larsen et al. 2010, Qin et 
al. 2012, Karlsson et al. 2013, Serino et al. 2013). Larsen et al. demonstrated that 
Bacteroidetes and Betaproteobacteria proportions were significantly enriched while 
proportions of the Firmicutes phylum, specifically within the Clostridia class were 
significantly decreased in adult males with T2D compared to their healthy 
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counterparts (Larsen et al. 2010). In a much larger study, Qin et al. concluded that 
the T2D associated microbiota was characterised by a moderate dysbiosis, an 
increase in the number of various opportunistic pathogenic bacterial species and a 
reduction in the levels of butyrate producing species (Qin et al. 2012). Similar 
results were reported by Karlsson et al. who, in a study examining the microbiome 
of type 2 diabetic European women, reported that four Lactobacillus species were 
enriched in the T2D diabetic cohort compared to the normal glucose tolerance 
control group, while conversely the abundance of five Clostridium species were 
decreased in the T2D cohort. Notably, the increases of Lactobacillus species and 
decreases in Clostridium species correlated positively and negatively respectively 
with fasting glucose, but did not correlate with BMI suggesting these alterations are 
related to the diabetic condition rather than the associated body weights of the 
subjects (Karlsson et al. 2013). Notably, when the same study analysed 
metagenomic gene clusters (MGCs), generated by shotgun sequencing of both their 
own cohort of European women and the Chinese cohort generated by Qin et al. (Qin 
et al. 2012), principal component analysis of MGC abundances of European and 
Chinese cohorts showed a clear separation which may reflect different genetics 
and/or different dietary habits. However, several striking similarities within the 
T2D-associated microbiota were also determined between the two groups, 
potentially revealing bacterial species that contribute to the development of T2D. 
More specifically, the metagenome of T2D patients in both European and Chinese 
cohorts were determined to have increased Lactobacillus and Clostridium 
clostridioforme MGCs and decreased Rosburia_272 MGCs. This increase in 
Lactobacillus is in agreement with previously mentioned study by Larsen et al., who 
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also reported a positive correlation between the abundance of Lactobacillus and 
blood glucose levels in T2D patients (Larsen et al. 2010).  
The reduced levels of Roseburia observed in both T2D cohorts may be critical as 
several of the bacterial species contained within the Roseburia genus (e.g. Roseburia 
inulinivorans) are amongst the most dominant butyrate producing members of the 
enteric microbiota (Aminov et al. 2006). Butyrate is the primary energy source for 
colonic enterocytes and has several beneficial impacts on host physiology which 
may be important in T2D, such as reducing intestinal inflammation and 
improvements in intestinal barrier function (Flint et al. 2007, Peng et al. 2007, Cani 
2013). Indeed, gut microbiota transplantations from lean donors to individuals with 
metabolic syndrome have been shown to increase Roseburia populations, increase 
butyrate production and improve insulin resistance (Vrieze et al. 2012). 
Furthermore, the microbiome of both European and Chinese T2D cohorts showed 
enrichment in metabolic functions related to oxidative stress further suggesting a 
link between the pathogenesis of T2D and alterations to the normal gut microbial 
composition as high oxidative stress has previously been linked to a predisposition 
to diabetic complications (Kashyap and Farrugia 2011). 
The present data shows that both composition and function of the gut microbiota is 
altered in T2D patients. While several bacterial species have been implicated in 
playing causative roles in T2D, environmental factors such as geographical location 
and dietary habits also influence the microbiota of T2D patients and thus larger 
human studies are required in order to develop novel diagnostic or therapeutic 
strategies.  
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1.3.5 Colorectal cancer 
There has been a rapid increase in incidence of colorectal cancer (CRC) in recent 
years and CRC is now the leading cause of cancer-related mortality worldwide 
(Jemal et al. 2011). As with several other GI diseases, the gut microbiota is also 
thought to play a role in CRC (Rowland 2009, Chen et al. 2013). Wang et al. 
demonstrated a clear structural segregation between the gut microbiota of CRC 
patients versus healthy individuals. The study reported that, when compared to 
healthy volunteers, the microbiota of CRC patients were enriched in Enterococcus, 
Escherichia/Shigella, Klebsiella, Streptococcus and Peptostreptococcus. Variations 
within the Bacteroides genus were also observed in that B. vulgatus and B. uniformis 
were decreased and B. fragilis increased in CRC patients (Wang et al. 2012). 
Notably, the enterotoxin produced by certain B. fragilis strains (Enterotoxigenic 
Bacteroides fragilis (ETBF)) have been shown to contribute to CRC both by direct 
genotoxicity and by the stimulation of epithelial cell shedding and gamma-secretase-
dependent E-cadherin cleavage (Wu et al. 2006, Wu et al. 2007). This cleavage in 
turn increases intestinal barrier permeability and alters -catenin/Wnt signal 
transduction within intestinal epithelial cells, resulting in the proliferation and 
oncogenic transformation seen in CRC (Wu et al. 2003). Notably, as seen in T2D 
patient studies, Wang et al. also demonstrated that abundances of the Roseburia 
genus were significantly lower in CRC patients (Wang et al. 2012).  
Several metagenomic studies comparing the microbiota composition of healthy 
individuals and CRC patients have identified the enrichment of representatives of 
the Fusobacterium genus in CRC patients (Castellarin et al. 2012, Kostic et al. 2012, 
Wang et al. 2012, Tahara et al. 2014). Furthermore, Kostic et al. showed that 
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Fusobacterium nucleatum can generate a pro-inflammatory microenvironment via 
the recruitment of tumour-infiltrating immune cells thus contributing to colorectal 
neoplasia progression (Kostic et al. 2013). E. coli have also been linked with CRC 
pathogenesis. Arthur et al. reported that the microbiota of colitis-susceptible (IL10
-/-
) 
mice harbour E. coli at levels that were ~100 fold higher than their wild-type 
counterparts. The same study also showed that azoxymethane treated IL10
-/-
 mice 
mono-associated with E. coli NC101 developed invasive mucinous adenocarcinomas 
and that upon deletion of the polyketide synthase (pks) genotoxic island from the 
E.coli strain, tumour multiplicity and invasion were significantly decreased (Arthur 
et al. 2012).  
Finally, as well as identifying specific members of the gut microbiota involved in the 
development of CRC, studies have shown that certain products of bacterial 
metabolism may also influence CRC. Hydrogen sulphide (H2S) is produced in the 
gut via the bacterial metabolism of diet-derived sulphate and other compounds such 
as sulphur amino acids by sulphate-reducing bacteria (SRB) (Magee et al. 2000). 
The production of H2S by the gut microbiota is of importance to CRC because H2S 
has been shown to be genotoxic to intestinal epithelial cells and, even at low 
concentrations (0.25-2mM), H2S can cause significant DNA damage to human cell 
lines (Attene-Ramos et al. 2007, Wallace 2007). Indeed CRC patients have 
previously been associated with an enrichment in SRB and higher stool sulphide 
levels suggesting that H2S production by members of the gut microbiota plays an 
important role in CRC (Kanazawa et al. 1996, Marchesi et al. 2011, Carbonero et al. 
2012, Kostic et al. 2012).  
It has also been proposed that the production of reactive oxygen intermediates 
(ROIs) such as hydrogen peroxide and extracellular superoxide, which can cause 
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DNA damage (Huycke et al. 2002), by members of the gut microbiota can also 
contribute to the genesis of CRC. More specifically, a study by Balamurugan et al. 
reported that CRC patients had lower levels of the butyrate producing bacterial 
species Eubacterium rectale and F. prausnitzii and concomitant relatively greater 
proportions of Enterococcus faecalis proportions which have been shown to produce 
genotoxic metabolic products such as superoxide (Huycke et al. 2002). The 
relationship between bacterial metabolites and CRC are reviewed in greater detail by 
Louis et al. (Louis et al. 2014).   
The data reviewed highlights the importance of the gut microbiota in several GI 
diseases. Therefore gut microbiota modulation towards a more desirable state 
presents an attractive viable target in the development of novel therapeutic 
strategies.  
1.4. Diet and the gut microbiota 
It is now widely accepted that diet is a driving force in determining the composition 
of the gut microbiota and the relationship between diet and the gut microbiota has 
been the subject of several comprehensive review articles (Flint et al. 2012, Scott et 
al. 2013, Flint et al. 2015). The type and amount of the main dietary macronutrients, 
i.e. carbohydrates, proteins and fats, have been shown to have a profound effect on 
the composition of the gut microbiota and the bacterial metabolites which it 
produces. 
1.4.1 Carbohydrate 
Each day approximately 40 g of dietary carbohydrate escape digestion by host 
enzymes and enters the human colon (Cummings and Englyst 1991). The primary 
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forms of carbohydrate entering the colon include resistant starches (RS), non-starch 
polysaccharides (NSP) and oligosaccharides. Under the anaerobic conditions of the 
colon, SCFAs are the major end products of carbohydrate fermentation, of which 
butyrate, propionate and acetate are the major SCFA produced by the gut microbiota 
(Flint et al. 2012). SCFAs have been shown to influence several host physiological 
processes, firstly SCFAs are absorbed and used as an energy source by the host, with 
butyrate acting as the primary energy source for intestinal epithelial cells (Peng et al. 
2007, Flint et al. 2015). SCFAs produced by members of the gut microbiota can 
influence host energy intake by acting as key signalling molecules for the G protein 
coupled receptors, free fatty acid receptor 2 (FFAR2) and free fatty acid receptor 3 
(FFAR3). Activation of these receptors results in the production and release of gut 
hormones such as peptide YY and glucagon-like peptide-1 (GLP-1), which stimulate 
satiety (Brown et al. 2003, Miyauchi et al. 2010, Sleeth et al. 2010). SCFAs, and 
particularly butyrate, also exert anti-inflammatory effects on the host (Segain et al. 
2000, Hamer et al. 2008). Indeed the gut microbiota of patients with inflammatory 
conditions such as UC have a marked reduction in butyrate producing species and 
oral administration of butyrate producing bacterial species such as F. prausnitzii has 
been shown to dramatically decrease the pathogenesis of inflammatory associated 
diseases (Sokol et al. 2008, Machiels et al. 2013). Several excellent reviews detailing 
the impact of SCFAs produced by the gut microbiota on the host have been 
published (Macfarlane and Macfarlane 2012, Scott et al. 2013, Tan et al. 2014).  
Resistant starches and non-starch polysaccharides 
Starch is a complex polysaccharide which is comprised of two glucose polymers, 
namely amylose and amylopectin. While the majority of dietary starch is digested 
within the small intestine, a variable fraction can evade host digestion and pass into 
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the colon. This dietary fibre is referred to as “resistant starch” (RS) (Macfarlane and 
Englyst 1986). RS is divided into four subgroups (RS1-RS4) based on its properties 
which allow it to escape digestion in the small intestine. These are plant cell wall 
polymers (type 1), granular structure (type 2), retrogradation (type 3) and chemical 
cross-linking (type 4) (Englyst et al. 1992). It is estimated that RS represents the 
largest diet-derived energy source for colonic bacteria (Nugent 2005).  
In a randomised crossover intervention study, Abell et al. reported that a bacterial 
group closely related to Ruminococcus bromi was significantly increased when 
volunteers were switched from a normal diet to one high in RS (Abell et al. 2008). A 
further study examining the effect of a high RS diet, this time in adult female pigs, 
demonstrated that a diet high in RS resulted in significantly higher proportions of F. 
prausnitzii with concomitant reductions in potential pathogenic bacterial species 
such as E. coli and Pseudonomas spp. when compared to pigs in receipt of a diet 
high in digestible starch. Furthermore, when compared to pigs consuming the high 
digestible starch diet, both cecal and colonic SCFA concentrations were significantly 
higher in pigs consuming the diet high in RS (Haenen et al. 2013). In a dietary 
intervention study with obese men by Walker et al., it was shown that changes to 
fecal bacterial populations occurred within three to four days after subjects had been 
switched to a diet supplemented with RS3. Among the changes to fecal bacterial 
populations, it was shown that the proportions of R. bromii and E. rectale were 
significantly enriched in response to RS3 (Walker et al. 2011). Another study, 
involving healthy individuals, found that increasing dietary RS2 led to increased 
proportions of R. bromii and E. rectale while increased RS4 consumption led to 
increased abundances of Bifidobacterium adolescentis and Parabacteroides 
distasonis suggesting amylolytic bacteria species harboured within the gut 
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microbiota vary in their ability to utilise different types of RS (Martínez et al. 2010). 
This suggestion was further evidenced in a study by Ze et al. who investigated the 
activities of four dominant amylolytic human gut bacterial species in the presence of 
different RS substrates. The results indicated that when raw or boiled RS2 or RS3 
was the substrate, R. bromii and B. adolescenttis showed much greater amylolytic 
activity then either Bacteroides thetaiotaomicron and E. rectale. Moreover, the same 
study suggested that R. bromii may be a keystone bacterial species in the breakdown 
of RS in the colon, in that it was shown in co-culture to stimulate RS2 and RS3 
utilisation by the other three bacterial species (Ze et al. 2012).  
While the aforementioned study by Walker and colleagues (Walker et al. 2011) did 
not report a significant change in the gut microbiota in response to wheat bran (a 
non-starch polysaccharide (NSP)) supplementation, the amount of supplemented 
wheat bran was considerably less (~5-fold) than RS which might account for the 
inability of wheat bran to modulate microbial populations (Walker et al. 2011). 
Hedemann et al. observed a significant increase in fecal SCFA concentrations in rats 
fed various sources of non-digestible carbohydrates, such a RS and NSPs such as 
pectin and inulin, which positively correlated with a significant increase in the 
thickness of the mucous layer when compared to rats fed a fibre free diet (Hedemann 
et al. 2009). A recent study by Tap et al. reported that increased dietary fibre 
resulted in increased microbial richness associated with increased abundances of 
Prevotella and Coprococcus as well as increased expression of genes encoding 
carbohydrate-active enzymes on fibre (Tap et al. 2015). Notably, increases in 
Prevotella abundances have previously been associated with the long term 
consumption of a diet high in plant polysaccharides (discussed in greater detail 
below). 
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 Prebiotics 
 Prebiotics are defined as “selectively fermented ingredients that result in specific 
changes, in the composition and/or activity in the GI microbiota, thus conferring 
benefit(s) upon host health” (Gibson et al. 2010). The key properties which define a 
prebiotic are; 1) a food ingredient which escapes assimilation in the small intestine, 
2) upon reaching the colon it can be fermented, 3) selective stimulation of bacterial 
species which confer a health benefit to the host (Gibson et al. 2010). The most 
commonly studied prebiotics are carbohydrates such as fructo-oligosaccharides 
(FOS) and galacto-oligosaccharides (GOS) (Macfarlane et al. 2008). To date, the 
spectrum of bacteria targeted with prebiotics has been relatively narrow, mainly 
focusing on stimulation of Bifidobacterium and Lactobacillus species, and this topic 
has been reviewed elsewhere (Manning and Gibson 2004, Gibson et al. 2010, 
Russell et al. 2011). Notably, however, prebiotic stimulation of bacterial such as 
Bifidobacterium may indirectly stimulate the growth of other beneficial bacterial 
species and/or increase production of beneficial microbial metabolites through 
bacterial cross-feeding. For example, prebiotic stimulation of Bifidobacterium 
populations leads to increased lactate production, which in turn can be converted to 
butyrate by other bacterial species such as Eubacterium halii (Duncan et al. 2004, 
Falony et al. 2006).  
As noted above, recent studies have highlighted several other gut bacterial species, 
such as R. bromii, R. intestinalis, E. rectale and F. prausnitzii, which may also 
confer substantial health benefits upon the host and thus represent new viable targets 
for prebiotic stimulation. Of these bacterial targets, perhaps the most attractive is F. 
prausnitzii. As previously discussed, F. prausnitzii abundances are decreased in 
inflammatory GI diseases such as UC and CD and that the bacterium has been 
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shown to exert anti-inflammatory effects on the host (Sokol et al. 2008, Willing et 
al. 2009, Machiels et al. 2013). Ranirez-Farias reported that abundances of F. 
prausnitzii were significantly increased in subjects during a period of daily inulin 
(10g/d) supplementation compared to a control period without supplementation 
(Ramirez-Farias et al. 2009). Furthermore, F. prausnitzii have been shown to utilise 
pectin (Lopez-Siles et al. 2012), suggesting it is a suitable prebiotic substrate in the 
stimulation of F. prausnitzii growth within the large intestine. 
More generally, several studies have reported a reduction in inflammatory markers 
after prebiotic supplementation suggesting that prebiotic intervention may reduce the 
severity of diseases such as obesity and T2D which are characterised by low grade 
inflammation. A study from Dehghan et al. showed that women with T2D who 
consumed an oligofructose-enriched inulin supplement (10g/d) over an eight week 
period exhibited a significant reduction in plasma lipopolysaccharide (LPS), fasting 
plasma glucose, interleukin-6 (IL-6) and tumour necrosis factor- (TNF- when 
compared to a control cohort consuming a maltodextran placebo (Dehghan et al. 
2014). Similar results have also been reported in studies employing galacto-
oligosaccharide (GOS) prebiotics. In a 12 week placebo (maltodextran)-controlled 
crossover study, overweight women (n=45) with increased risk factors associated 
with metabolic syndrome were provided a daily GOS supplement (5.5g/d). Prebiotic 
consumption increased fecal Bifidobacterium abundance with concomitant decreases 
in Bacteroides and opportunistic pathogens such as C. histolyticum. Prebiotic 
consumption also lead to a reduction in the inflammatory state (as determined by 
fecal calprotectin and plasma CRP), and significantly decreasing total cholesterol 
and plasma tri-glyceride concentrations (Vulevic et al. 2013). Furthermore, other 
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studies have reported that consumption of prebiotics improved symptoms in UC and 
CD patients (Lindsay et al. 2006, Casellas et al. 2007, Zachos et al. 2007). 
1.4.2 Protein  
Each day approximately 15g of protein reaches the human colon. However, its 
impact on the colonic bacteria is currently poorly understood (Cummings 1997). 
Dietary protein is crucial for the supply of amino acids and also serves as the major 
nitrogen source for the growth of saccharolytic bacteria within the gut (Cummings 
and Macfarlane 1991). Compared to carbohydrate fermentation, bacterial 
metabolism of protein results in a more diverse range of metabolites, some of which 
are putrefactive and thus a predominantly saccharolyic gut environment is generally 
regarded as preferable (Conlon and Bird 2014, Rastall and Gibson 2015).  
The primary pathway of protein fermentation occurring in the human colon is amino 
acid deamination, resulting in the formation of SCFAs and ammonia. Bacteria 
known to carry out these reactions include species within the Clostridium, 
Bacteroides, Enterobacterium and Lactobacillus genera (Cummings and Macfarlane 
1991). It is thus unsurprising that ammonia, which has a normal fecal concentration 
of ~15mM, has been shown to increase in response to high protein intake (Hughes et 
al. 2000). Increased ammonia production in the gut may have implications for 
diseases such as CRC as ammonia has been shown in rat models to be a potent 
carcinogenic agent even at low concentrations (Windey et al. 2012). In addition to 
ammonia, protein fermentation by members of the gut microbiota also results in the 
formation of other detrimental metabolites, e.g. phenylacetic acid, phenols, indoles 
and p-cresol, implicated in the pathogenesis of diseases such as UC, CD and CRC 
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(Cummings and Macfarlane 1991, Jantchou et al. 2010). This topic is reviewed in 
greater detail by Windley  et al. (Windey et al. 2012). 
Other nitrogenous compounds produced through bacterial fermentation of dietary 
protein, particularly N-nitroso compounds (NOCs), may also be detrimental to gut 
health. A study by Russell et al. showed that during a period of low 
carbohydrate/high protein consumption, volunteers displayed an increase in NOC 
and branched chain fatty acids (BCFAs) concentrations with a concurrent decrease 
in beneficial microbial products such as butyrate (Russell et al. 2011). NOCs can be 
formed endogenously by the nitrosation of amines derived from the microbial 
fermentation of dietary protein in the colon and gut bacteria such as several 
members of the Proteobacteria phylum, which encode nitrate reductases, are thought 
to contribute to these nitrosation reactions. NOCs are potent carcinogenic agents 
which promote tumour formation via DNA alkylation leading to mutagenesis (Gill 
and Rowland 2002). 
To date only a small number of studies have examined the effect of dietary proteins 
on the enteric microbiota and tend to focus on altered bacterial metabolites rather 
than specific taxonomic changes. However, it has been shown that individuals on a 
high protein/low carbohydrate diet for 4 weeks displayed altered gut microbiota and 
fatty acid profiles, which included a reduction in Roseburia and E. rectale and in 
colonic butyrate levels (Russell et al. 2011). The limited data available also suggests 
that the bacterial metabolites formed by proteolytic fermentation are highly 
dependent on the type of protein ingested. For example, in a series of studies by 
Tolden et al. rats consuming high protein diets, where the protein source was casein 
(25%), white meat (25%), red meat (35%) or soya (25%), displayed significantly 
higher colonocyte genetic damage than was the case for animals consuming a more 
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typical protein diet (15% casein). Notably, this detrimental effect was absent when 
whey protein (25%) was the protein source in a high protein diet (Toden et al. 2007, 
Toden et al. 2007, Toden et al. 2007). These studies also further highlighted the 
importance of the composition of the protein source in that, for example, red meat 
was shown to induce greater genetic damage than white meat, which was attributed 
to red meat containing higher levels of heme, which has previously been shown to 
stimulate the production of n-nitroso compounds within the human gut (Kuhnle et al. 
2007). Moreover, animal protein was shown to cause DNA damage, which was 
associated with thinning of the colonic mucous barrier layer, to a significantly higher 
degree than plant or dairy protein (Toden et al. 2007). Substitution of casein as the 
dietary protein source with a less digestible protein source was shown to 
significantly increase intestinal BCFA concentrations and excretion of urinary p-
cresol which was associated with increased tumorigenesis (Le Leu and Young 
2007). 
Finally, murine and human intervention studies have shown that administration of 
prebiotics and/or probiotics can exert a shift in gut microbial metabolism from 
proteolytic to saccharolytic fermentation in that urinary p-cresol and urinary nitrogen 
concentrations were observed to decrease in rats upon administration of RS (Heijnen 
and Beynen 1997, Toden et al. 2005). In a randomised crossover study Birkett et al. 
also demonstrated that high RS consumption significantly lowered fecal 
concentrations of ammonia and phenols (associated with protein fermentation) 
(Birkett et al. 1996). Ndagijimana and colleagues used 
1
H nuclear magnetic 
resonance (
1
HNMR) to show that the consumption of a synbiotic (combined 
prebiotic and probiotic) food (0.5g FOS, 10
9
 CFR Bifidobacterium longum and 10
9
 
CFU Lactobacillus acidophilus x2/day) for 30 days resulted in a metabolite profile 
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shift more indicative of saccharolytic fermentation rather than proteolytic 
fermentation (Ndagijimana et al. 2009). These results are in agreement with other 
synbiotic intervention studies (Oberreuther-Moschner et al. 2004, De Preter et al. 
2011). 
The current data indicates that utilisation of dietary protein by the gut microbiota is 
associated with increased production of metabolic end-products which are 
detrimental to gut health. However, the effect by which the amount and type dietary 
protein entering the colon exerts on specific taxonomies within the gut microbiota is 
still poorly understood and requires further investigation.  
1.4.3 Fat 
The majority of dietary fat is adsorbed in the human small intestine. However, using 
13
C labelled fat, Gabert and colleagues showed that ~7% of dietary fat escapes the 
digestive process and is excreted in faeces. Thus, a substantial amount of fat reaches 
the colon and may influence the gut microbiota (Gabert et al. 2011). Several high fat 
diet associated rodent studies have suggested that alterations to the composition of 
the gut microbiota results from dietary fat rather than the obese phenotype. Zhang et 
al. reported that mice fed a high fat diet for 12 weeks to induce obesity harboured a 
gut microbiota considerably different to that of control mice consuming a normal 
chow diet. However, when the obese mice were switched to a normal chow diet for a 
further 10 weeks, the composition of their gut microbiotas became indistinguishable 
from those within the control cohort despite having significantly higher body 
weights even after the 10 week normal chow period. Thus the strong response of the 
gut microbiota to the high fat diet was reversible and was independent of the obese 
phenotype (Zhang et al. 2012). These results are in accordance with another study in 
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which RELMknockout mice in receipt of a high fat diet did not develop obesity 
but did display significant differences in gut microbial populations in comparison to 
their normal chow fed counterparts (Hildebrandt et al. 2009). When examining the 
results of these comparison studies, it is important to account for the variability in 
the macronutrient ratios of the diets used. For example, high fat diets are normally 
lower in carbohydrates and so the possibility exists that reported alterations to the 
gut microbiota of animals consuming a high fat diet in comparison to those on 
control diets may stem from differing amount of fermentable carbohydrates within 
the diet (Neyrinck et al. 2011, Scott et al. 2013).  
High fat diets have also been shown to increase the production and release of bile 
acids microbiota such as deoxycholic acids (DCA) from the gall bladder and 
increase the concentrations of secondary bile acids produced by 7 -dehydroxylation 
of primary bile acids by members of the gut microbiota (Rafter et al. 1987). Notably, 
the supplementation of a murine diet with DCA was shown to alter the composition 
of the gut microbiota, where an increased F:B ratio and an outgrowth of several 
bacteria within the Erysipelotrichi and Clostridia classes were reported (Islam et al. 
2011). Furthermore, increased production of secondary bile acids by the gut 
microbiota has been implicated in pathogenesis of GI diseases such as CRC (Ou et 
al. 2012).  
Finally, alterations to the gut microbiota in response to high fat/low carbohydrate 
diets are thought to contribute to low grade inflammation, characterised by increased 
levels of circulating LPS and other plasma inflammatory markers which have been 
shown to be mitigated after treatment with prebiotics such as FOS or arabinoxylans 
(Cani et al. 2007, Moreira et al. 2012). Supplementation of a high fat diet with FOS 
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was shown to restore Bifidobacterium spp. populations, reduce the expression of 
pro-inflammatory cytokines and improve glucose tolerance (Cani et al. 2007). 
Neyrinck et al. showed an improvement in circulating levels of IL-6 and MCP-1 
following supplementation of a high fat murine diet with the prebiotic arabinoxylan, 
which was accompanied by a restoration of Roseburia populations and an 
enrichment of Bifidobacterium (Neyrinck et al. 2011). The increase in levels of 
circulating inflammatory markers resulting from high fat feeding has been associated 
with an increase in gut barrier permeability and, thus, increasing butyrate producing 
bacteria such as those within the Roseburia genus may ameliorate these symptoms, 
given that butyrate improves intestinal barrier function (Peng et al. 2007, Peng et al. 
2009). Indeed, Cani et al. showed that supplementation of a high fat diet with the 
prebiotics FOS and arabinoxylan resulted in a selective increases in Lactobaccillus 
and Bifidiobacterium populations as well as the butyrate producing C. coccides-E. 
rectale cluster, which was accompanied with an improvement in intestinal barrier 
function mediated through a microbially driven increased production of  GLP-2 
(Cani et al. 2009).   
1.4.4 Impact of long term dietary patterns on the gut microbiota 
Metagenomic studies comparing the gut microbiota of cohorts from different 
geographical locations where the habitual long term dietary patterns are significantly 
different have highlighted the importance of the diet in determining the microbiota 
structure. In a study of 98 US adults, Wu et al. linked long term dietary habits with 
bacterial enterotypes, where the microbiota of individuals consuming higher amount 
of dietary fibre (rich in fruits and vegetables) were associated with the Prevotella 
enterotype whereas the microbiota of individuals consuming with a more ‘western’ 
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diet higher in protein and fat were associated with the Bacteroides enterotype (Wu et 
al. 2011).  
These results are in agreement with those reported in a comparison study of children 
from a rural African village in Burkina Faso and European children. The diet of the 
children from Burkina Faso, akin to that of early human settlements, was high in 
plant polysaccharides, starch and fibre and low in animal protein and fat. 
Comparatively, European children consumed a typical ‘western’ diet, high in animal 
protein, sugar, starch and low in fibre. Analysis of the fecal microbiota revealed 
distinct differences in the structure of the European and African childrens’ gut 
microbiota. The gut microbiota of Burkina Faso children contained significantly 
lower proportions of Firmicutes and were significantly enriched in the Prevotella 
and Xylanibacter genera, which encode several xylan and cellulose hydrolysis genes, 
when compared to their European counterparts. This data suggests that the human 
gut microbiota co-evolved with a polysaccharide-rich diet allowing for increased 
energy extraction from the diet but also indicating that the microbiota may confer 
protection to the host against inflammatory and non-infectious colonic disease 
through increased SCFA production and, given the significantly higher levels of 
Enterobacteraceae harboured by European children, may also confer protection to 
the host against opportunistic gut pathogens (De Filippo et al. 2010).  
In another study, the gut microbiota of city dwelling African Americans, which have 
a markedly increased risk of CRC, were compared by Ou and colleagues with native 
Africans with a very low incidence of CRC. 16S rRNA gene sequence data revealed 
distinct differences in microbial composition between the two cohorts, with a 
predominance of the Prevotella enterotype in the native African populations and of 
Bacteroides in the African American cohort. Furthermore, the native African 
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population were noted to have significantly higher levels of SCFAs while other 
bacterial metabolites associated with CRC, such as secondary bile acids, were 
significantly higher in the African American cohort (Ou et al. 2013).  
Claesson et al. reported that differences in dietary patterns were responsible for the 
variations in gut microbial populations observed between community dwelling 
elderly individuals and those residing in long term care facilities. The study noted 
that community dwelling individuals which consumed a healthier and more diverse 
diet (low to moderate fat and high fibre), harboured a more diverse gut microbiota 
than individuals living in residential care. As well as a reduction in overall 
biodiversity, taxonomic differences were also detected between long stay care and 
community dwelling individuals, where the microbiota of community dwelling 
individuals were associated with greater abundances of Prevotella, Coprococcus and 
Roseburia and lower abundances of Parabacteroides, Eubacterium, Anaerotructus, 
Lactonifactor and Coprobacillus than those individuals residing in long term care 
facilities (Claesson et al. 2011). The authors of the study also linked the observed 
alterations in gut microbial composition to length of stay, i.e. the longer the 
individual stayed in the resident care facility, and thus consumed a less diverse diet, 
the more dissimilar their microbiota became to that of the community dwelling 
individuals (Claesson et al. 2011).   
Finally, a number of studies have highlighted differences in the fecal microbiota of 
individuals consuming vegetarian or omnivorous diets (Liszt et al. 2009, Kabeerdoss 
et al. 2012, Matijašić et al. 2014). Results from these studies indicated that the 
increased carbohydrate and fibre intake associated with vegetarianism results in 
increased SCFA production by enteric microbes, which lowers intestinal pH and  
may inhibit the growth of GI pathogens such as E. coli and other Enterobacteriaceae 
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spp. (Zimmer et al. 2012). However when compared to vegetarians, the gut 
microbiota of omnivorous individuals were shown to harbour an increased 
abundance of the Clostriudium XIVa class which contains several important butyrate 
producing bacterial strains such as R. inulinivorans, E. rectale and E .hallii (Liszt et 
al. 2009, Louis and Flint 2009, Kabeerdoss et al. 2012).  
Taken together, these studies highlight that diet plays a key role in enteric microbial 
structure and function. Pioneering work in the development of pre, pro and synbiotic 
treatments have shown that dietary interventions can beneficially modulate the gut 
microbiota to confer a health benefit on the host via such mechanisms as stimulating 
beneficial microbial populations and increasing SCFA production, which has in turn 
paved the way for the development of non-pharmaceutical, novel treatments for 
diseases such as T2D and IBS (Ringel et al. 2012, Rastall and Gibson 2015). Other 
studies have highlighted other bacterial species, such as F. prausnitzii, whose 
stimulation or probiotic administration may confer further health benefits to the host 
(Conlon and Bird 2014). However, current knowledge regarding the impact of 
macronutrient sources, particularly different protein sources, on specific members of 
the gut microbiota remains extremely limited. Certainly, when compared to 
carbohydrate utilisation by the gut microbiota, proteolytic fermentation results in the 
formation of several potentially putrefactive metabolites. However, the type of 
protein consumed appears to play a pivotal role in determining fermentation end 
products, for example whey protein was observed to result in less colonocyte DNA 
damage when compared to other protein sources (Toden et al. 2007) and therefore 
dietary proteins may represent an “untapped” resource in stimulating beneficial 
bacterial species or inhibiting potential pathogens.   
34 
 
Advances in technology and application of transcriptomic and metabolomic 
approaches in combination with existing metagenomic data promises to further 
advance our understanding of the complex relationship between diet and the gut 
microbiota and allow for the development of novel methods of gut microbiota 
modulation.  
1.5 Bovine milk proteins as novel beneficial modulators of the gut microbiota? 
The consumption of dairy whey proteins, and their associated bioactive peptides, has 
been associated with a wide range of health benefits, however their impact on enteric 
microbial populations remains largely understudied. In this section we review the 
properties of bovine whey proteins, their influence on physiological processes and 
discuss the current knowledge on their impact on the gut microbiota.  
1.5.1 Bovine whey proteins 
Whey is the milk serum which remains after casein curd, formed by the action of 
chymosin [rennet], has been separated from the milk during the cheese making 
process (Figure 2). Whey is comprised of proteins, vitamins, lactose (~75% of total 
whey solids), minerals and small amounts of fats (Zadow 1994). Caseins account for 
80% (W/W) of the total protein content in milk with whey containing the remaining 
20%. Unlike proteins from the casein fraction of milk proteins, whey proteins do not 
coagulate in the acid conditions of the stomach and thus reach the jejunum quickly, 
are rapidly digested, can influence several metabolic functions such as lipid and 
glucose metabolism and can act as therapeutic agents in the treatment of diseases 
such as hypertension and cardiovascular disease (Hulmi et al. 2010). Traditionally 
thought of as a waste by-product of the cheese manufacturing process, whey is now 
regarded as a valuable co-product with several commercial applications.  
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1.6 Whey component proteins 
Whey is comprised of several component proteins including -lactoglobulin, -
lactalbumin, bovine serum albumin, lactoperoxidase, lactoferrin (each discussed in 
greater detail below) as well as other minor proteins such as immunoglobulins. 
Whey is a high quality protein source and contains all essential amino acids, 
including high concentrations of branched chained amino acids (BCAAs) such as 
leucine, isoleucine and valine, which are important factors in biological processes 
such as muscle repair  (Millward et al. 2008, Hulmi et al. 2010).  
1.6.1 -lactoglobulin 
-lactoglobulin (-lac) is the major protein in whey, accounting for about half of the 
total whey protein content and ~12% of total bovine milk proteins. -lac is a 
globular protein which consists of 162 amino acid residues in its primary structure 
and has a molecular weight of 18.4 kDa (Eigel et al. 1984). While -lac is the major 
protein of bovine whey, it is essentially absent from the milk of both humans and 
rodents. Indeed, -lactoglobulin is the primary allergen in cow’s milk and it’s 
removal from whey has been suggested for the production of hypoallergenic food 
products such as milk formula (Chiancone and Gattoni 1991). As well as providing a 
rich source of both essential and branched chain amino acids (Harper 2004), -lac 
was also shown (in preruminant calves) to play an important role in the intestinal 
uptake of small hydrophobic ligands such as retinol, triglycerides and long chain 
fatty acids (Kushibiki et al. 2001). While not known for its antimicrobial activity, 
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proteolytic digestion of -lac by trypsin results in the formation of four negatively 
charged peptides that possess bactericidal effects against Gram positive bacteria 
(Pellegrini et al. 1999). Notably, -lac has also been proposed as a vehicle for the 
delivery of prebiotic compounds, viable probiotic bacteria and pH-sensitive drugs to 
the colon owing to -lac’s high resistance to gastric digestion, GRAS (generally 
regarded as safe) status and relative in-expense (Livney 2010, Mehraban et al. 2013, 
Kent and Doherty 2014). 
1.6.2-lactalbumin 
Bovine -lactalbumin (-La), which consists of 123 amino acid residues, is the 
second most abundant protein found in whey and accounts for ~20% of the total 
protein content of bovine whey. -La is synthesised in the mammary gland where it 
acts as a coenzyme in the biosynthesis of lactose, an important energy source for the 
new-born (De Wit 1998). -La contributes to a reduced risk of incidence of some 
cancer types through several mechanisms such as the anti-proliferative effects 
demonstrated in assays with colon adenocarcinoma cell lines (Sternhagen and Allen 
2001). Indeed, BAMLET, which is a complex of bovine -La and oleic acid, was 
shown by Rammer et al. to have the ability to kill tumour cells which are highly 
resistant to apoptosis (Rammer et al. 2010).  
Due to its particularly high tryptophan content, diets enriched in -La also have 
beneficial effects with respect to mood and cognition. Tryptophan is a precursor to 
5’hydroxytryptomine, also known as serotonin, a neurotransmitter involved in 
several important neuro-processes such as sleep regulation and cognitive processes 
(Jouvet 1999). Indeed, a decreased serotonin level is associated with mood disorders 
such as anxiety and depression (Maes and Meltzer 1995). A human study by Markus 
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et al. demonstrated that evening intake of -La resulted in improved brain-sustained 
attention processes, which were associated with increased plasma tryptophan 
availability (Markus et al. 2005). In another study, rats consuming a -La enriched 
diet showed enhanced serotonin release resulting in the induction of anxiolytic and 
rewarding effects within the brain suggesting that a -La enriched diet may have a 
beneficial effect on mood (Orosco et al. 2004). When examined against several 
Gram positive and Gram negative bacteria, native bovine -La did not exhibit any 
bactericidal activity (Pellegrini et al. 1999), however Pihlanto-Leppälä et al. 
demonstrated that -La reduced the metabolic activity of E. coli JM103 by 79% 
when pre-hydrolysed with pepsin or trypsin (Pihlanto-Leppala et al. 1999). 
Furthermore, Brück et al. showed that a combination of -La and 
glycomacropeptide inhibited the association between CaCo-2 cells and the GI 
pathogens enteropathogenic E. coli (EPEC), Salmonella typhimurium and Shigella 
flexneri, thus suggesting milk supplementation with both -La and GMP might be 
effective in the prevention of some GI infections (Brück et al. 2006).  
1.6.3 Bovine serum albumin 
Unlike other whey proteins, bovine serum albumin (BSA) is not synthesised in the 
mammary gland but instead enters milk following its leakage from the blood stream 
and thus may be considered a whey associated protein. BSA, which contains 583 
amino acid residues, is involved in the maintenance of colloid osmotic pressure and 
also acts as a carrier protein for free fatty acids, catecholamines and other hormones 
(Danon and Sapira 1972, Hankins 2006). While a good source of essential amino 
acids, there is currently little knowledge on the therapeutic potential of BSA. One 
notable property associated with the protein was its ability to inhibit tumour growth 
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in a MCF-7 human breast cancer cell line (Laursen et al. 1989). BSA may also 
beneficially influence fat mass accumulation as a recent study by McManus et al. 
(2015) reported C57BL/6 mice which had consumed a high fat diet where BSA was 
the dominant dietary protein source for 13 weeks had significantly reduced 
subcutaneous fat mass, plasma leptin and plasma corticosterone relative to animals 
which consumed a high fat diet where casein was the dominant dietary protein 
source. 
1.6.4 Lactoferrin 
Lactoferrin (Lf) is a single chained iron-binding member of the transferrin protein 
family and accounts for ~1% of the total proteins in bovine whey. Lf is produced by 
mucosal epithelial cells in several mammalian species and is found in mucosal 
secretions such as tears, saliva and GI fluids (Van der Strate et al. 2001, Öztafl and 
Özgünefl 2005). Of all the proteins contained within bovine whey, Lf is the most 
widely studied. Lf is a multifunctional protein whose properties include anti-
bacterial activity and stimulation of beneficial intestinal bacteria (discussed 
presently), as well as other functional properties such as anti-viral, 
immunomodulatory, anti-cancer and anti-inflammatory activities (reviewed 
elsewhere (Van der Strate et al. 2001, Madureira et al. 2007, Garcia-Montoya et al. 
2012)). Due to the wide range of beneficial properties associated with this whey 
protein, Lf may now be thought of as a nutraceutical protein and strategies have 
been developed to facilitate its use in nutritional and pharmaceutical applications.  
While multiple functional properties of Lf have been investigated, its antimicrobial 
activity is its most widely studied function and both in vitro and in vivo studies have 
reported Lf activity against both Gram positive and Gram negative bacteria. In terms 
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of its antibacterial activity, Lf exerts both bacteriostatic and bactericidal activity. Lf 
comprises two homologous lobes, each of which can bind one ferric ion (Fe
2+
 or 
Fe
3+
) (Baker et al. 2003, Adlerova et al. 2008). Lf therefore exerts bacteriostatic 
activity through the sequestration of iron away from bacterial pathogens, thus 
limiting the use of this vital nutrient and down-regulating expression of virulence 
factors (Arnold and Cole 1977, Arnold et al. 1980, Reyes et al. 2005). Studies have 
shown that Lf also invokes bactericidal effects on pathogenic bacteria through direct 
interactions with bacterial surface proteins. Ellison et al. were the first to report that 
Lf damaged the outer membrane of Gram negative bacteria through interactions with 
lipopolysaccharide (LPS) (Ellison et al. 1988). More specifically, the damage to the 
LPS layer was shown to result from the binding of Lf to lipid A of LPS, causing 
structural changes and loss of membrane potential and integrity. The binding of Lf to 
LPS also reduces LPS-induced toxicity (Miyazawa et al. 1991) and can inhibit the 
adherence of several enteric pathogenic bacteria including Salmonella, 
enterotoxigenic E. coli (ETEC), EPEC, and enterohemorrhagic E. coli (EHEC) to 
intestinal cells thereby negating their ability to establish infection (Ellison et al. 
1988, Appelmelk et al. 1994, Kawasaki et al. 2000, Ochoa et al. 2003, Ochoa and 
Cleary 2009). Interestingly, the binding of Lf to LPS and other bacterial surface 
proteins also potentiates the action of other antibacterial enzymes, such as lysozyme, 
or certain antibiotics, such as novobiocin (Ellison et al. 1988, Sanchez and Watts 
1999).  
The proteolytic enzymes found in the GI tract and sites of infection catalyse the 
release of several functional peptides from native Lf which confer anti-bacterial 
activity. Of these anti-bacterial peptides, which include lactoferrampin and LF1-11, 
the most widely studied is lactoferricin (Lfcin). Lfcin, which represents amino acid 
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residues 17-41 of native Lf, is a 25 amino acid residue multifunctional peptide 
resulting from the pepsin cleavage of native Lf. Lfcin contains two cysteine residues 
which are linked by a disulphate bridge, creating a looped region which contains 
many hydrophobic and positively charged residues (Bellamy et al. 1992). Bellamy et 
al. reported that bovine Lfcin exerts antibacterial activity against a wide range of 
both Gram positive and Gram negative bacteria and that its bactericidal effects were 
more potent than that of native Lf (Bellamy et al. 1992). Indeed, in a comparison 
study of human, bovine, murine and caprine Lfcin by Vorland et al., bovine Lfcin 
was shown to be the most potent (Vorland et al. 1998). The bactericidial activity of 
Lfcin is derived from its ability to bind to the LPS layer of Gram negative bacteria 
(Yamauchi et al. 1993) and teichoic acid found within the cell wall of Gram positive 
bacteria (Vorland et al. 1999), resulting in membrane disruption, inhibition of 
macromolecular biosynthesis and, ultimately, cell death (Ulvatne et al. 2004). 
Kuwata et al. reported that Lfcin was produced in the human stomach following 
ingestion of bovine lactoferrin in physiologically functional quantities suggesting 
that Lfcin may play an important defence role within the GIT and that functional 
foods enriched with bovine lactoferrin may reduce enteric bacterial infection through 
increased Lfcin production (Kuwata et al. 1998). Notably, while Lfcin possesses 
potent anti-bacterial activity against a wide range of bacteria, certain bacterial 
species, some of which have been associated with improving gut health such as 
Bifidobacterium bifidum strains, are highly resistant to Lfcin (Bellamy et al. 1992, 
Khailova et al. 2009).Indeed, with respect to Bifidobacterium, Lf may also be 
thought of as a growth promoter of several strains of Bifidobacterium. This is 
particularly notable given the probiotic properties associated with many strains from 
this genus, as noted above and reviewed elsewhere (Russell et al. 2011).  
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Several in vitro studies have shown that bovine Lf (BLf) promotes the growth of 
several Bifidobacterium spp.. Saito et al. reported that both apo-BLf (iron free) and 
holo-BLf (iron saturated) exhibited bifidogenic activity with respect to eight strains 
of Bifidobacterium, with a considerable bifidogenic effect being reported for B. 
breve ATCC 15700 and B. bifidum ATCC 15696 (Saito et al. 1996). Furthermore, 
Rahman et al. reported that both apo-BLf  and holo-BLf promote the growth of 
fourteen strains of B. infantis, B. breve, B. bifidum and B. longum with the 
bifidogenic effect of holo-BLf noted to be slightly more effective than that of apo-
BLf (Rahman et al. 2010). Kim et al. suggested that the bifidogenic activity of Lf is 
dependant on the ability of the bacterial strains to bind Lf. More specifically, the 
authors reported that Lf increased growth of three strains of Bifdiobacterium, namely 
B. breve ATCC 15700, B. bifidum ATCC 15696, B. infantis ATCC 15697, as well as 
Lactobacillus acidophilus CH-2, all of which were shown to contain Lf binding 
proteins within the membrane protein fraction while, conversely, no Lf binding 
proteins were detected in the membrane protein fraction of B. longum whose growth 
was not enriched in the presence of Lf (Kim et al. 2004). It should be noted, 
however, that Petchow et al. reported that while Lf binding may be involved, Lf 
exerts a bifidogenic effect via a mechanism which is independent of both iron 
saturation and receptor binding (Petschow et al. 1999). Multiple in vivo studies have 
also established that Lf exerts bifidogenic effects. Hentges et al. reported gnotobiotic 
mice associated with a human infant gut microbiota consuming a milk fortified with 
bovine Lf had increased counts of Bifidobacterium compared with mice consuming 
un-supplemented formula (Hentges et al. 1992). Furthermore, recombinant human 
Lf (rhLf) was shown by Hu et al. to modulate the intestinal microbiota of piglets and 
increase illeal populations of Bifidobacterium spp. and Lactobacillus spp. (Hu et al. 
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2012). A recent study by Mastromarino et al. demonstrated a correlation between the 
level of Lf present in breast milk and the proportions of Lactobacillus and 
Bifidobacterium present in the feces of new born babies (Mastromarino et al. 2014). 
Notably, poor maternal health in associated with variations in breast milk 
composition which include a reduced level of Lf  (Hennart et al. 1991).  
Ultimately, these combined results suggest that the ingestion of Lf or peptides 
resulting from its digestion can have prebiotic effects.  
1.6.5 Lactoperoxidase 
A member of the mammalian peroxidases family, the lactoperoxidase (LP) enzyme 
accounts for 0.25-0.50% of the total protein content of whey and is found in 
biological secretions such as tears, saliva and milk. One of the most abundant 
enzymes in plain milk, LP plays an important role in its preservation and has several 
commercial applications such as food and crop preservation and protection of the 
oral cavity against bacterial infection (Reiter et al. 1963, Seifu et al. 2005, Boots and 
Floris 2006). The anti-bacterial activity of LP relies on the presence of both the 
thiocyanate anion (SCN
-
; which is present in significant levels in natural secretions 
such as saliva and milk) and hydrogen peroxide (H2O2) and is based upon the ability 
of LP to catalyse the oxidation of the SCN
-
 (Reiter and Härnulv 1984, Reiter and 
Perraudin 1991). This LP-catalysed reaction results in the formation of the short-life 
intermediary compounds, primarily hypothiocyante (OSCN
-
) and hypothiocyanous 
acid (HOSCN), which are thought to invoke anti-bacterial activity via the inhibition 
of essential bacterial metabolic pathways such as glycolysis by the oxidation of 
sulfhydryl groups of bacterial proteins in both Gram positive and Gram negative 
bacteria (Reiter and Härnulv 1984, Reiter and Perraudin 1991, Tenovuo 2002). The 
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formation of intermediary compounds from the LP-catalysed oxidation of SCN
-
 is 
pH dependant and may result in the formation of other bactericidal compounds such 
as cyanosulphurous acid (HO2SCN) and cyanosulphuric acid (HO3SCN). However, 
at physiological pH, OSCN
-
 is the major oxidation product (Björck 1978, Pruitt and 
Tenovou 1982). The LP anti-bacterial system plays an important role in the 
maintenance of oral health, where the LP/SCN
-
/H2O2 system was shown by Welk et 
al. to have bactericidal activity against both Streptococcus mutans and S. sanguinis, 
which are associated with both dental caries and periodontal disease (Loesche 1986, 
Kolenbrander and London 1993, Welk et al. 2011). 
1.7 Beneficial effects of dietary whey protein 
Bovine whey proteins have been the subject of much interest due to the beneficial 
effects which they have been shown to exert on a variety of physiological processes 
such as energy balance, appetite and glucose metabolism, all of which are relevant to 
the use of whey proteins in the treatment of diseases such as obesity and T2D. 
(Table 1). 
1.7.1 Weight loss and body composition 
With the current worldwide obesity epidemic, the anti-obesity properties associated 
with whey proteins have attracted much attention in recent years. Several studies 
have highlighted the anti-obesity effects of whey proteins or, more specifically, their 
ability to reduce high fat diet associated increased body weight and fat mass 
accumulation. Shertzer et al. reported female C57BL/6J mice fed a high fat diet with 
100g whey protein isolate (WPI)/L drinking water showed reduced body fat and 
body weight gain, while having increased lean mass, compared to their littermates 
which did not receive WPI supplemented drinking water (Shertzer et al. 2011). 
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Similarly, in another study using C57BL/6J, Shi et al. reported a dose dependant 
reduction in weight gain and the development of fatty liver upon replacing 5%, 50% 
or 100% of the dietary casein protein-derived energy with WPI enriched in LP and 
Lf (Shi et al. 2011). Pilvi et al. have suggested several mechanisms by which whey 
proteins may reduce symptoms of obesity in a series of studies in C57BL/6J mice 
consuming high fat diets. Initially, it was shown that mice in receipt of a diet 
consisting of 60% of total calories from fat, 18% from whey (WPI) and 1.8% 
calcium carbonate (CaCO3) showed a significant decrease in weight gain and body 
fat coupled with significantly higher levels of fat excretion when compared to mice 
in receipt of a similar diet where casein was the protein source and which had with a 
lower percentage of CaCO3 (0.4%). It was suggested that the reduction in weight 
gain and fat excretion results from the high leucine content of whey modulating 
insulin signalling, thus directing energy towards muscle biosynthesis rather than fat 
storage in adipose tissue (Pilvi et al. 2007). In a follow-up study employing the same 
diet groups for the same 21 week study period, the authors observed the same 
inhibition of fat mass accumulation within the whey consuming cohort combined 
with a significant up-regulation of leptin and 3-adrenergic receptor genes, leading 
the authors to suggest that whey protein attenuates symptoms of obesity via 
improved leptin sensitivity and increased lipolysis (Pilvi et al. 2008). Finally, in a 
later study by the same group, mice with diet induced obesity were placed on a low-
calorie weight loss diet containing different whey proteins (-La, -lac, WPI and Lf) 
for 50 days before being returned to a high fat diet containing the same whey 
protein/WPI for a further 50 days. Mice which consumed the -La diet showed a 
significant loss of fat mass during the calorie restricted period and a subsequent 
reduction in visceral fat during the weight recovery period compared to all other 
45 
 
dietary groups (Pilvi et al. 2009). Pichon et al. suggested that -lac is the most 
efficient whey protein in reducing weight gain after reporting a greater reduction in 
body weight and adipose tissue in rats consuming a high protein diet comprised of 
WPI enriched in -lac than rats consuming a diet containing other protein sources 
such as whole milk and whey protein concentrate (WPC). Notably, however, this 
study did not include a diet enriched with -La (Pichon et al. 2008).  
1.7.2 Appetite  
Another mechanism by which whey proteins may influence energy balance is 
through appetite control via their satiating properties. While it is generally accepted 
that dietary protein induces a greater satiating effect than other macronutrients such 
as carbohydrates or fats (Tomé et al. 2009), data from several studies have suggested 
that whey proteins are more potent satiety inducers than other protein sources. A 
study by Hall et al. reported that the intake of whey protein (48g) delayed the desire 
to consume a subsequent meal by 180 minutes when compared to casein in lean 
individuals (Hall et al. 2003). In another human study it was shown that the 
consumption of a diet of protein, carbohydrate and fat, which provided 10%, 55% 
and 35% energy, respectively, reduced hunger more effectively when whey protein 
was included in the diet rather than casein or soy protein (Veldhorst et al. 2009). In a 
further study in lean subjects, Pal and Ellis reported significantly reduced mean 
energy intake and reduced appetite during a subsequent buffet meal (4h later) in 
individuals who had consumed a blended drink containing whey protein, compared 
to those which had consumed a blended drink containing the same amount (50g) of 
either egg, tuna or turkey protein (Pal and Ellis 2010).   
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It has been suggested that whey provides a more satiating effect that other proteins 
due to its higher content of BCAAs and, in particular, leucine (Mastromarino et al. 
2014). Leucine, which enters the brain more rapidly than any other amino acid 
(Yudkoff et al. 2005), has been shown through intracerebroventricular injection to 
play an important role in appetite suppression, which suggests that whey proteins 
invoke a central effect on energy intake (Morrison et al. 2007). It is also possible 
that these effects are mediated by the high tryptophan content in whey. As 
previously stated, tryptophan is a precursor to serotonin which is an important 
regulator of appetite (Ashley et al. 1979), thus the high tryptophan content of -La 
may in turn increase satiety through increased serotonin production. Regardless, a 
study by Veldhorst et al. demonstrated that a breakfast diet where -La provided 
either 10% or 25% energy reduced lunchtime energy intake when compared to a 
breakfast diet deriving protein energy from casein, soy or whey (Veldhorst et al. 
2009). This is consistent with the observations of Hursel et al. who also reported that 
an -La enriched diet had a greater effect on appetite suppression than a whey diet 
(Hursel et al. 2010). These results suggest a use for -La in appetite control.  
Another mechanism by which whey proteins (or whey peptides resulting from 
gastric digestion) may influence energy intake is by the stimulation of 
gastrointestinal hormones which are important regulators of energy intake (Pimentel 
and Zemdegs 2010). Cholecystokinin (CCK) is a hormone secreted by I cells of the 
small intestine whose stimulation results in increased satiety (Figlewicz et al. 1992). 
GMP was shown by Pederson et al. to stimulate the production of CCK in 
anesthetised rats (Pedersen et al. 2000), thus suggesting a role for GMP in food 
intake regulation. Furthermore, results of the aforementioned Veldhorst et al. study 
support this suggestion in that they reported a greater satiety effect in subjects 
47 
 
consuming a breakfast diet comprising 10% whey protein compared to those 
consuming a breakfast diet comprising 10% whey protein without GMP (Veldhorst 
et al. 2009). 
Other important gut hormones which influence energy intake are glucagon-like 
peptide-1 (GLP-1) and ghrelin, whose activation decrease and increase energy 
intake, respectively (Turton et al. 1996, Wren et al. 2001). In one study in which 
dietary whey protein intake (50g) decreased appetite in both lean and overweight 
individuals, it was found that this change was coupled with increased plasma levels 
of CCK and GLP-1 and reduced levels of ghrelin when compared to glucose intake 
(Bowen et al. 2006). The results of this study are in line with those of other studies 
in both human and animal models (Hall et al. 2003, Zhou et al. 2011). These results 
suggest that whey protein or their associated bioactive peptides can reduce energy 
intake by the activation or suppression of important appetite regulating hormones 
within the gut.  
Notably, while the previously discussed results suggest a use for whey proteins in 
the development of treatments for obesity, some studies have suggested that the 
satiating effect of whey proteins may be reduced in obese individuals/animals. In a 
study using DIO mice, a similar energy intake pattern was observed in mice which 
had whey supplemented drinking water (100g/L) compared with those provided with 
un-supplemented drinking water, despite the former group having significantly 
lower body weights (Eller and Reimer 2010). This trend has also been shown in 
humans where whey protein supplementation reduced subsequent energy intake in 
normal weight but not obese individuals (Bellissimo et al. 2008). These observations 
are consistent with results reported in another human study by Bowen et al. (Bowen 
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et al. 2006). Results from these studies suggest that the beneficial effects of whey 
proteins on appetite suppression may be more potent in lean than obese individuals.  
 
1.7.3 Glucose metabolism 
Dietary whey protein has been shown to exert insulinotropic and glucose lowering 
properties in several studies of healthy, insulin resistant and type-2-diabetic subjects. 
In a study of healthy individuals, Peterson et al. demonstrated  that consumption of a 
single dose of carbohydrate (50g) supplemented with whey protein (20g) resulted in 
a significant reduction in postprandial blood glucose (Petersen et al. 2009). 12 weeks 
of whey protein supplementation was shown to decrease both fasting plasma insulin 
and insulin resistance in overweight subjects, suggesting that long term whey protein 
consumption improves insulin sensitivity (Pal et al. 2010). A significant 
hypoglycaemic effect was observed in insulin resistant subjects who consumed a 
drink containing 50g of glucose and 30g of whey compared with those who 
consumed a drink containing the same 50g of glucose with or without canola oil 
(Lan-Pidhainy and Wolever 2010). Furthermore, whey proteins have been shown to 
exert a greater insulinotropic effect than other dietary proteins, such as casein (Pal 
and Ellis 2010), gluten and codfish (Mortensen et al. 2009). 
One proposed mechanism by which whey proteins may invoke insulinotropic effects 
is via the formation of whey-associated bioactive peptides which, in turn, act as 
endogenous inhibitors of dipeptidyl peptidase 4 (DPP-IV). DPP-IV is an antigenic 
enzyme whose principal in vivo function is the rapid degradation of the incretins 
GLP-1 and gastric inhibitory peptide (GIP) which induce insulin secretion (Kieffer 
et al. 1995, Holst and Gromada 2004). Gunnarsson et al. showed a significant 
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reduction in DPP-IV activity upon administration of whey protein in anesthetised 
C57BL/6J mice (Gunnarsson et al. 2006), while other studies, using both healthy 
and diabetic subjects, have reported increases in both GIP and GLP-1 after whey 
protein supplementation (Hall et al. 2003, Ma et al. 2009, Veldhorst et al. 2009). The 
balance between these incretins and DPP-IV appears to be altered in T2D patients 
where increased DPP-IV activity and decreased postprandial GLP-1 levels have 
been reported (Mannucci et al. 2005, Petersen et al. 2009). These results therefore 
suggest a use for dietary whey proteins in non-pharmaceutical treatment for the 
improvement of insulin sensitivity and, potentially, in the treatment of diabetic 
patients.  
1.8 Whey proteins and the gut microbiota 
The composition of the gut microbiota undergoes dramatic changes throughout the 
life cycle of the host. Component proteins of whey appear to play important roles in 
the development of the infant gut microbiota by stimulating beneficial bacteria 
species such as members of the Bifidobacterium and Lactobacillus genera and 
providing protection against opportunistic pathogens such as E. coli (Adlerberth and 
Wold 2009, Hascoët et al. 2011, Mastromarino et al. 2014, Subramanian et al. 2015). 
However, the impact of dietary whey protein intake on the stable adult gut 
microbiota is currently poorly understood. Some promising results have been 
reported in the few studies examining the effect of dietary whey protein on the gut 
microbiota. Firstly, as noted above, when compared to other dietary protein sources 
such as red and white meat, soya and casein, whey proteins were shown to exert 
significantly less colonocyte DNA damage in rats (Toden et al. 2007, Toden et al. 
2007). This result suggests that bacterial fermentation of whey proteins does not 
result in a large array of putrefactive metabolites traditionally associated with high 
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dietary protein intake, and therefore whey proteins represent potential novel 
candidates for beneficial gut microbiota modulation. Sprong et al. reported that 
consumption of diet containing cheese whey protein increased in fecal Lactobacillus 
and Bifidobacterium counts in Wistar rats when compared to those consuming the 
same diet but where the protein energy source was casein (Sprong et al. 2010).  
Similar results were reported by McAllen et al. who, using 16S rRNA sequencing, 
demonstrated significantly higher Lactobacillus and Bifidobacterium populations 
with a concurrent significant decrease in Clostridium populations in C57BL/6 mice 
consuming a high fat diet containing WPI (20% kJ) compared to mice consuming a 
high fat diet containing casein (20% kJ) (McAllan et al. 2014). However, in a similar 
study, Tranberg et al. did not observe any difference in the composition of the gut 
microbiota between two groups of C57BL/6 mice consuming a high fat diet where 
the protein source was either casein or whey, although in this case microbiota 
analysis was determined by less detailed denaturant gradient gel electrophoresis 
(DGGE) (Tranberg et al. 2013). Notably, a recent study showed that, in comparison 
to a standard diet, an enteral whey-peptide based murine diet significantly increased 
concentrations of cecal SCFAs. While results from this study indicate that the 
microbial fermentation of whey proteins or associated bioactive peptides promote 
gut health though increased SCFA production, the authors did not examine the 
composition of the gut microbiota and thus the effect that whey proteins have on 
SCFA producing bacterial species was not ascertained (Smith et al. 2013, Tomoda et 
al. 2015). In our own recent study, the effect of replacing casein (20%) as the protein 
source in a high fat murine diet with the whey proteins Lf and BSA on the 
composition on the gut microbiota was examined over an eight week intervention 
period. High-throughput sequencing of the murine fecal microbiota revealed that 
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both BSA and Lf reversed several of the high fat associated alterations in microbial 
taxonomy and, in the case of Lf, significantly enriched the proportions of the 
Roseburia genus (Chapter 3).  
Finally, Clarke et al. observed a significantly higher microbial diversity, which as 
noted earlier is a biomarker of good gut health associated with the gut of 
professional rugby players relative to controls. This higher diversity was positively 
correlated with protein intake with, notably, whey protein supplements representing 
a significant proportion of the athlete’s total protein consumption (Clarke et al. 
2014). While data from these initial studies suggest a potential use for whey proteins 
in the beneficial modulation of the gut microbiota, more studies using specific 
component proteins of whey are required to fully elucidate their effects on enteric 
bacterial populations.  
1.9 Conclusions 
It is now well established that the gut microbiota plays a pivotal role in maintaining 
human health and that imbalances in the complex microbial communities residing 
within the gut can have serious health implications in several GI disease states. 
Given that the current strategies employed to prevent/reduce the growing trend of 
inflammatory diseases such as obesity have been largely unsuccessful (Roberto et al. 
2015), selective modulation enteric microbial communities is an area which has the 
potential to deliver novel and effect treatments for such diseases (Walsh et al. 2014). 
To date, efforts to selectively modulate these microbial communities using dietary 
components have been restricted to non-digestible carbohydrates which have been 
shown to stimulate the growth of beneficial bacterial species and improve disease 
severity (Manning and Gibson 2004, Dehghan et al. 2014), while dietary protein has 
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received less attention and been associated with the formation of putrefactive 
bacterial metabolites (Louis et al. 2014). Dairy whey proteins have been shown to 
exert beneficial effects of a variety of physiological processes, such as energy 
balance and glucose metabolism, however their impact on gut microbial populations 
is less well known. Similar to prebiotic intervention studies, preliminary studies 
examining the effect of dairy whey protein on the gut microbiota, have shown whey 
protein consumption to enrich populations of beneficial bacteria such as 
Lactobacillus and Bifidobacterium (Sprong et al. 2010, McAllan et al. 2014). 
Notably whey protein consumption was shown to exert significantly less colonocyte 
DNA damage than other dietary protein sources (Toden et al. 2007) suggesting that 
whey proteins may beneficially modulate the gut microbiota without the formation 
of putrefactive metabolites traditionally associated with proteolytic bacterial 
fermentation. These primarily studies suggest that whey proteins may represent 
novel agents to beneficially modulate the gut microbiota however.  
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Table 1. Bioactive properties of bovine whey proteins. 
 Whey 
component 
Protein 
AA 
residues 
Associated Bioactive properties References 
-lactoglobulin 162 
Intestinal uptake of retinol, triglycerides and long chain fatty 
acids. 
(Kushibiki et al. 2001) 
Delivery vehicle for prebiotic compounds (Livney 2010, Kent 
and Doherty 2014) 
Bactericidal activity (upon trypsin digestion) against Gram 
positive bacteria 
(Pellegrini et al. 
1999) 
-lactalbumin 123 
Co-enzyme in lactose production 
 
(De Wit 1998) 
Inhibition of tumour growth and proliferation (Sternhagen and 
Allen 2001, Rammer 
et al. 2010) 
Improvements in mood and cognition due to high tryptophan 
content 
(Orosco et al. 2004, 
Markus et al. 2005) 
 
582 
Maintenance of colloid osmotic pressure 
 
(Hankins 2006) 
Bovine Serum 
Albumin 
Carrier protein for catecholamines, free fatty acids and other 
hormones 
 
(Danon and Sapira 
1972) 
Inhibition of tumour cells in MCF-7 human breast cancer cell 
lines 
 
(Laursen et al. 1989) 
  Reduction of fat mass accumulation (McManus et al. 
2015) 
Lactoferrin 700 
Anti-viral 
 
(Van der Strate et 
al. 2001) 
Anti-carcinogenic (Hayes et al. 2006, 
Nakajima et al. 2011) 
Anti-inflammatory 
 
(Conneely 2001) 
Bacteriostatic activity via iron sequestration 
 
(Arnold et al. 1980, 
Reyes et al. 2005) 
Bactericidal activity against a wide range of Gram positive and 
Gram negative bacteria 
(Ellison et al. 1988, 
Appelmelk et al. 
1994) 
(Kawasaki et al. 2000, 
Ochoa et al. 2003, 
Ochoa and Cleary 
2009) 
Increased potency of other antibacterial agents 
 
(Sanchez and Watts 
1999) 
Release of potent antimicrobial peptides upon gastric 
digestion 
(Bellamy et al. 1992, 
Vorland et al. 1998) 
(Yamauchi et al. 
1993, Vorland et al. 
1999) 
Growth promotion of Bifidobacterium species (Saito et al. 1996, 
Rahman et al. 2010) 
(Mastromarino et al. 
2014) 
Lactoperoxidase 612 
Preservation of plain milk 
 
(Seifu et al. 2005) 
Protection of the oral cavity against bacterial infection (Boots and Floris 
2006, Welk et al. 
2011) 
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Figure 1. Gut microbiota in health and disease. Diagram representing some of the 
health benefits conferred benefits conferred to the host by the ‘normal/functioning’ 
gut microbiota (left) and chronic GI diseases associated with perturbations to the gut 
microbiota (right). 
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Figure 2. Bovine milk protein system. 
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2.1 ABSTRACT 
Macronutrient quality and composition are important determinants of energy balance 
and the gut microbiota. Here, we investigated how changes to protein quality (casein 
versus whey protein isolate; WPI) and the protein to carbohydrate (P/C) ratio within 
a high fat diet (HFD) impacts on these parameters. Mice were fed a low fat diet 
(LFD)(10% kJ) or a high fat diet (HFD; 45% kJ) for 21 weeks with either casein 
(20% kJ, HFD) or WPI at 20%, 30% or 40% kJ. In comparison to casein, WPI at a 
similar energy content normalised energy intake, increased lean mass and caused a 
trend towards a reduction in fat mass (P=0.08), but the protein challenge did not 
alter oxygen consumption or locomotor activity. WPI reduced HFD-induced plasma 
leptin and liver triacylglycerol, and partially attenuated the reduction in adipose 
FASN mRNA in HFD-fed mice. High throughput sequence-based analysis of faecal 
microbial populations revealed microbiota in the HFD-20% WPI group clustering 
closely with HFD controls, although WPI specifically increased 
Lactobacillaceae/Lactobacillus and decreased Clostridiaceae/Clostridium in HFD-
fed mice. There was no effect of increasing the P/C ratio on energy intake, but the 
highest ratio reduced HFD-induced weight gain, fat mass and plasma triacylglycerol, 
non-esterified fatty acids, glucose and leptin levels, while it increased lean mass and 
oxygen consumption. Similar effects were observed on adipose mRNA expression, 
where the highest ratio reduced HFD-associated expression of UCP-2, TNFα and 
CD68 and increased the diet-associated expression of β3-AR, LPL, IR, IRS-1 and 
GLUT4. The P/C ratio also impacted on gut microbiota, with populations in the 
30/40% WPI groups clustering together and away from the 20% WPI group. Taken 
together, our data show that increasing the P/C ratio has a dramatic effect on energy 
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balance and the composition of gut microbiota, which is distinct from that caused by 
changes to protein quality. 
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2.2 INTRODUCTION 
It is widely recognised that levels of obesity and related clinical conditions such as 
diabetes, stroke, hyperlipidemia and cardiovascular disease are increasing worldwide 
(Caterson et al. 2004). Importantly, the development of obesity increases the set 
point at which the body weight, more specifically body fat, is defended, thus making 
its reversal difficult to achieve (Guo et al. 2009, Ryan et al. 2012). As such, there is 
an increased research interest to develop effective treatments for this disease. 
Dairy proteins belonging to the whey fraction (a by-product of cheese 
manufacture) have been increasingly tested for their potential anti-obesity effect, 
specifically for their ability to reduce high fat diet (HFD)-associated body weight 
and fat mass gain (Pilvi et al. 2007, Shertzer et al. 2011, Shi et al. 2011). Shi et al., 
(2012) showed that replacing 5%, 50% or 100% of the dietary casein protein-derived 
energy content with a lactoperoxidase and lactoferrin-enriched whey protein isolate 
(WPI) caused a proportional suppression of body weight gain in HFD fed mice. We 
have previously demonstrated that a WPI-related reduction in body weight and fat 
mass gain in HFD fed mice was accompanied by a normalisation of energy intake 
and complete or partial reversal of energy balance-related gene expression in the 
adipose tissue and the hypothalamus (McAllan et al. 2013). While these data suggest 
that whey proteins have a specific-effects on energy balance, such effects appear be 
modified by the macronutrient composition in the diet (Pichon et al. 2008). In the 
latter study, it was shown that increasing the lipid to carbohydrate ratio within a 
whey protein-rich diet significantly reduced energy intake and bodyweight gain in 
rats. Collectively, these data suggest that protein quality and macronutrient 
composition are important determinants of energy balance. 
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Interestingly, diet is also an important factor in determining the composition 
of the gut microbiota (Turnbaugh et al. 2009, Wu et al. 2011) and specific gut 
microbiota signatures are associated with obesity phenotypes in animals and humans 
(Backhed et al. 2004, Turnbaugh et al. 2006, Murphy et al. 2010). Notably, studies 
have shown specific whey proteins to possess anti-microbial activity (Yamauchi et 
al. 1993, Freedman et al. 1998, Shin et al. 2000), and that the digestive process itself 
facilitates the formation of potent antimicrobial whey-derived peptides, such as 
pepsin catalysed lactoferrin to lactoferricin (Hoek et al. 1997). A study by Sprong et 
al., (Sprong et al. 2010) demonstrated that in comparison to casein, whey protein 
intake increased levels of lactobacilli and bifidobacteria in a rat model of colitis. 
However, in a more recent study, whey protein intake was found to have no 
influence on gut microbiota composition in mice fed a HFD for 7 or 13 weeks 
(Tranberg et al. 2013). Several key unanswered questions are; could whey proteins 
specifically influence the gut microbiota composition associated with prolonged 
high fat feeding, and would any changes relate to energy balance? Could changes to 
protein to carbohydrate ratio within a HFD vary the gut microbiota profile and 
energy balance in a different way to changes to protein quality? 
To assess WPI specific effects on above parameters, we subjected male 
C57BL/6J mice to 21 weeks of either a low fat diet (LFD) with 20% kJ casein or a 
HFD with 20% kJ casein or WPI. In addition, using two additional HFD dietary 
groups on 30 or 40% kJ WPI, we evaluated the impact of increasing the protein to 
carbohydrate (P/C) ratio within the HFD on parameters of interest. Our data show 
that WPI has a specific effect on energy balance and gut microbiota, while 
increasing the P/C ratio within the HFD leads to dramatic alterations in energy 
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balance, body composition, metabolic health and the composition of the gut 
microbiota.  
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2.3 MATERIALS AND METHODS 
2.3.1 Ethics Statement 
All research involving mice was licensed under the Cruelty to Animal Act 1876 and 
received ethical approval from the University College Cork Animal Ethics Review 
Committee (#2011/005). 
2.3.2 Animals 
Male 3-4 week old C57BL/6J mice (Harlan, Oxon, UK) were group housed either 5 
per cage (Study 1) or 4 per cage (Study 2) in individually ventilated cages and 
acclimatised for four weeks in a light (06:00-18:00), temperature (21 ± 1
o
C) and 
humidity (45-65%) controlled environment with free access to water and a low fat 
diet (LFD; 10% kJ fat and 20% kJ casein; #D12450, Research diets; New 
Brunswick, NJ, USA).  
2.3.3 Experimental protocol 
Two studies were performed to assess how the WPI-derived energy content within a 
HFD (study 1) or LFD (study 2) impacts on energy balance-related parameters in 
mice over a 21  week (study 1) or 7 week period (study 2). 
Study 1: Following the acclimatisation period, weight-matched dietary 
groups were maintained on the LFD or switched to either a HFD (45% kJ fat and 
20% kJ casein; #D12451) or a HFD with WPI (Alacen
tm
 895 NZMP, New Zealand) 
at an energy content of  20% kJ (HFD-20% WPI), 30% kJ (HFD-30% WPI) or 40% 
kJ (HFD-40% WPI) (Supplementary table 1) (n = 10) for a total of 21 weeks. Body 
weights were measured weekly. Energy intake in group housed mice was measured 
by weighing the food hopper each week until week 16. During weeks 17-20, energy 
intake and metabolic activity in individual mice was measured using TSE 
Phenomaster cages (TSE systems, Bad Homburg, Germany). Following this analysis 
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and prior to re-housing the mice in home cages, faecal pellets were collected from 
individual mice for examination of microbial composition via pyrosequencing and 
subsequent bioinformatic analysis. At the end of the experimental period, mice were 
fasted for 6 hours and the body composition was measured using the Bruker 
minispec LF50H (Bruker optics, Ettlingen, Germany). Mice were then anesthetised 
using ketamine (65mg/kg bodyweight) and xylazine (13mg/kg bodyweight). Blood 
was collected from anesthetised mice into vacutinater EDTA tubes (BD, USA) and 
treated with Aprotinin (500,000 KIU/L final concentration; Sigma, Ireland) and 
Diprotin A (0.1mM final concentration; Sigma, Ireland) to protect plasma peptides 
from proteolytic degradation. Plasma was isolated from blood by centrifugation at 
2000rpm at 4
o
C for 15 mins. Mice were sacrificed by cervical dislocation, and 
tissues of interest were dissected and snap frozen in liquid nitrogen (liver, adipose 
and stomach) or on dry ice (brain). Plasma and tissue samples were stored at -80
o
C 
until analysis.  
Study 2: Weight matched mice were provided for 7 weeks with either the 
LFD or a LFD with WPI replacing the casein protein (LFD-WPI; 10% kJ fat and 
20% kJ WPI) (n = 8). Body weights were measured weekly. Energy intake and 
metabolic activity in individual mice was measured during weeks 5 and 6 using the 
TSE Phenomaster system. After the analysis, mice were re-housed, as before, in the 
home cages and the experiment was terminated at the end of week 7. 
2.3.4 Analysis of metabolic parameters 
The TSE Phenomaster cages comprised an open-circuit indirect calorimetry system 
with gas sensing units to measure oxygen consumption (ml/h/kg) (VO2) and CO2 
production (ml/h/kg) (VCO2). The cages also contained high precision sensor 
associated-feeding baskets to accurately measure food intake (g), with a meal 
110 
 
defined as intake over 0.01g. A multi-dimensional infrared beam system allowed the 
measurement of locomotor activity, which was defined as the total number of 
infrared beam breaks in the X and Y axis. Mice were singly housed in TSE 
Phenomaster cages for a total of 3 days, with data collected during the final 24 
hours, following a 2 day acclimatisation to the new cage environment. The 
acclimatisation period was established based on the data from our previous study 
(McAllan et al. 2013). Heat production (kcal/h/kg) in individual mice was calculated 
using the Weir equation (3.941 × VO2 + 1.106 × VCO2)(Weir 1949)), and this was 
converted to kJ/h/kg using 1kcal = 4.184 kJ. The respiratory exchange ratio (RER) 
was calculated by VCO2/VO2. Energy intake was calculated from food intake 
measurements using the energy content of the diets supplied by the manufacturer. 
2.3.5 Microbial DNA extraction, amplification and high throughput DNA 
sequencing 
Total metagenomic DNA was extracted from individual faecal samples using QIamp 
DNA Stool Mini Kit (Qiagen, Hilden, Germany), after an additional bead-beating 
step. Bacterial composition was determined by sequencing of 16S rRNA amplicons 
(V4-V5 region; 408nt long) generated by a separate PCR reaction for each sample 
(in triplicate) using universal 16S primers, where, the forward primer (5’-
AYTGGGYDTAAAGNG), with attached molecular identifier tags between 454 
adapter sequence and target-specific primer sequence, and reverse primer V5 (5’-
CCGTCAATTYYTTTRAGTTT) (Claesson et al. 2010), were used along with 
Biomix Red (Bioline, London UK). The template DNA was amplified under the 
following PCR conditions for a total of 35 cycles: 94˚C for 2 minutes and 1 minute 
respectively (initialization and denaturation), 56˚C for 60 seconds (annealing) and 
72˚C for 60 seconds (elongation), proceeded by a final elongation stage of 2 
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minutes. Negative control reactions with PCR grade water in place of template DNA 
were used to confirm a lack of contamination. Amplicons were pooled and cleaned 
using the AMPure XP purification system (Beckman and Coulter, Takeley, UK) and 
DNA concentration was determined using the NANODROP 3300 
Fluorospectrometer (Thermo Scientific, USA) coupled with the Quant-it™ 
Picogreen® dsDNA Assay Kit (Invitrogen, Paisley, UK). Equal volumes of each 
sample were then pooled together and underwent a final cleaning and quantification 
stage. Amplicons were sequenced in-house on a Roche GS FLX Titanium platform. 
2.3.6 Bioinformatics 
Raw sequencing reads were ‘de-noised’ using traditional techniques implemented in 
the Ribosomal Database Project Pyrosequencing (RDP) Pipeline with ambiguous 
bases, non exact primer matches and reads shorter than 150bp being excluded. 
Trimmed FASTA files were then BLASTed against a previously published 16S-
specific database using default parameters. The resulting files were then parsed 
using the MEGAN software package, which assigns reads to the National Centre for 
Biotechnology Information (NCBI) taxonomies via the lowest common ancestor 
algorithm. Results were filtered prior to tree construction and summarization by the 
use of bit scores from within MEGAN where a cut-off bit score of 86 was employed 
(Urich et al. 2008, Rea et al. 2011). The QIIME software suite was employed to 
achieve clustering of sequence reads into operational taxonomic units (OTUs) 
(Caporaso et al. 2010). Chimeric OTUs were removed using the ChimeraSlayer 
program (Haas et al. 2011) and phylogenetic trees constructed using the FastTreeMP 
tool (Price et al. 2010). Beta diversity values were calculated based on Bray Curtis, 
weighted and unweighted UniFrac distances, and the KING viewer was used to 
visualise resulting PCoA plots (Huson et al. 2007, Chen et al. 2009). Sequence reads 
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were deposited in the European Nucleotide Archive (EHA) under the accession 
number PRJEB4636. 
2.3.7 Plasma analysis 
Colorimetric assays were used to measure plasma levels of glucose (Calibochem, 
Darmstadt, Germany), triacylglycerol (TAG; Wako Chemicals, Richmond, VI, 
USA) and non-esterified fatty acids (NEFA; Abcam, Cambridge, UK). 
Commercially available ELISA kits were used to analyse plasma levels of insulin, 
leptin (Crystal Chem, Downers Grove, IL, USA), glucagon-like peptide 1 (GLP-1; 
Millipore, St. Charles, MO, USA) and corticosterone (Enzo Life sciences, 
Farmingdale, NY, USA). The homeostasis model assessment of insulin resistance 
(HOMA-IR) was determined using the formula: fasting plasma insulin (µU/ml) × 
fasting plasma glucose (mmol/L)/ 22.5 (Matthews et al. 1985).  To measure plasma 
amino acid levels, samples were first deproteinised by mixing with equal volumes of 
24% (w/v) tri-chloroacetic acid. The samples were then allowed to stand for 10 
minutes before been centrifuged at 14400 x g (Microcentaur, MSE, UK) for 10 
minutes. Supernatants were mixed with 0.2 M sodium citrate buffer, pH 2.2, and the 
plasma concentration of amino acids were quantified using a Jeol JLC-500/V amino 
acid analyser (Jeol Ltd., Garden city, UK) fitted with a Jeol Na
+
 high performance 
cation exchange column. 
2.3.8 Liver TAG analysis 
Total lipids from liver samples (approx. 50mg) were extracted as described 
previously (McAllan et al. 2013) using the Folch extraction method (Folch et al. 
1957). Briefly, total lipids were extracted using 2:1 (v/v) chloroform: methanol 
solution, into which a 0.88% NaCl solution was added before centrifugation at 
2000rpm and 4
o
C for 30mins. Aliquots of the organic phase were collected, dried 
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and re-suspended in the LabAssay TAG reagent (Wako Chemicals, Richmond, VI, 
USA) to measure TAG levels using LabAssay TAG kit according the 
manufacturer’s protocol.  
2.3.9 Real-Time PCR analysis 
Total RNA was isolated from tissues using RNeasy mini (liver and stomach) or 
RNeasy lipid mini (adipose and hypothalamus) kits (Qiagen, Hilden, Germany) 
according to manufacturers’ instructions. RNA was treated with DNase (Qiagen, 
Hilden, Germany) during RNA isolation to eliminate any possible genomic DNA 
contamination. Reverse transcription of 1μg of RNA was performed using 2.5ng/µl 
random hexamer primers (Bioline, London, UK), 0.5mM dNTP (Promega, Madison, 
VI, USA), 2U/μl RNase inhibitor (Promega, Madison, VI, USA), and the Superscript 
II first stand system (Invitrogen, Carlsbad, CA, USA) according to manufactures’ 
instructions. Gene expression was measured by the Roche Lightcycler 480 system 
(Rotkreuz, Switzerland) via amplification of 1μl complementary DNA using the 
Lightcycler SYBR Green I Mastermix kit (Roche, Penzberg, Germany) and 2.5μM 
gene specific primers (Eurofins MWG operon, Ebersberg, Germany) in a 10μl total 
reaction volume. Primer sequences used are listed in supplementary table 2. PCR 
conditions were; 10mins at 95
o
C, followed by 50 cycles of 95
o
C for 10s, 58-65
o
C for 
5s and 72
o
C for 15s.  Authenticity of PCR products was determined by melting 
curve analysis and by automated sequencing. Crossing point (Cp) of fluorescence 
signals were used to calculate target gene expression by 2
-ΔΔCp
, following 
normalisation against housekeeping gene according to ΔΔCp= ΔCp target gene – 
ΔCp housekeeping gene. Housekeeping genes used were β-actin (liver, stomach and 
hypothalamus), YWHAZ (liver and hypothalamus), 18-S (adipose) and 
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glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (adipose and stomach).  
Relative gene expression is shown compared to the LFD group. 
2.3.10 Statistical analysis 
Data are expressed as means ± standard error of the mean (SEM). Differences 
between experimental dietary groups were analysed by one-way or two-way 
ANOVA followed by pairwise comparisons using tukey or bonferroni post hoc tests 
respectively. Body weight trajectories were analysed by two-way repeated measures 
ANOVA with bonferroni post hoc tests. Non-parametric data was compared by 
Kruskal-Wallis ANOVA followed by Dunn’s pairwise comparisons. Significance 
levels were set at P ≤ 0.05, and statistical analysis was performed using Graphpad 
prism (ver. 5.04; San Diego, CA, USA) and Minitab (ver.15; State College, PA, 
USA). 
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2.4 RESULTS 
2.4.1 WPI inclusion or increasing the P/C ratio within a HFD alters body 
composition and plasma amino acids 
Fig. 1A-B demonstrates that body weight gain of HFD-20%WPI fed mice was 
similar to HFD controls. However, intake of WPI was seen to have a specific effect 
on body composition, with HFD-20% WPI fed mice having an increased lean mass 
(%) (P < 0.05), and a trend towards a reduction in fat mass (%) (P = 0.08) compared 
to the HFD control group. Increasing the WPI derived energy content in the HFD to 
40% and proportionally reducing the carbohydrate energy content led to a significant 
reduction in body weight gain compared to all other HFD-WPI groups (P < 0.001), 
with observed values similar to that seen for the LFD group. This was accompanied 
by significantly reduced body fat mass and increased lean mass levels in the HFD-
40% WPI fed mice compared to HFD control and other WPI diets groups (P < 
0.001), while the body composition of HFD-30% WPI group did not differ from that 
of the HFD-20% WPI group (Fig. 1C).  
Comparison of the plasma amino acid profiles including those that could 
influence lean and fat mass, revealed an impact of WPI and the P/C ratio (Table 1). 
WPI specific effects were observed on glutamic acid, aspartic acid and glycine, 
which either decreased (glutamic acid and aspartic acid) or increased (glycine) 
compared to HFD fed mice (P < 0.05) (Table 1). Changes in macronutrient ratio in 
HFD-40%WPI, decreased plasma histidine, phenylalanine, serine and threonine 
levels compared to the lowest P/C ratio (20% WPI) (P < 0.01) (Table 1).  
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2.4.2 WPI-enriched HFD normalised energy intake, while increasing the P/C 
ratio accentuated metabolism 
The cumulative energy intake (MJ) for the dietary groups (2 cages/group, all with 
n=5 mice), measured over the first 16 weeks did not differ between LFD, HFD and 
HFD-20% WPI groups (24.73 ± 2.70 vs. 27.69 ± 1.54 vs. 29.40 ± 0.31 respectively). 
In contrast data gathered by individually housing the mice in TSE Phenomaster 
cages in week 17-20 demonstrated that the energy intake of the HFD-WPI groups 
was greater than that of the HFD control group during both the light and dark phases 
(P < 0.05), while being similar to that of the LFD group (Fig. 2A). Increasing the 
P/C ratio had no significant effect on cumulative energy intake (MJ) in HFD fed 
mice (20%WPI, 29.40 ±0.31 vs. 30%WPI, 30.01 ± 0.62 vs. 40%WPI, 26.71 ± 0.15). 
Energy intake measurements from TSE Phenomaster cages corroborated this data 
(Fig 2A). There was also no significant effect on meal number or meal size of 
altering the P/C ratio (i.e. between WPI groups; Fig 2B-C). 
The HFD-20% WPI diet had no impact on VO2, heat production, locomotor 
activity or respiratory exchange ratio (RER) when compared to HFD fed mice (Fig. 
3A-D) Increasing the P/C ratio was found to impact on energy expenditure with 
HFD-40% WPI fed mice having significantly increased levels of dark phase VO2 
compared to HFD-20 and 30% WPI fed mice (P < 0.001) (Fig 3A). A similar 
change in heat production was observed between the groups, albeit data was only 
significant between HFD-40% and HFD-30% WPI groups (P < 0.05) (Fig 3B). 
There was no effect of WPI or P/C ratio on locomotor activity (Fig 3C). RER values 
of all HFD groups were lower than the LFD group in both the light and dark phases, 
consistent with increased fat metabolism (P < 0.001) (Fig 3D).  
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Investigation of the above parameters in mice fed a LFD with WPI or casein 
for 7 weeks (study 2) revealed that WPI does not influence body weight, energy 
intake, VO2, locomotor activity or RER in a low fat background (Supplementary 
Figure 1A-D). 
2.4.3 Increasing the protein to carbohydrate ratio attenuated adverse metabolic 
impact of HFD 
Specific effects of WPI and the P/C ratio were observed on lipid metabolism-
related gene expression and on tissue lipid deposition. Firstly, the decrease in 
epididymal adipose tissue fatty acid synthase (FASN) mRNA expression with HFD 
feeding, was somewhat attenuated by WPI challenge (P < 0.05), with no added 
benefit of increasing the P/C ratio on expression of this gene (Fig 4A). Notably, the 
epididymal mRNA expression of a number of other genes were altered by the P/C 
ratio, specifically, fatty acid transporter 1 (FATP1), beta-3 adrenergic receptor (β3-
AR), peroxisome proliferator-activated receptor gamma (PPARγ), uncoupling 
protein 2 (UCP-2) and lipoprotein lipase (LPL) (P ≤ 0.05) (Fig 4). In the liver, WPI 
specifically reduced TAG levels (Table 2) and the mRNA expression of fatty acid 
binding protein 1 (FABP1) compared to HFD fed mice (Table 3). The highest P/C 
ratio (40% WPI) significantly decreased mRNA levels of cluster of differentiation 
36 (CD36) and PPARγ group (P < 0.05) (Table 3), dramatically reduced liver TAG 
levels compared to 20/30% WPI fed mice (Table 2), and normalised the elevated 
plasma levels of TAG and NEFA observed with HFD feeding (P ≤ 0.05) (Table 2). 
Finally, the mRNA level of lipid metabolism-related carnitine palmitoyltransferase 
1a-c (CPT1a-c), fatty acid transport protein 5 (FATP5) and PPARα, in tissues of 
interest, was not influenced by the dietary challenges (Tables 3-4). 
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Increasing the P/C ratio reduced plasma glucose levels, particularly in the 
40% WPI group (P < 0.05) (Table 2). In parallel HOMA-IR values were also 
reduced (P < 0.05), but the change in plasma insulin concentration did not reach 
statistical significance (Table 2). At a cellular level, the highest P/C ratio normalised 
the HFD-induced reduction in adipose expression of insulin receptor (IR) and insulin 
receptor substrate 1 (IRS-1), and partially prevented the HFD-induced reduction in 
glucose transporter 4 (GLUT4) (Fig. 4B) (P < 0.001). In the hypothalamus, WPI 
specifically increased IR mRNA expression (P < 0.05), as did P/C ratio, with the 
highest P/C ratio having the greatest impact (Table 4). Epididymal adipose tissue 
mRNA expression of inflammatory markers, namely tumour necrosis factor (TNF)-α 
and cluster of differentiation (CD) 68 only responded to the highest P/C ratio, which 
significantly reduced the expression of both in a HF background (Fig. 4B) (P < 
0.001). In the hypothalamus, whilst TNFα mRNA was elevated by HFD feeding, 
neither WPI nor the P/C ratio influenced its levels, although there was a trend 
towards a decrease for the highest P/C ratio (40% WPI) (Table 4). None of the 
dietary challenges influenced hepatic glucose transporter 2 (GLUT2), IRS-1 and 
TNF-α mRNA expression (Table 3) or hypothalamic IRS-1 mRNA expression 
(Table 4). 
The increased plasma leptin concentration in response to the HFD was 
significantly blunted by WPI intake with dramatic reductions seen at the highest P/C 
ratio (P < 0.001) (Table 2). Yet, the hypothalamic expression of genes known to be 
responsive to plasma leptin levels were unaffected, specifically mRNA levels of 
leptin receptor (ObR), pro-opiomelanocortin (POMC), neuropeptide Y (NPY) and 
growth hormone secretagogue receptor (GHS-R) (Table 4). In addition, gastric 
mRNA expression for the orexigenic hormone ghrelin was not found to significantly 
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differ between all dietary treatment groups (1.00±0.37, LFD vs. 1.11 ±0.40, HFD vs. 
0.73±0.35, 20%-WPI vs. 0.29±0.28, 30%-WPI vs. 1.07 ± 0.45, 40%-WPI). Plasma 
corticosterone levels were also elevated with HF feeding, but were not influenced by 
protein source (WPI or casein) or P/C ratio (Table 2). Similarly, there was no effect 
of WPI on the HFD-associated suppression of adipose 11β-hydroxysteroid 
dehydrogenase type 1 (11βHSD1) (Fig 4B), or the HFD-induced increase in 
glucocorticoid receptor (GCCR) in the hypothalamus (Table 4). 
2.4.4 WPI inclusion or increasing the P/C ratio within a HFD altered the 
composition of gut microbiota  
A total of 251,395 V4-V5 16S rRNA sequence reads were generated which 
corresponded to an average of 50,279 reads per diet group or 5,130 reads per animal. 
α-diversity values were calculated for biodiversity (Shannon index), species richness 
(Chao1) and the number of species relative to the abundance in the sample (Simpson 
diversity index). When α-diversity values were compared by diet group, the only 
difference observed was a significantly higher microbial richness (Chao1) within the 
HFD microbiota compared to the HFD-30% WPI (P = 0.028). Principal coordinate 
analysis (based on unweighted UniFrac distances) (Fig. 5) of the sequence data 
highlighted a clustering of the LFD, HFD and HFD-20% WPI group microbial 
populations, while HFD-30% and 40% WPI groups clustered in a close proximity to 
each other and distinctly from the LFD, HFD and HFD-20% WPI group clusters. 
Indeed, the LFD diet with casein as a protein source clustered most closely with the 
HFD containing the casein protein. 
Phylogenetic analysis revealed several significant microbial population shifts 
between the HFD control and WPI groups (Table 5). At the family level, all WPI 
diet groups had significantly increased proportions of Lactobacillaceae and 
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significantly decreased proportions of Clostridiaceae compared to the HFD control 
group. Bifidobacteriaceae populations were increased in both the HFD-20% WPI 
and HFD-30% WPI diet groups compared to the HFD control, while in contrast they 
were significantly lower in the HFD-40% WPI group compared to the HFD control. 
The aforementioned patterns were also observed with respect to the corresponding 
genera (Lactobacillus, Clostridium and Bifidobacterium respectively) (Table 5). 
Also at genus level, proportions of Rikenella were significantly higher in the HFD-
40% WPI group compared to HFD-20/30% WPI groups, while proportions of 
Peptostreptococcus were significantly higher in the HFD-40% WPI group than in 
any other diet group (Table 5). Specific comparison of the microbiota of the HFD-
20% WPI and HFD control was deemed particularly important given that the 
changes occurring here reflected changes resulting specifically from the presence of 
whey protein, rather than casein, in the diet, and not simply a change in the P/C ratio 
in the diet. In addition to the changes in the Lactobacillus, Clostridium and 
Bifidobacterium populations (and associated families) referred to above, it was also 
noted that proportions of Desulfovibrio and Mucisprillum (genus) were increased in 
the HFD-20% WPI, relative to HFD control animals. 
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2.5 DISCUSSION 
The key findings of this study are that WPI has a specific effect on HFD-induced 
energy intake, metabolic health and gut microbiota composition. Additionally, with 
the exception of energy intake, increasing the P/C ratio, by increasing WPI dietary 
content, was seen to dramatically alter the above parameters. 
Cumulative energy intake measured up to week 16 did not differ between LFD and 
HFD fed mice. While this is consistent with data reported elsewhere (Pilvi et al. 
2007), HF feeding has also been shown to increase or decrease energy intake in 
rodents (Sclafani et al. 1993, Lin et al. 2000). Differences between data reported 
may relate to variances in diet composition including fat source/composition, or it 
may be due to differences in the palatability of the LFD used as the control (Sclafani 
et al. 1993, West and York 1998). 
 In this study, there was a discrepancy in energy intake in HFD fed mice depending 
on the housing environment (single or group housed). In contrast to the group house 
environment up to week 16, HFD fed mice when individually housed in metabolic 
cages during weeks 17-20 showed a hypophagic response compared to LFD fed 
mice. It is possible that these differences may be related to the accuracy of the 
method used to measure food intake in group versus single housed mice, or 
alternatively, the different behavioural responses could be result of social isolation, 
which has been shown to decrease energy intake and elevate plasma corticosterone 
levels (Saegusa et al. 2011). However, in the latter study this response was found to 
be transient in nature as socially isolated mice adapted to the new environment and 
ate similar as grouped housed mice 6 hr post-novelty stress. Indeed, we also showed 
that group housed mice on a LFD when placed in isolation adapt to the new 
environment and continue to consume similar food in day 2 and 3 in the new 
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location [8]. In contrast to mice fed a LFD, mice on a HFD are known to have an 
over-active hypothalamic-pituitary-adrenal axis (Dallman 2010) resulting in elevated 
plasma corticosterone levels, as demonstrated here. Consequently, in a HFD 
background, it’s possible that social isolation-induced stress responses could have 
had a greater impact on energy intake with effects lasting up to or even beyond the 3 
day housing period as used in this study.  Irrespective of the underlying cause of the 
hypophagic response in HFD mice, replacing the casein protein with an equivalent 
WPI content normalised energy intake in HFD-fed mice in a manner similar to that 
observed in our previous study (McAllan et al. 2013). This appeared to be due to a 
WPI specific effect on the HFD-induced neuroendocrine state because mice on the 
LFD with WPI showed similar energy intake to casein diet-fed controls. Since 
neither WPI nor increasing the P/C ratio influenced plasma corticosterone levels, 
adipose expression of 11β-HSD1 or hypothalamic expression of GCCR in HFD fed 
mice, it is unlikely that these behavioural changes were due to a WPI effect on stress 
responses. Given that leptin decreases meal size and number (Hulsey et al. 1998, 
Bady et al. 2006, Brown et al. 2006), and WPI reduced the HFD-induced increase in 
plasma leptin levels, it’s possible that WPI-derived bioactives could have 
specifically influenced circadian rhythm of leptin production and/or action within 
the neuroendocrine state of HFD-fed mice in a socially isolated environment. 
Additionally, the reduction in plasma amino acids associated with WPI intake (see 
below), could also have acted as a possible central trigger to increase energy intake 
in WPI groups compared to HFD control in the single house environment.  
HFD feeding has been shown to cause a gain of weight in rats up to the duration of a 
test period lasting 76 weeks, with animal’s body weight gain responding to changes 
to the dietary fat content introduced at various time points (Peckham et al. 1962). 
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Lin et al., (Lin et al. 2000) demonstrated that mice on a HFD for 19 weeks are 
responsive to intracerebroventricular administration of leptin. These data suggest 
that energy balance related mechanisms are able to respond to energetic challenges 
even after prolonged high fat intake. High protein intake within a HFD suppresses 
energy intake (Pichon et al. 2006, Freudenberg et al. 2012) albeit not consistently 
(Shertzer et al. 2011, Schwarz et al. 2012), and in our study, the P/C ratio did not 
alter energy intake in either housing environment. This could be a result of the 
quantity or composition of the macronutrient used in the test diets. Indeed, data from 
human trials showed that increasing protein dietary content (10/15% to 30%) only 
decreased energy intake when the carbohydrate content was kept constant (Weigle et 
al. 2005, Blatt et al. 2011). This further highlights the importance of designing 
appropriate experimental diets with the correct macronutrient composition for 
uncovering the energy balance related impact of the dietary component under 
investigation. 
Replacement of the casein protein with an equivalent energy content of WPI (i.e. 
20%) did not specifically alter metabolic activity, heat production or locomotor 
activity in HFD or LFD fed mice. In contrast, Acheson et al., (Acheson et al. 2011) 
showed that whey has a greater thermic effect than casein or soy in humans. These 
differences in data may be related to the fact that the latter study only investigated an 
acute post-prandial response to a defined test meal, or it may relate to how different 
species (humans versus mice) digest and metabolise dietary proteins. Shetzer et al, 
found that mice consuming a HFD and WPI supplemented drinking water have 
enhanced oxygen consumption compared to mice drinking unsupplemented water 
(Shertzer et al. 2011). In this instance, the increased metabolic activity may have 
arisen due to the increased protein intake (proteins from diet and from water 
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supplemented WPI). In fact, this corroborates with the data presented here, which 
show that increasing the P/C ratio resulted in increased energy expenditure (VO2 and 
heat production) and dark phase locomotors activity, resulting presumably from the 
increased catabolism of ingested dietary protein, coupled with thermic effects of 
WPI compared to casein (Acheson et al. 2011) and/or due to increased deposition of 
lean mass with WPI content  (Tipton et al. 2007, Pennings et al. 2011, Kanda et al. 
2013). Interestingly, Zhang et al. (Zhang et al. 2007) showed that HFD fed mice on 
leucine supplemented drinking water have reduced fasting plasma levels of aspartic 
acid, glutamic acid, and phenylalanine, as well as increased VO2 and reduced 
adiposity compared to HFD controls. Given the influence of leucine on WPI-induced 
muscle hypertrophy (Rieu et al. 2007, Norton et al. 2012) and its unique ability to 
regulate the translation of protein synthesis (Norton and Layman 2006), it is possible 
that the elevated leucine content found normally in the WPI diets may have 
enhanced muscle protein synthesis by directing other amino acids towards protein 
synthesis and/or catabolism, with the required energy (Garlick et al. 1999, Bender 
2012) been derived possibly from fat catabolism (McAllan et al. 2013). Consistent 
with the latter suggestion, we found an increased lean mass and a reduced fat mass 
with decreased plasma levels of several amino acids, but not leucine, when the 
casein protein in a HFD was replaced with WPI or when the WPI P/C ratio in the 
HFD was increased. 
WPI intake appeared to cause a trend towards reduction in fat mass, and in the liver 
this manifested as a WPI specific reduction in TAG levels, which was accompanied 
by the suppression of FABP1 mRNA expression, similar to previous findings (Pilvi 
et al. 2008, Hamad et al. 2011, Shertzer et al. 2011, Shi et al. 2011). In the 
epididymal adipose tissue, WPI prevented the HFD-induced FASN gene expression, 
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albeit a recent study reported that WPI does not affect the weight of the epididymal 
tissue in HFD fed mice, but instead cause a reduction in subcutaneous fat pad weight 
(Tranberg et al. 2013). These data suggest that WPI affects cellular activity in the 
liver and in specific adipose tissue depots. While it has been suggested that whey 
protein may facilitate enhanced postprandial chylomicron clearance via an alteration 
in LPL expression/activity (Mortensen et al. 2009, Pal et al. 2010), here we did not 
find a WPI specific effect on LPL expression or plasma TAG levels, but we did 
observe that intake of the highest P/C ratio (40%-WPI) led to an increase adipose 
tissue LPL mRNA expression which was accompanied by significant reduction in 
plasma TAG levels, and a complete reversal of genes involved in lipid accumulation 
(PPARγ), fatty acid transport (FATP1), and lipolysis (β3-AR). Given that HF 
feeding/obesity down-regulates β3-AR mRNA expression (Collins et al. 1999), our 
data suggests an increased adipocyte lipolysis, and reduction in adipose TAG storage 
in HFD-40%WPI fed mice. Yet the endogenous CPT1b-associated β-oxidation 
pathway and the UCP-2-associated pathway in epididymal adipose tissue seem to be 
unaffected (CTP1b) or suppressed (UCP-2) by raising the P/C ratio. This data raises 
the possibility that the free fatty acids generated from the potentially increased 
availability of β3-AR in the adipose may have been re-directed for utilisation by 
other physiological processes active in HFD-40% group, leading to the increased 
metabolic activity (VO2) observed in the animals. It is also noteworthy that WPI has 
been shown to increase faecal fat excretion compared to casein (Pilvi et al. 2007), 
which may have also contributed to the decreased plasma TAG and NEFA seen here 
with intake of the highest P/C ratio diet (HFD-40%WPI).  
Given the link between HFD-induced obesity, low-grade inflammation and insulin 
resistance (Gustafson et al. 2009, McGillicuddy et al. 2011), one could argue that the 
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dramatic reduction in fat mass observed with the highest P/C ratio may underlie the 
effects on inflammatory markers in the adipose tissue (TNFα and CD68) and the 
hypothalamus (TNFα), along with simultaneous changes in expression of genes 
involved in insulin signalling (INSR, IRS-1 and GLUT4 in the adipose, IRS-1 in 
liver and INSR in the hypothalamus), and the reduction in plasma glucose in these 
mice. Improvements to insulin sensitivity with WPI have been reported previously 
(Belobrajdic et al. 2004, Pichon et al. 2008), but our data suggested that only an 
increased P/C ratio in the HFD facilitated improvements to insulin signalling 
pathway associated gene expression with prolong high fat feeding, particularly in the 
adipose, in parallel with  reduced HOMA-IR values.  
While many of the effects described above may be due to direct WPI or P/C ratio-
host interactions, the effect of WPI and P/C ratio on the composition of the gut 
microbiota may also play an important role in adiposity and weight gain in these 
animals. Here, high throughput sequencing based analyses of faecal microbial 
populations revealed the clustering of the microbiota from animals in receipt of 30 
and 40% WPI diets away from those in receipt of 20% kJ WPI or HFD-casein diets. 
Tranberg et al (Tranberg et al. 2013) recently suggested that the efficient absorption 
of dairy whey proteins in the small intestine may explain the absence of changes in 
the faecal microbiota. This may explain the clustering of the microbiota from 
animals fed 20% WPI or HFD-casein diets in our study. However, it is apparent that 
the high concentrations of WPI present in the 30 and 40% WPI diets employed in 
our study had a more profound effect, possibly due to additional whey proteins 
finding their way to the large intestine and/or the overall change in the P/C ratio in 
the diet. Consumption of the 30 and 40% WPI diets did not result in a shift in the 
microbiota toward that of the LFD animals and thus the effects on weight gain are 
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not simply due to an overall conversion to a LFD-like microbiota. Specific 
taxonomic changes were also noted in response to the different diets. In all cases 
dietary WPI resulted in significant increases in Lactobacillaceae/Lactobacillus and 
decreases in Clostridiaceae/Clostridium. Increased proportions of Lactobacillus 
have previously also been observed in a study of individuals following a regime of 
calorie restriction and exercise (Santacruz et al. 2009).  However, in contrast, 
increased proportions of Lactobacillus have also been noted in HFD fed rats (Parnell 
and Reimer 2012) and diet-induced obese mice (Clarke et al. 2013). While specific 
species of Lactobacillus have been associated with both lean and obese gut 
microbiota profiles and also to play a role in obesity and immune response 
regulation (Ouwehand et al. 1999, Erickson and Hubbard 2000, Armougom et al. 
2009), due to the length of the 16S sequences generated and the high degree of 
sequence homology, we cannot assess changes in proportions of Lactobacillus at the 
species level. An increase in the proportions of Bifidobacteriaceae/Bifidobacterium 
was also observed in both the HFD-20% WPI and HFD-30% WPI compared to the 
HFD group. This result, combined with the aforementioned increases in 
Lactobacillaceae/Lactobacillus, mirror those reported by Sprong et al  who suggest 
that whey proteins act as grow factors for certain species of bacteria by an amino 
acid composition mediated mechanism (Sprong et al. 2010). Our observations are 
also consistent with previous findings that high proportions of the class Clostridiales 
are associated with the gut microbiota of animals fed a HFD (Hildebrandt et al. 
2009), while fasting reduces the levels of Clostridium (Sonoyama et al. 2009). 
Notably, Clostridiaceae can produce short chain fatty acids as a product of their 
metabolism (Sousa et al. 2007), which can play an important role in the regulation of 
immune cells and has been associated with inflammation and obesity (Schwiertz et 
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al. 2010). These differences, as well as others in the Proteobacteria Actinobacteria 
Deferribacteres (phylum), Desulfovibrionaceae Deferribacteraceae Veillonellaceae 
(family), Desulfovibrio and Mucispirillum taxa in the HFD-20% whey protein, 
relative to HFD controls (20% casein) are particularly notable as these reflect 
changes resulting from the specific presence of whey proteins in the diet, in place of 
casein, rather than changes in the P/C ratio. Changes in relative proportions may be 
attributed to (a) the ability of bacteria to utilise whey proteins as a growth medium, 
(b) the anti-microbial activity of whey protein/peptide components, (c) decreased 
competition as a result of the whey proteins/peptides antimicrobial activity or (d) 
even to whey protein mediated changes in the host. Ultimately, the question of cause 
versus effect remains unanswered, and so while the changes to the microbiota 
observed may contribute to the mechanisms involved in controlling weight gain, 
further studies with, for example germ free animals, will be required to determine 
this definitively. 
In summary, our results show that WPI specifically normalises energy intake, 
increases lean mass and cause a trend towards a reduction in fat mass associated 
with prolonged high fat feeding.  Raising the P/C ratio had no effect on energy 
intake but augmented metabolic activity and beneficially altered gene expression 
profiles for lipid metabolism, inflammation and insulin signalling, particularly in the 
adipose tissue. High throughput analysis of gut microbiota revealed distinct changes 
in microbial populations with increased P/C ratio causing clustering of 30/40% WPI 
groups together and distinct from those of HFD and 20% WPI groups, but with 
specific phylogenetic differences existing between the latter groups. These data 
indicate that changes to P/C ratio have a dramatic effect on energy balance and the 
composition of gut microbiota distinct from that seen with changes to protein source.  
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Future studies should focus on determining whether the effects demonstrated for 
highest P/C ratio are specific to the WPI content, a consequence of macronutrient 
change, or both.  
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Table 1. Plasma amino acid levels (µmol/L) in mice fed a 45%kJ high fat diet (HFD) or 
HFD with 20%, 30% or 40% kJ whey protein isolate (WPI) for 21 weeks
 
 
 
Data are means ± SEM (n = 7-10). In each row values without a common letter significantly 
differ, P < 0.05;NS, non-significant 
  
 1 
 HFD 20% WPI 30% WPI 40% WPI P value 
Alanine 170.91±8.82
a
 163.83±11.59
ab
 137.44±9.72
ab
 127.15±8.46
b
 <.05 
Arginine 41.74±4.82 38.41±7.16 56.39±7.60 39.08±4.34 NS 
Aspartic acid 7.47±1.25
a
 3.63±0.51
b
 3.49±0.51
b
 4.85±1.02
ab
 <.05 
Cyteine 11.95±1.34 8.87±1.37 8.93±1.33 7.86±1.72 NS 
Glutamic acid   90.76±3.42
a 
74.74±1.89
b 
75.25±1.86
b 
71.25±2.69
b 
<.001 
Glycine 106.22±4.28
a 
131.43±3.57
b 
116.45±4.52
ab 
131.92±2.69
b 
<.001 
Histidine 75.43±2.12
a 
74.93±2.98
a 
68.21±3.35
ab 
64.21±2.51
b 
<.05 
Isoleucine 213.81±8.87 207.87±9.09 195.27±5.74 186.78±10.17 NS 
Leucine 91.86±9.66 81.36±6.65 66.93±6.69 69.71±10.21 NS 
Lysine 113.81±5.88 108.18±8.30 102.57±8.39 88.29±4.07 NS 
Methionine 23.94±1.77 23.65±0.75 21.05±0.97 20.40±1.08 NS 
Phenylalanine 46.92±1.70
a 
41.13±1.13
ab 
38.23±1.52
bc 
33.30±2.35
c 
<.001 
Proline 118.26±10.14 127.63±9.63 106.04±11.02 104.39±11.93 NS 
Serine 68.18±5.69
ab 
74.98±2.29
a 
62.42±2.57
ab 
55.73±2.12
b 
<.01 
Threonine 92.71±2.93
a 
87.63±2.49
a 
78.29±2.95
ab 
69.28±3.96
b 
<.01 
Tyrosine 40.29±2.47
a 
36.37±1.12
ab 
33.76±1.54
ab 
29.63±2.77
b 
<.01 
Valine 154.51±8.65
a 
130.59±5.99
ab 
118.40±6.69
b 
113.16±9.49
b 
<.01 
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Table 2. Tissue lipid parameters and plasma levels of hormones and metabolites in 
mice fed a 10%kJ low fat diet (LFD), 45%kJ high fat diet (HFD) or HFD with 20%, 
30% or 40% kJ whey protein isolate (WPI) for 21 weeks 
 
Data are means ± SEM (n = 5-10). In each row results without a common letter 
significantly differ, P ≤ 0.05 NS, non-significant. 
TAG, triacylglycerol. NEFA, non-esterified fatty acids. GLP-1, glucagon-like peptide 
1. HOMA-IR, homeostasis model assessment of insulin resistance. 
  
 1 
 LFD HFD 20% WPI 30% WPI 40%WPI P value 
Liver TAG (mg/g tissue) 71.47±9.17
a
 139.03±6.92
b
 104.94±5.88
c
 107.21±8.83
c
 70.82±7.64
a
 <.001 
Leptin (ng/ml) 4.41±0.75
a
 84.69±3.17
b
 53.78±5.67
c
 51.12±4.69
c
 15.01±4.07
a
 <.001 
TAG (mg/dl) 39.85±2.91
a
 56.90±6.31
b
 45.15±4.32
ab
 52.36±3.91
ab
 40.19±3.96
a
 <.05 
NEFA (mmol/L) 0.37±0.09
a
 0.67±0.07
b
 0.64±0.05
b
 0.63±0.06
b
 0.36±0.05
a
 <.01 
Corticosterone (ng/ml) 150.0±21.7
a
 319.0±48.6
b
 286.8±31.9
ab
 334.1±36.7
b
 277.1±35.5
ab
 <.01 
GLP-1 (pM) 25.03±2.47 33.15±2.83 28.07±2.3 27.88±1.98 24.03±2.25 NS 
Glucose (mmol/L) 9.14±1.24
a
 15.68±0.83
b
 13.92±0.95
b
 14.08±1.05
b
 9.25±0.77
a
 <.001 
Insulin (ng/ml) 0.29±0.05 0.55±0.08 0.40±0.10 0.37±0.04 0.31±0.06 NS 
HOMA-IR 2.48±0.67
a 
9.79±1.07
b 
6.81±2.58
ab 
6.20±0.95
ab 
3.04±0.64
a 
<.01 
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Table 3. Relative hepatic gene expression in mice fed a 10%kJ low fat diet (LFD), 
45%kJ high fat diet (HFD) or HFD with 20%, 30% or 40% kJ whey protein isolate 
(WPI) for 21 weeks
 
 
Data are means ± SEM (n = 7-10). In each row results without a common letter 
significantly differ, P < 0.05; NS, non-significant. 
 
Gene expression shown relative to the LFD control group set at 1.00. 
CD36, cluster of differentiation 36; PPARγ, peroxisome proliferator activated 
receptor gamma; FABP1, Fatty acid binding protein 1; IRS-1, Insulin receptor 
substrate 1; CPT1a, carnitine palmitoyltransferase 1a; GLUT2, Glucose transporter 
2; FATP5, Fatty acid transporter 5; FASN, Fatty acid synthase; TNF-α, Tumour 
necrosis factor alpha. 
  
 1 
 LFD HFD 20% WPI 30% WPI 40% WPI P value 
CD36 1.00±0.20
a
 2.85±0.34
b
 2.98±0.45
b
 2.17±0.25
ab
 1.50±0.25
a
 <.05 
PPARγ 1.00±0.12a 3.00±0.57b 2.30±0.49b 1.88±0.46b 0.85±0.13a <.001 
FABP1 1.00±0.09
ab
 1.27±0.10
b
 0.86±0.06
ac
 1.27±0.17
bc
 0.71±0.09
a
 <.001 
IRS-1 1.00±0.15
a
 0.58±0.04
b
 0.69±0.05
ab
 0.68±0.06
ab
 0.79±0.06
ab
 <.01 
CPT1a 1.00±0.08 0.85±0.08 0.97±0.06 0.90±0.13 0.86±0.10 NS 
GLUT2 1.00±0.09 0.76±0.04 1.02±0.08 0.97±0.09 0.89±0.05 NS 
FATP5 1.00±0.21 0.89±0.07 0.88±0.07 1.16±0.07 1.24±0.12 NS 
FASN 1.00±0.36 0.46±0.14 0.54±0.19 0.40±0.06 0.32±0.04 NS 
PPARα 1.00±0.04 1.13±0.05 1.21±0.05 1.17±0.10 1.28±0.11 NS 
TNFα 1.00±0.26 0.84±0.15 1.12±0.18 0.80±0.09 0.71±0.10 NS 
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Table 4. Relative hypothalamic gene expression in mice fed a 10%kJ low fat diet 
(LFD), 45%kJ high fat diet (HFD) or HFD with 20%, 30% or 40% kJ whey protein 
isolate (WPI) for 21 weeks 
 
Data are means ± SEM (n = 5-10). In each row values without a common letter 
significantly differ, P < 0.05; NS, non-significant.  
Gene expression shown relative to the LFD control group set at 1.00.  
IR, Insulin receptor; GCCR, Glucorticoid receptor; TNF-α, Tumour necrosis factor 
alpha; POMC, Pro-opiomelancortin; NPY, Neuropeptide Y; ObR, Leptin receptor; 
GHS-R, Growth hormone secretatgogue receptor; PPARγ, peroxisome proliferator 
activated receptor gamma; CPT1c, carnitine palmitoyltransferase 1c IRS-1, Insulin 
receptor substrate 1. 
  
 1 
 LFD HFD 20% WPI 30% WPI 40% WPI P value 
IR 1.00±0.03
ab
 0.97±0.07
a
 1.22±0.04
bc
 1.37±0.04
cd
 1.55±0.08
d
 <.05 
GCCR 1.00±0.09
a
 1.40±0.10
b
 1.34±0.07
ab
 1.30±0.08
ab
 1.42±0.09
b
 <.05 
TNFα 1.00±0.05a 1.76±0.09b 1.57±0.13b 1.47±0.14ab 1.40±0.25ab <.01 
POMC 1.00±0.08 0.99±0.06 1.01±0.06 0.98±0.06 1.00±0.08 NS 
NPY 1.00±0.04 1.02±0.09 0.90±0.06 0.88±0.05 0.92±0.08 NS 
ObR 1.00±0.11 0.92±0.05 0.99±0.05 1.07±0.07 0.95±0.05 NS 
GHS-R 1.00±0.07 0.98±0.06 0.98±0.08 1.02±0.11 1.04±0.09 NS 
PPARγ 1.00±0.36 1.07±0.04 0.95±0.05 0.99±0.05 0.98±0.07 NS 
CPT1c 1.00±0.09 0.92±0.04 0.91±0.01 0.97±0.06 0.86±0.04 NS 
IRS-1 1.00±0.04 0.99±0.04 0.97±0.02 1.06±0.08 1.00±0.06 NS 
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Table 5. Gut microbiota composition as % of reads
 
in mice fed a 45%kJ high fat diet 
(HFD) or HFD with 20%, 30% or 40% kJ whey protein isolate (WPI) for 21 weeks
 
 
Data are means ± SEM (n = 10). Statistically significant differences generated using the 
Kruskal-Wallis algorithm. In each row values without a common letter significantly differ, P 
≤ 0.05.  
  
 HFD 20% WPI 30% WPI 40% WPI 
Phylum     
Proteobacteria 0.36
a 
0.63
b
 0.34
ab 
0.32
a 
Actinobacteria 0.63
a
 1.82
b
 3.79
b
 0.36
c 
Deferribacteres 0.57
a 
1.61
b
 1.56
ab 
2.03
b
 
     
Family     
Desulfovibrionaceae 0.12
a 
0.31
b
 0.21
ab 
0.23
ab 
Rikenellaceae 6.71
ab 
7.54
b
 3.9
a 
6.4
ab 
Bacteroidaceae 0.44
a
 0.42
a
 0.16
b 
0.21
b 
Lactobacillaceae 0.21
a 
3.03
b
 4.6
b
 2.14
b
 
Bifidobacteriaceae 0.43
a
 1.71
b
 3.66
b
 0.22
c 
Deferribacteraceae 0.57
a 
1.59
b
 1.32
ab 
2.03
ab 
Peptostreptococcaceae  0.62
a 
1.79
a 
1.54
a 
8.01
b 
Succinivibrionaceae 0.13
a
 0.15
a
 0
b 
0
b 
Clostridiaceae 1.31
a
 0
b 
0
b 
0
b 
Veillonellaceae 0.02
a 
0.12
b
 0
a 
0
a 
     
Genus     
Anaerobiospirillum 0.13
a
 0.15
a
 0
b 
0
b 
Desulfovibrio 0.07
a 
0.22
b
 0.17
ab 
0.15
ab 
Alistipes 4.33
ab 
4.41
a
 2.24
b 
3.76
ab 
Rikenella 1.04
ab 
0.49
b 
0.68
b 
1.08
b 
Bacteroides 0.44
a
 0.4
a 
0.16
b 
0.21
ab 
Oscillibacter 0.24
a 
0.67
ab 
0.42
ab 
0.52
b
 
Lactobacillus 0.2
a 
3.03
b
 4.6
b
 2.39
b
 
Bifidobacterium 0.43
a
 1.71
b
 3.66
b
 0.22
c 
Mucispirillum 0.57
a 
1.61
b
 1.56
ab 
1.92
ab 
Coprococcus 0.11
ab 
0.23
b
 0.06
a 
0.06
ab 
Turicibacter 0.56
a
 0.35
a 
0.15
ab 
0
b 
Clostridium  1.3
a
 0
b 
0
b 
0
b 
Peptostreptococus  0.1
a 
0.14
a 
0.12
a 
0.78
b 
 1 
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Figure. 1. Impact of whey protein isolate and protein to carbohydrate ratio on 
body weight and composition. (A) shows the body weight trajectories of mice 
during 21 weeks of dietary treatment with a 10% kJ low fat diet (LFD), 45% kJ high 
fat diet (HFD) or a HFD with 20, 30 or 40% kJ whey protein isolate (WPI). Body 
weight gain (B) and body composition (C) of mice after 21 weeks on experimental 
diets are also shown. Data represent mean values ± S.E.M. (n = 10 per group). 
Groups that do not share a common letter are significantly different at P < 0.05. 
 
149 
 
Figure. 2. Impact of whey protein isolate and protein to carbohydrate ratio on 
energy intake. Energy intake (A) and feeding behaviour (meal size & meal number) 
(B-C) was measured using TSE Phenomaster cages at 17-20 weeks for mice on 
either a 10% kJ low fat diet (LFD), 45% kJ high fat diet (HFD) or a  HFD with 20, 
30 or 40% kJ whey protein isolate (WPI). Experimental data collected from 
individual mice at 9 minute intervals over a 24 hour period are shown as mean 
values ± SEM (n = 8-10 per group) for light and dark phases. In  light and dark 
phase, groups that do not share a common letter are significantly different at P < 
0.05. 
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Figure 3. Impact of whey protein isolate and protein to carbohydrate ratio on 
metabolic activity. Metabolic activity was measured using TSE Phenomaster cages 
at 17-20 weeks for mice on either a 10% kJ low fat diet (LFD), 45% kJ high fat diet 
(HFD) or a HFD with 20, 30 or 40% kJ whey protein isolate (WPI). Experimental 
data for (A) oxygen consumption (VO2), (B) heat production, (C) locomotor activity 
and (D) respiratory exchange ratio (RER), collected from individual mice at 9 
minute intervals over a 24 hour period, are shown as mean values ± SEM (n = 8-10 
per group) for light and dark phases. In light and dark phase, groups that do not 
share a common letter are significantly different at P < 0.05. 
 
  
151 
 
Figure 4. Impact of whey protein isolate and protein to carbohydrate ratio on 
adipose cellular activity. Epididymal adipose tissue gene expression was 
investigated in mice after 21 weeks on a 10% kJ low fat diet (LFD), 45% kJ high fat 
diet (HFD), or HFD with 20, 30 or 40% kJ whey protein isolate (WPI). Relative 
mRNA expression is shown for (A) fatty acid synthase (FASN), fatty acid 
transporter 1 (FATP1), cluster of differentiation 36 (CD36), beta-3 adrenergenic 
receptor (β3-AR), uncoupling protein 2 (UCP-2), lipoprotein lipase (LPL) and 
carnitine palmitolytransferase 1b (CPT1b), and (B) for peroxisome proliferator 
activated receptor gamma (PPARγ), insulin receptor (IR), insulin receptor substrate 
1 (IRS-1), glucose transporter 4 (GLUT4), 11β-hydroxysteroid dehydrogenase type 
1 (11β-HSD1), tumour necrosis factor alpha (TNF-α) and cluster of differentiation 
68 (CD68). Data represent mean values ± SEM (n = 9-10 per group). Gene 
expression is shown relative to the LFD control group set at 1.00. Groups that do not 
share a common letter are significantly different at P < 0.05.  
 
152 
 
Figure 5. Impact of whey protein isolate and protein to carbohydrate ratio on 
the gut microbiota composition. Principal Coordinate analysis (PCoA) of 
unweighted Unifrac distances of the 16SrRNA sequences, demonstrating where 
sequences cluster according to diet group. Data were generated from analysis of 
faecal samples collected from mice on 10% kJ low fat diet (LFD, Δ) or 45% kJ high 
fat diet (HFD, ♦) or a HFD with 20% kJ whey protein isolate (HFD-20% WPI, ○), 
30% kJ WPI (HFD-30% WPI, ◊) or 40% kJ WPI (HFD-40% WPI, ●)(n=10). 
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Chapter 3 
Impact of the dairy whey proteins lactoferrin and serum albumin on 
the composition of the gut microbiota 
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3.1 ABSTRACT 
The obesity pandemic has become perhaps the most prevalent health issue of our 
time. Although, obesity is primarily caused by a long term positive energy 
imbalance, it is becoming increasingly appreciated that the composition and 
functionality of our enteric microbial communities can greatly influence the 
pathogenesis of obesity and related conditions. By extension, it is a reasonable 
assumption that selective modulation of the gut microbiota may yield novel 
treatments for diseases such as obesity. Whey proteins have been shown to reduce 
body weight and to improve the outcomes in obesity related conditions such as type-
2-diabetes. However, their effect on the gut microbiota is poorly understood. We 
previously demonstrated, in C57BL/6J mice, that the replacement of casein as the 
dietary protein source with whey protein isolate (WPI) reduced the animal’s body 
weight and enriched enteric populations of Lactobacillus and Bifidobacterium. 
However the large array of bioactive proteins and associated peptides contained 
within WPI makes drawing conclusions between specific protein sources and 
alterations to the gut microbiota difficult. Therefore this study employed a two 
armed approached and next generation high-throughput DNA sequencing 
technologies to evaluate the impact of two component proteins of whey, namely 
bovine serum albumin (BSA) and lactoferrin (Lf), on the composition and diversity 
of 1) the human gut microbiota by means of an ex vivo distal colon anaerobic 
fermentation system and 2) the gut microbiota of C57BL/6J mice in receipt of a high 
fat diet (HFD).  Results from the simulated colonic fermentation revealed that BSA 
did not invoke significant direct alterations of the gut microbiota. Furthermore, 
native Lf (nLf), Lf which had undergone pre-processing by heat treatment (hLf) or 
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conjugation with fructooligosaccharide (FOS) (mLF) followed by an upper GI 
simulated gastric digestion, all invoked similar and subtle alterations to the human 
gut microbiota, including the enrichment of bacteria such as Veillonellaceae, 
Acidominococcus and Phascolarctobacterium. In mice, replacement of casein as the 
protein source of a high fat diet with either BSA or Lf reversed several of the high 
fat associated taxonomic shifts and, in the case of Lf, significantly increased the 
proportions of the Roseburia genus. PICRUSt analysis revealed that the microbiome 
of both BSA and Lf-fed animals was more akin to that of LFD fed animals. These 
results suggest a use for bovine whey proteins in the beneficial modulation of the gut 
microbiota.  
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3.2 INTRODUCTION 
The WHO estimated that, in 2014, 1.9 billion people worldwide were overweight, of 
which nearly 600 million were obese. Obesity is a complex multifactorial condition 
which primarily occurs as a result of a long term positive energy balance. The 
increase in the incidence of obesity over the last 20-25 years to its current epidemic 
status has been associated with modern eating habits combined with an increased 
sedentary lifestyle. However, other factors, such as host genetics and the indigenous 
microbial populations, have also been show to contribute to the onset of obesity (Ley 
et al. 2006, Thorleifsson et al. 2009). While the rapid rise of obesity has been well 
documented, there has been a failure in the treatment of the current epidemic with 
either sustained lifestyle changes or medical interventions (Wing and Hill 2001, 
Fallah-Fini et al. 2014, Roberto et al. 2015). Obese individuals are at a considerably 
higher risk of developing several clinical conditions such as type 2 diabetes, 
hypertension and cardiovascular disease (Eckel et al. 2005). Given these associated 
increased health risks coupled with the considerable economic cost of treating 
obesity and obesity related diseases (Finkelstein et al. 2009, Lobstein 2014), there is 
an urgent requirement to develop novel strategies for the long term treatment and 
prevention of obesity.  
One such proposed novel strategy involves the beneficial modulation of gut 
microbial populations (Walsh et al. 2014). The gut microbiota is predominantly 
comprised of bacterial species which are members of the Firmicutes and 
Bacteroidetes phyla, with the remaining species being members of the 
Actinobacteria, Verrucomicrobia, Proteobacteria, Fusobacteria and Cyanobacteria 
phyla (Qin et al. 2010). It is estimated that over 1000 bacterial species are contained 
within the human microbiota, each of which possesses a genome encoding an 
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average of ~5,000 genes (Consortium 2012). The human microbiota and associated 
metagenome therefore carries with it a genetic repertoire which far outweighs that of 
the human host (~23,000 genes) and is capable of carrying out metabolic functions 
not encoded by the human genome. The vast majority of these microbial inhabitants 
(1.5 kg or 100 trillion cells) reside within the gut (Lander et al. 2001, Eckburg et al. 
2005, Consortium 2012). The gut microbiota has been shown to impact on obesity 
through several different mechanisms including the production of short chain fatty 
acids (SCFAs), modulation of host inflammation and increased dietary calorie 
extraction (Bäckhed et al. 2004). Initially, an increase in the Firmicutes : 
Bacteroidetes (F:B) ratio was noted in studies with obese rodents (Ley et al. 2005) 
and humans (Ley et al. 2006) leading to an increased F:B ratio being proposed as a 
potential biomarker of obesity. However these findings have been the subject of 
much debate (Murphy et al. 2010, Schwiertz et al. 2010) and, indeed, other studies 
attributed this shift in the dominant gut phyla to high fat feeding which was 
independent of the obese state (Hildebrandt et al. 2009). Regardless of this issue, 
several studies, particularly those using germ free (GF) mice, have highlighted the 
importance of the gut microbiota in the development of obesity. Initially, it was 
shown that GF mice are protected from diet induced obesity while their 
conventionalised counterparts are not, thus highlighting the importance of the gut 
microbiota in the aetiology of obesity (Bäckhed et al. 2007, Ridaura et al. 2013). 
Furthermore, other GF studies have shown that the obese-associated microbiota may 
be more efficient at harvesting dietary calories in that GF mice conventionalised 
with a microbiota from genetically obese (ob/ob) mice had an increase of body fat 
when compared to mice conventionalised with a microbiota from lean animals 
(Turnbaugh et al. 2006). While the exact components and activities of the gut 
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microbiota that influence obesity require further investigation, it is clear that gut 
microbial composition is altered in obesity as well as obesity related conditions such 
as metabolic syndrome and type 2 diabetes, and thus modulation of these obesity 
related shifts in microbial populations and diversity might in turn aid in the 
treatment and prevention of obesity.  
Dairy proteins originating from the whey fraction (20% of total milk proteins) have 
been shown to possess anti-obesity properties. More specifically, incorporation of 
dietary whey protein has been shown to reduce body weight and fat mass 
accumulation in both high fat diet (HFD) fed rodents (Shertzer et al. 2011, Shi et al. 
2011) and obese humans (Pal et al. 2010, Baer et al. 2011).  Whey contains several 
bioactive proteins such as α-lactoglobulin, β-lactalbumin, lactoferrin and serum 
albumin, some of which have been shown to possess antimicrobial activity 
(Yamauchi et al. 1993, Shin et al. 2000). Furthermore, digestion of these proteins 
may result in the formation of other antimicrobial peptides, such as the pepsin 
catalysed formation of the antimicrobial peptide lactoferricin (Lfcin) from 
lactoferrin (Hoek et al. 1997). While studies have examined the effect of whey 
proteins in terms of body weight, to date few studies have examined the effect of 
these milk derived proteins on enteric microbial populations. Two such studies, by 
McAllan et al. and Sprong et al., reported an increase in the proportions of both the 
Lactobacillus and Bifidobacterium genera when the dietary protein energy source of 
casein was substituted with whey. However, these results were not replicated in 
other such studies (Sprong et al. 2010, Tranberg et al. 2013, McAllan et al. 2014).  
The use of whey protein isolate (WPI) makes drawing conclusions between the 
specific proteins contained within whey (and associated digested peptides), and the 
effect which they may invoke on the gut microbial populations, difficult. Therefore 
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this study aimed to examine the effect of two whey proteins, namely bovine serum 
albumin (BSA) and lactoferrin (Lf), on the adult human microbiota in an ex vivo 
distal colon model and the microbiota of C57BL/6 mice consuming a high fat diet 
(HFD). To our knowledge, it is the first study to examine the effect of specific whey 
proteins on enteric microbial populations. 
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3.3 MATERIALS AND METHODS 
3.3.1 Materials used in distal colon model experiments 
BSA was purchased from Sigma Aldrich, USA. Food grade bovine Lf (Vivinal 
lactoferrin TD, 95.6% protein) was kindly donated by FrieslandCampina 
(Wageningen, Netherlands) and oligofructose (Orafti®P95, 95% oligofructose) 
(FOS) was kindly donated by BENEO (Universal Network LTD, Rosh HaAyin, 
Israel). Fresh (frozen) porcine bile used for in vitro gastro-intestinal digestion was 
acquired from Lahav Research Institute (Kibbutz Lahav, Israel). All other chemicals 
and enzymes were purchased from Sigma-Aldrich (St. Louis, MO). All solutions 
were prepared with deionized water (DW) and all reagents were of analytical grade. 
3.3.2 Preparation of Maillard reaction products (MRPs) and heated Lf 
Lf-based MRPs were prepared by mixing native lactoferrin with FOS as detailed in 
previous work (Moscovici et al. 2014). Briefly, the protein powder was dissolved 
with FOS at a practical 3:1 w/w ratio in DW while mixing at ambient temperature 
for 4 h. The solution was adjusted to pH 7.0 with 1 M NaOH, freeze dried and 
pulverized into a fine powder which was incubated at 60 °C under water restricted 
conditions (79 % RH achieved over saturated potassium bromide) for 24 h. Heated 
Lf was produced similarly without the addition of FOS, to isolate the thermal effect 
from the Maillard reaction. Finally, resulting samples were dialyzed to remove 
unreacted carbohydrates (dialysis tubing 12-14 kDa MW cut-off, Thomas Scientific, 
Swedesboro, NJ). Dialyzed samples were then lyophilized, pulverized and kept in a 
desiccator until further analysis. Lf-FOS MRPs were termed mLf, heated Lf was 
termed hLf. The native protein control (not heated) was termed nLf. 
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3.3.3 In vitro adult gastro-intestinal digestion 
In vitro adult gastro-intestinal digestion of nLf, hLf and mLf was performed 
according to a recently standardized static method by COST action FA1005 
INFOGEST (Minekus et al. 2014) with slight modifications. Simulated gastric fluid 
(SGF) and simulated intestinal fluid (SIF) were also prepared according to Minekus 
et al. Briefly, five parts of a 0.05 g/ml sample solution dissolved in distilled water 
(DW) was mixed with four parts of SGF. After mixing and incubation at 37 °C for 
10 min, DW, CaCl2, 1 M HCl and porcine pepsin were added to achieve 2000 U/ml 
pepsin, 0.075 mM CaCl2 and pH 3.0 in the final reaction mixture. Digesta aliquots 
were withdrawn before pepsin addition and at different time points along the gastric 
phase: after 5, 60 and 120 min. These were rapidly neutralized with 0.5 M 
ammonium bicarbonate and placed on ice, and were denoted: G0 for a sample before 
pepsin addition, G5 for a sample withdrawn 5 min after pepsin addition and so-forth.   
After 2h of gastric phase, five parts of gastric chyme were mixed with four parts of 
SIF followed by the addition of 1 M NaOH, DW, CaCl2, porcine bile, trypsin and α-
chymotrypsin to achieve 0.3 mM CaCl2, 10 mM bile, 100 U/ml trypsin, 25 U/ml α-
chymotrypsin and pH 7.0 in the final reaction mixture. To partly mimic absorption 
of low MW digestion products similarly to previous reports (Mills et al. 2008), the 
reaction mixture was dialyzed against SIF while mixing at 37 °C for 2 h (dialysis 
tubing 1 kDa MW cut-off, Membrane Filtration Products Inc., Seguin, TX). Digesta 
aliquots were taken 60 and 120 min after addition of enzymes, and indexed I60 and 
I120, respectively. These aliquots were rapidly mixed with the serine protease 
inhibitor phenylmethanesulfonylfluoride (PMSF) and placed on ice. 
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The remaining digesta following gastro-intestinal digestion was snap-freezed in 
liquid nitrogen and freeze dried to be used as samples for colonic fermentations as 
detailed below.  
3.3.4 Monitoring gastro-intestinal proteolysis by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) 
Comparison of peptide breakdown profiles of digesta samples was based on SDS-
PAGE as described in previous works (Moscovici et al. 2014). 
3.3.5 Distal Colon Model 
Fecal media, prepared according to Fooks et al (Fooks and Gibson 2003), was 
autoclaved along with the vessels of the Multifors fermentation system (Infors, UK) 
at 121˚C for 15 minutes. Once cooled, the media was adjusted to pH 6.8 and added 
(160 ml) to each of the fermentation vessels. Proteins of interest were then added to 
the media (as appropriate, see below) and vessels were sparged with N2 for 120 
minutes to establish anaerobic conditions. A human microbiota was inoculated into 
the vessels of the fermentation system by means of a fresh composite fecal slurry. 
On the morning of each experiment, fresh fecal samples were collected from three 
healthy donors, aged 20-40 years, who had not used antibiotics within the previous 
six months. A 20% (BSA experiment) or 10% (Lf experiment) fecal slurry was made 
by homogenising weighed fecal samples with previously boiled and cooled 
phosphate buffer solution containing 0.05% cysteine in a sterile stomacher bag for 
one minute. Immediately after homogenising, 40ml of the fecal slurry was 
inoculated into each vessel to achieve a total volume of 200 ml. Throughout the 
experiment, pH was maintained at 6.8 by the automatic addition of 1M NaOH or 
HCL (as appropriate), incubated at 37˚C, continuously mixed with an automatic 
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stirrer (100 rpm) and constantly sparged with N2 to maintain anaerobic conditions. 
Experiments were carried out in triplicate using the same fecal donors for each run. 
For the BSA experiment, BSA () was added to two of the three fermentation vessels 
to achieve final concentrations of 2.5% (5g BSA) and 5% (10g BSA), respectively. 
No BSA was added to the third vessel, which served as a control. For Lf 
experiments, 2g of nLf, hLf and mLf were added to their respective fermentation 
vessels to give a total final concentration of 1%. 2g of FOS was added to another 
fermenter to serve as a positive control. Three mls of fermentate were drawn out of 
each vessel at each sampling point. Drawn off samples were then centrifuged at 
15,000 x rpm for 15 minutes where, the remaining pellet was used for DNA 
extraction and subsequent compositional sequencing as detailed below. For the BSA 
experiment, samples were drawn from each vessel at 0h and 24h after fecal slurry 
inoculation. For the Lf experiment, samples were drawn from each vessel at 0, 4, 8 
and 24h after fecal slurry inoculation.  
3.3.6 Animals and diets  
The use and care of animals adhered to the license obtained under the Cruelty to 
Animals Act 1876.  All subsequent work was in accordance with University College 
Cork Animal Ethics Committee approval (#2011/005). Weight matched (17.89 ± 
1.68g) male C57/BL6J mice (Harlan, Middlesex, UK) aged 3-4 weeks were 
randomly group housed in individually ventilated cages (4 per cage, 8 per group) in 
a light (06:00-18:00), temperature (21 ± 1˚C) and humidity (45-65%) controlled 
environment. Mice were given ad libitum access to fresh water and one of three diets 
(Research Diets): LFD (10% energy fat and 20% energy casein; D12450B), HFD 
(45% energy fat and 20% energy casein; D12451), HF-BSA (D12451 in which BSA 
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replaced 20% energy casein, BSA; Sigma Aldrich, USA) or HF-Lf (D12451 in 
which Lf replaced 20% energy casein, Lf; Glanbia, USA). 
3.3.7 In vivo experimental protocol 
Experimental protocol was carried out as per McManus et al. (McManus et al. 2015, 
McManus et al. 2015) After 12 weeks of the trial, fecal pellets were taken from 
individual mice for DNA extraction and subsequent compositional sequencing.   
3.3.8 DNA extraction 
DNA was extracted from centrifuged fermentate pellets and individual murine fecal 
pellets using the QIAmp DNA Stool Mini Kit (Qiagen, Crawley, West Sussex, UK), 
which was combined with an additional bead beating step (30s x 3). Extracted DNA 
was quantified using the Nanodrop 1000 spectrophotometer and stored at -20˚C. 
Sequencing was performed on the Roche 454 GLS FLX genome sequencing 
platform (Roche Diagnostics Ltd, Burgess Hill, West Sussex, UK) or Illumina 
MiSeq sequencing platform (Illumina, San Diego, CA, USA). 
3.3.9 Roche 454 high-throughput pyrosequencing 
Bacterial composition was determined by high-throughput DNA sequencing of 16s 
rRNA amplicons (V4-V5 region; 408bp long) generated by a separate PCR reaction 
(in triplicate) for each sample. Universal 16s rRNA primers designed to bind to an 
estimated 94.6% of all 16s genes present were employed for PCR amplification 
where forward primer (5’-AYTGGGYDTAAAGNG), with attached molecular 
identifier tags between the 454 adapter sequence and target-specific primer 
sequence, and reverse primer V5 (5’-CCGTCAATTYYTTTRAGTTT) were used 
(Claesson et al. 2010) in combination with Biomix Red (Bioline, London, UK.) PCR 
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amplification of template DNA was carried out under the following conditions for a 
total of 35 cycles: 94˚C for 2 minutes and 1 minute respectively (initialization and 
denaturation), 56˚C for 1 minute (annealing) and 72˚C for 1 minute (elongation) 
followed by a final elongation step of 2 minutes. A negative control, whereby 
template DNA was substituted with PCR grade water, was employed and did not 
yield an amplicon. Amplicons were subsequently cleaned using the Ampure 
purification system (Beckman and Coulter, Takeley, UK), quantified using the 
Quant-it™ Picogreen® ds DNA Assay Kit (Invitrogen, Waltham, MA, USA) 
coupled with the NANODROP 3300 Fluorospectrometer (Thermo Scientific, USA) 
and finally pooled to an equimolar concentration. Samples were then sequenced in 
house on a 454 Genome Sequencer FLX platform (Roche Diagnostics Ltd, Burgess 
Hill, West Sussex, UK) in accordance to manufactures protocols. 
3.3.10 Illumina MiSeq 16s rRNA amplicon sequencing 
The V3-V4 variable region of the 16s rRNA gene was amplified from each extracted 
DNA sample according to the 16S metagenomic sequencing library protocol 
(Illumina, CA, USA). Initially the template DNA was amplified using primers 
specific to the V3-V4 region of the 16s rRNA gene which also allowed for the 
Illumina overhang adaptor, where, the forward primer 
(5’TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWG
CAG) and reverse primer 
(5’GTCTCGTGGGCTCGGAGATGTGTATAAGAGACA 
GGACTACHVGGGTATCTAATCC) were used. Each PCR reaction contained 2.5 
µl DNA template, 5 µl forward primer (1µM), 5 µl reverse primer (1µM) (Sigma, 
Ireland) and 12.5 µl Kapa HiFi Hotstart Readmix (2X) (KAPA Biosystems Inc, 
USA). The template DNA was amplified under the following PCR conditions for a 
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total of 25 cycles: 95˚C for 3 minutes and 30 seconds respectively (initialization and 
denaturation), 55˚C for 30 seconds (annealing), 72˚C for 30 seconds (elongation) 
followed by a final elongation period of 5 minutes. A negative control reaction 
whereby the template DNA was replaced with PCR grade water was employed to 
confirm lack of contamination and PCR products were visualised using gel 
electrophoresis (1X TAE buffer, 1.5% agarose gel, 100v) post PCR reaction. 
Successful amplicons were then cleaned using the AMpure XP purification system 
(Labplan, Dublin, Ireland). A second PCR reaction was then completed using the 
previously amplified and purified DNA as the template. Two indexing primers 
(Illumina Nextera XT indexing primers, Illumina, CA, USA) were used per sample 
to allow all samples to be pooled, sequenced on one flow cell and subsequently 
identified bioinformatically. Each reaction contained 25 µl Kapa HiFI HotStart 
ReadyMix (2X), 5 µl template DNA, 5 µl index 1 primer (N7xx), 5 µl index 2 
primer (S5xx) and 10 µl PCR grade water. PCR conditions were the same as 
previously described with the samples undergoing just 8 cycles instead of 25. PCR 
products then underwent the same electrophoresis and cleaning protocols as 
described above. Samples were then quantified using the Qubit 2.0 fluorometer 
(Invitrogen) in conjunction with the broad range DNA quantification assay kit (Life 
technologies, Carlsbad, CA, USA). All samples were then pooled to an equimolar 
concentration and the pool underwent a final cleaning step. Quality of the pool was 
determined using the Agilent Bioanalyser prior to sequencing. The sample pool was 
then denatured with 0.2M NaOH, diluted to 4pM and combined with 10% (v/v) 
denatured 4pM PhiX. Samples were then sequenced in house on the MiSeq 
sequencing platform using a 2.300 cycle V3 Kit following protocols outlined by 
Illumina. 
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3.3.11 Bioinformatic analysis 
Raw Roche 454 high-throughput sequence data was quality trimmed using a locally 
installed RDP pyrosequencing pipeline where, reads shorter than 150bp, ambiguous 
bases and non-exact primer matches were removed. The trimmed FASTA files were 
then BLASTed (Altschul et al. 1997) against a locally installed version of SILVA 
16s rRNA database (Pruesse et al. 2007) using default parameters. Resulting BLAST 
output files were then parsed through MEGAN (Huson et al. 2007) which assigns 
National Centre for Biotechnology Information (NCBI) taxonomies using the lowest 
common ancestor algorithm. Bit scores were employed to allow for the filtering of 
results prior to tree construction and summarization where, a bit score of 86 was 
employed from within MEGAN (Urich et al. 2008, Rea et al. 2011). Sequence reads 
were clustered into operational taxonomic units (OTUs) using the QIIME software 
suite (Caporaso et al. 2010). Chimeric OTUs were removed using the Chimeraslayer 
program and phylogenetic trees constructed using the FastTreeMP tool (Price et al. 
2010, Haas et al. 2011). Beta diversity values were calculated based on Bray Curtis, 
weighted and unweighted Unifrac distance matrices with resulting PCoA plots being 
visualised using the King viewer (Chen et al. 2009). For Illumina MiSeq 16s rRNA 
amplicon sequence data, three hundred base pair paired-end reads were assembled 
using FLASH (fast length adjustment of short reads to improve genome assemblies). 
Paired-end reads were further processed with the inclusion of quality filtering based 
on a quality score of > 25 followed by subsequent removal of mismatched barcodes 
and sequences below length threshold using QIIME. USEARCH v7 (64-bit) was 
then used for denoising and chimera detection as well as clustering into operational 
taxonomic units (OTUs). PyNAST was used to align OTUs and taxonomy was 
assigned by using BLAST against the SILVA SSURef database release 111. QIIME 
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was used to generate Alpha and Beta diversities, calculated based on Bray Curtis, 
weighted and unweighted Unifrac distance matrices. Principal coordinate analysis 
(PCoA) plots were then visualised using EMPeror v0.9.3-dev. 
The nonparametric Kruskal-Wallis test was employed from within the 
Minitab (ver. 15, State College, PA, USA) statistical package to determine statistical 
significance between nonparametric data where significance was set at p≤0.05. 
Predictive functional profiling was performed using the PICRUSt (phylogenetic 
investigation of communities by reconstruction of unobserved states) tool (Langille 
et al. 2013) where again statistical significance was determined using the Karskal-
Wallis test with significance taken as p≤0.05. 
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3.4 RESULTS 
3.4.1 Undigested BSA does not invoke changes to the gut microbiota in an ex 
vivo distal colon model. 
Ex vivo and in vivo studies were carried out to determine the impacts of specific 
whey proteins on the composition of the gut microbiota. Due to the nature of the ex 
vivo studies, i.e. fresh fecal samples were collected on the morning of each 
experiment and thus each experiment commenced with a different inoculating 
microbiota, statistical analysis of the sequence results was not possible and, thus, the 
focus was on identifying general patterns of change. The composition of an ex vivo 
distal colon microbiota, to which BSA was added at 0, 2.5% (5g BSA) and 5% (10g 
BSA), was investigated through the collection of samples at 0 (i.e. prior to the 
addition of BSA) and 24h and sequencing of the V4-V5 16s rRNA amplicons 
generated. -diversity, based on unweighted Uifrac distances (Supplementary figure 
1), did not show distinct clustering of the microbiota from the control (no BSA), 
2.5% BSA or 5% BSA-containing samples. Taxonomic data was examined to find 
consistent alterations to individual populations across all three fermentation 
experiments. To this end, only Prevotella was observed to display a consistent 
pattern (figure 1). More specifically, the proportions of Prevotella decreased such 
that, Prevotella was not detected at the 24h end point from any of the control 
vessels, but was retained in vessels containing 2.5% (average 33% of 0h levels) or 
5% (average 34% of 0h levels) BSA.  
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3.4.2 Digested lactoferrin and modified forms thereof are rapidly digested in an 
in vitro adult gastro-intestinal model. 
Lf-FOS Maillard reaction products (MRPs) were characterized in a previous work 
(Moscovici et al. 2014). It was chosen to further study the longest heating duration 
of 24h, to elucidate the effects of thermal processing without and with FOS, the 
latter leading to the formation of MRPs, on digestive fate throughout the 
gastrointestinal tract. Based on SDS-PAGE of digesta collected from an in vitro 
adult gastro-intestinal model (Figure 2),  Lf is highly susceptible to in vitro adult 
gastric digestion even following thermal processing, as previously shown 
(Moscovici et al. 2014). The Lf band at ~80kDa is barely observed after 5min of 
gastric digestion in the native Lf sample (nLf) (Figure 2A). The Lf band is not 
observed at G5 in both samples of heated Lf (hLf) and Maillard (mLf) (Figure 2B 
and 2C, respectively), however, the proteolysis seems slower in mLf compared to 
hLf, as evident by the peptide breakdown profile. Nevertheless, based on the SDS-
PAGE analysis, no significant differences were observed between nLf, hLf and mLf 
at the end of the gastro-intestinal digestion, which served as the "feeding material" 
for the ex-vivo distal colon model. 
3.4.3 Digested lactoferrin and modified forms thereof have a similar impact on 
the β diversity of an ex vivo distal colon microbiota. 
Calculated alpha diversity values showed an overall reduction in microbial diversity 
throughout the 24 hour experiment but that there were no differences with respect to 
the net impact of the lactoferrin variants on -diversity (Figure S2). Scatter plot 
analysis highlighted that the FOS containing vessel had the highest alpha diversity 
values at the 24 h time point. -diversity (based upon unweighted unifrac distances) 
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showed a clear clustering by experimental run, and thus initial differences in the 
composition of the inoculating microbiota had a significant influence in this regard. 
When -diversity was examined by time point (Figure 3), a tight clustering was 
observed between all treatments groups (FOS, nLf, hLf and mLf) at 0h after fecal 
slurry inoculation. As the fermentation progressed, PCoA analysis showed that all 
groups remain closely clustered at the 4 and 8 hour time points. At the 24h time 
point the nLf, hLf and mLf groups remain clustered tightly together and away from 
all other time points while the FOS control remains clustered in close proximity to 
the 4 and 8h points. This cluster pattern was observed across all three experimental 
runs. 
Model distal colon microbiota inoculated with 1% pre-digested nLf, hLf and mLf 
have taxonomic profiles which are similar, but which differ from microbiota 
inoculated with 1% FOS  
Immediately after fecal slurry inoculation, the bacterial profiles of all the groups in 
the experiment were the same with Firmicutes and Bacteroidetes being the dominant 
phyla (Figure S3). As the fermentation proceeded, the anticipated enrichment in the 
Actinobacteria phylum (and, more specifically Bifidobacteriaceae/Bifidobacterium) 
became apparent in the FOS control vessel for all three experimental runs 
(Supplementary figure 3a and figure 4). This was not observed in the nLf, hLf or 
mLf containing fermentation vessels. An increase in the proportions of the 
Proteobacteria phylum was observed from 4 hours after fecal slurry inoculation in all 
fermentation vessels (Figure S3a). This increase was notably higher in the nLf, hLf 
and mLf-containing vessels. By 24h Proteobacteria populations showed an average 
increase of 1284% (FOS), 2914% (nLf), 2197% (hLf) and 2563% (mLf). 
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Furthermore, proportions of the Proteobacteria-associated 
Enterobacteriaceae/Eschericha-Shigella (family/genus) were notably increased 
from 0 to 4 hours of fermentation in all vessels (Figure 4). However, this increase 
was observed to a considerably higher degree in the nLf, hLf and mLf containing 
vessels throughout the remainder of the fermentation period. 
Bacteroidaceae/Bacteroidetes populations remained consistent throughout the 
fermentation in the FOS containing vessel but decreased considerably in the nLf, 
hLf and mLf containing vessels from 8 to 24 hours of fermentation. Relative 
abundances of representatives of the family Veillonellaceae were noted to steadily 
increase in the nLf, hLf and mLf containing vessel resulting in a dramatic increase in 
overall proportions of this family between the 0h and 24h time points. This pattern 
was not observed in the FOS containing vessel. The associated genera 
Acidominococcus and Phascolarctobacterium followed a similar pattern in that they 
increased in each of the lactoferrin containing vessels from 8h to 24h of 
fermentation but not in the FOS control vessel. Figure 4 and Figure S3b provide a 
visual representation of the total assigned genus and family level taxonomies, 
respectively, for each of the three fermentation periods. 
3.4.4 Replacement of casein as the protein source of a high fat murine diet with 
either Lf or BSA alters β diversity but not α diversity of the C57BL/6 mice 
McManus et al. conducted a study to investigate the effect of four different diets 
(HFD, LFD, HF-Lf and HF-BSA) on energy balance in C57BL/6 mice (McManus et 
al. 2015, McManus et al. 2015). Fecal pellets were taken from the same mice after 
12 weeks of consuming the set diets to investigate, by high throughput DNA 
sequencing, their impact on the composition of the gut microbiota -diversity values 
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for biodiversity (Shannon index), observed species and species number relative to 
abundance within the sample (Simpson diversity index), number of observed species 
and species richness (Chao1). After 12 weeks of consuming set diets, no significant 
differences were established between any of the four diet groups for any of the 
measured alpha diversity indices (Figure 5). -diversity (built upon unweighted 
unifrac distances) of the generated 16s rRNA sequences highlighted taxonomic 
differences between the gut microbiotas of animals consuming the LF, HF, HF-BSA 
and HF-Lf diets (Figure 6). PCoA analysis revealed a separation in clustering 
between the animals consuming the LF diet and those consuming the HF diet. 
Sequence data from animals who had consumed the HF-BSA and HF-Lf diets also 
showed a distinct clustering from each other as well from both the LF and HF diet 
consuming cohorts.  
3.4.5 Replacement of casein with either Lf or BSA in a high fat murine diet 
reverses several of the high fat associated shifts in microbial taxonomy  
Several of the significant taxonomic differences observed between the HFD and 
LFD cohorts were noted to be reversed upon the replacement of casein in the high 
fat murine diet with either Lf or BSA. At phylum level, proportions of Firmicutes 
were significantly higher in the HFD cohort when compared with either the LFD 
(p=0.027), HF-Lf (p=0.005) or HF-BSA (p=0.027) cohorts (Figure 7A). Conversely, 
Deferribacteres populations were determined to be significantly higher in the LFD 
(p=0.021) and HF-Lf (p=0.036) groups compared to the HFD group.  
Proportions of Alcaligenaceae (family) and Parasutterella (genus) were 
significantly higher in the LFD (p=0.004), HF-Lf (p=0.011) or HF-BSA (p<0.001) 
cohorts when compared with the HFD cohort (figure 7B and 7C). Both 
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Deferribacteraceae and Mucispirillum were also significantly higher in the LFD 
(p=0.021) and HF-Lf (p=0.036 and p=0.016, respectively) cohorts. Other significant 
differences observed between the HFD and LFD groups included significantly 
higher proportions of the Bacteroides (p=0.036), Lachnospiraceae Incertae Sedis 
(p=0.046), Catabacter (p=0.020) and Anaerotruncus (p=0.036) genera in the LFD 
group compared to the HFD group, while the HFD cohort contained significantly 
higher populations of the Peptostreptococcaceae Incertae Sedis (p=0.028) and 
Akkermansia (p=0.027) genera compared to that of the LFD cohort (Figure 7). 
Replacement of casein as the protein source of a high fat murine diet with either Lf 
or BSA also resulted in significant alterations to other taxonomic populations. At 
phylum level, a significant increase in the Proteobacteria populations were observed 
within the microbiotas of the HF-Lf (p=0.006) and HF-BSA (0.016) groups 
compared to the HFD group (figure 7A).Bacteroidetes proportions were also higher 
in the Hf-Lf group (p=0.027) when compared with the HFD group. At family level 
(figure 7B), Streptococcaceae proportions were determined to be significantly lower 
in both the HF-Lf and HF-BSA groups than either the HFD or LFD groups 
(p=0.001) and Anaeroplasmataceae proportions were significantly lower in the HF-
Lf group when compared to the HFD group (p=0.011). Genus level taxonomic 
analysis revealed (figure 7C) that both HF-Lf and HF-BSA diet groups had 
significantly lower Lactococcus populations than either the LFD group (p=0.001) or 
the HFD group (p=0.004). Notably, the microbiota of the HF-Lf diet fed animals 
contained significantly higher levels of Roseburia compared to animals consuming 
the LFD (p=0.021), HFD (p=0.012) or the HF-BSA diet (p=0.014) (Figure 7C). 
Furthermore, several statistically significant differences in microbial taxonomy were 
observed between the gut microbiotas of animals consuming the HF-BSA and HF-Lf 
175 
 
diets. Animals consuming the HF-Lf diet had significantly higher proportions of 
Bacteroidaceae (p=0.046), Lachnospiraceae (p=0.027) and Peptococcaceae 
(p=0.016) at family level and Bacteroides (p=0.046) at genus level compared to 
those animals consuming the HF-BSA diet. Conversely, proportions of the genus 
Oscillibacter (p=0.027) were significantly higher in the animals consuming the HF-
BSA compared those provided with the HF-Lf diet. Figure 7 provides a visual 
representation of the statically significant taxonomic differences while Table S1 
represents the relative abundance of all microbial taxonomies detected.    
3.4.6 PICRUSt analysis revealed that the metabolic potential of the HF-Lf and 
HF-BSA gut microbiota more closely resembles that of the LFD, than the HFD, 
mice.  
When compared to metabolic pathway scores assigned by PICRUSt within the HFD 
group, 44 and 27 pathways were determined to be significantly different within the 
HF-Lf and HF-BSA groups, respectively. Notably, only 7 metabolic pathways 
significantly differed in their frequencies between the LFD group and the HF-Lf 
group and no differences were determined between the LFD group and the HF-BSA 
group. Of the significantly altered metabolic pathways, glycolysis/gluconeogenesis 
and tyrosine metabolism were determined to be significantly higher in the HFD 
group than any of the other dietary groups (p<0.05) while conversely, valine, leucine 
and isoleucine degradation was higher in all other diet groups compared to the HFD 
group (p<0.05). A summary of all significantly altered metabolic pathways are 
summarised in Table 1.  
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3.5 Discussion 
To date the effect of dietary proteins on the composition of the microbiota has not 
been extensively studied. It is clear, however, that protein fermentation is associated 
with a more diverse metabolite profile than other dietary macronutrients such as 
carbohydrates (Hamer et al. 2012) and that several of these metabolites play 
important roles in gut homeostasis, such as the formation of SCFAs and providing 
nitrogen for the growth of saccharolytic bacteria (Cummings and Macfarlane 1991, 
Conlon and Bird 2014). However, other metabolites resulting from microbial protein 
fermentation such as N-nitroso compounds, amines and p-cresol are potentially toxic 
or carcinogenic and thus a saccharolytic gut environment has been favoured over a 
proteolytic one (Gill and Rowland 2002, Rastall and Gibson 2015). This study 
examined the impact of the whey proteins BSA and Lf on the composition of the gut 
microbiota as assessed using an ex-vivo human and in vivo C57BL/6 murine models. 
Anaerobic batch fermentation systems allow for the primary analysis of the impact 
of compounds of interest on the human gut microbiota. Addition of either 2.5% or 
5% BSA into the batch fermentation system did not result in dramatic alterations to 
the gut microbial populations. One notable feature was the greater retention of the 
Prevotella genus within the BSA inoculated vessels which was not observed within 
the control vessel (Figure 1). Certain members of the Prevotella genus, such as 
Prevotella ruminicola, have been associated with protein fermentation owing to the 
highly active dipeptidyl peptidases and dipeptidases which they produce (Wallace 
1996) and, thus, be more likely to benefit from the provision of BSA than other taxa.  
Inoculation of the colonic fermentation system with Lf resulted in a similar 
taxonomic profile regardless of the pre-processing process that the Lf was exposed 
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to (i.e. thermal processing (hLf) or conjugation with FOS (mLf)) which differed 
from that achieved by FOS inoculation. This was also in agreement with SDS-PAGE 
results of gastro-intestinal proteolysis (Figure 2). As fermentation proceeded, a clear 
enrichment in the proportions of Veillonellaceae, Acidominococcus and 
Phascolarctobacterium (Figure 4 and Figure S3b) was observed in the vessels 
containing nLf, hLf or mLf but not within the FOS containing vessel. These 
bacterial groups have been shown to preferentially ferment amino acids and possess 
only limited saccharolytic activity, however they may contribute to improved gut 
health through the production of the SCFA propionate which can influence several 
cellular processes such as intestinal inflammation (Macfarlane and Macfarlane 1997, 
Arpaia et al. 2013, Scott et al. 2013, Smith et al. 2013). The Bacteroides genus is the 
dominant saccharolytic genus within the gut microbiota due to the large array of 
carbohydrate utilisation enzymes encoded within it (Salyers et al. 1977, Salyers et al. 
1977, Xu et al. 2003, Sonnenburg et al. 2010). The present fermentation profile 
resulted in stable proportions of Bacteroides within the FOS containing vessel 
throughout the fermentation period (Figure 4), which is consistent with the ability of 
members of this genus to utilise FOS as a growth source (Endo et al. 2012). 
However, the dramatic decrease in the Bacteroides proportions observed within the 
Lf containing vessels between the 8 and 24 sampling points likely due to 
carbohydrate exhaustion, allowing for the enrichment of the aforementioned amino 
acid fermenting bacterial groups.   
As expected (Kaplan and Hutkins 2000, Rossi et al. 2005, Russell et al. 2011, Flint 
et al. 2012), proportions of Bifidobacterium were observed to steadily increase 
throughout the fermentation period in the FOS containing vessel (Figure 4) due to its 
prebiotic properties. However, although Lf has been associated with playing an 
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important role in the establishment of the Bifidobacterium dominated infant gut 
microbiota and has also been shown to stimulate the growth of several species 
within the genus (such as Bifidobacterium breve) in vitro (Petschow et al. 1999, Kim 
et al. 2004, Mastromarino et al. 2014), no such enrichment was evident in the ex vivo 
model containing either nLf, hLf nor mLf. This may be as a consequence of the use 
of a more complex adult gut microbiota or the possibility that higher concentrations 
of Lf are required to invoke a bifidogenic effect.  
Moreover, Lf is a natural defence protein possessing potent antimicrobial activity, 
driven mainly through two separate mechanisms. Firstly, Lf invokes bacteriostatic 
effects on enteric pathogens through its ability to sequester iron thus depriving 
microorganisms of this vital nutrient (Arnold and Cole 1977, Arnold et al. 1980). 
The second mechanism by which Lf invokes antimicrobial activity is by the direct 
interaction of the Lf molecule with the bacterial cell surface (Kalmar and Arnold 
1988, Bortner et al. 1989, Farnaud and Evans 2003). Furthermore, pepsin digestion 
of Lf produces low molecular weight peptides knows as lactoferricin (Lfcin) and 
Lactoferrampin (Lfampin) which show antimicrobial activity against a wide range of 
both gram positive and gram negative bacteria. Indeed Lfcin and Lfampin have a 
greater antimicrobial potency than native Lf (Bellamy et al. 1992, van der Kraan et 
al. 2004, Van der Kraan et al. 2006). In the present study, a notable increase in the 
relative abundance of a subset of the Proteobacteria phylum which corresponded to 
Enterobacteriaceae at family level and Escherichia-Shigella at genus level was 
observed in each of the Lf containing vessels compared to the FOS containing 
equivalent. This result suggests that a higher concentration may be required for Lf to 
invoke a beneficial modulatory effect on the adult gut microbiota, as previous 
studies have shown Lf (and Lf associated peptides) to display antimicrobial activity 
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against several members of the Eschericha-Shigella bacterial genus (Bellamy et al. 
1993, Shin et al. 1998, Gomez et al. 2002).  
It is now widely accepted that diet has a significant impact on gut microbiota 
composition. This relationship was apparent yet again here in that mice consuming a 
LFD, HFD, HF-Lf diet or HF-BSA diet for 12 weeks differed significantly with 
respect to their gut microbiota with beta diversity analysis based upon unweighted 
Unifrac distances revealing a clustering according to diet. Consistent with data 
generated from the ex vivo study of Lf on the composition of the adult human gut 
microbiota, switching the HFD protein source from casein to either Lf or BSA 
significantly increased the populations of Proteobacteria. As well as being associated 
with enteric inflammatory diseases (as stated above), increase in the Proteobacteria 
populations may also be detrimental to gut health due to their formation of N-nitroso 
compounds (NOCs) which can exert carcinogenic effects via DNA alkylation 
(Rowland 2000, Gill and Rowland 2002, Windey et al. 2012). The significant 
increase in Proteobacteria proportions observed in both the ex vivo and in vivo 
studies suggests that Lf (or associated peptide(s)) promotes increased populations of 
Proteobacteria within the gut microbiota and thus the antibacterial activity of Lf (at 
concentrations used presently) against members of the Proteobacteria phylum 
observed in in vitro studies (Shin et al. 1998, Gomez et al. 2002) does not appear to 
occur in the complex enteric microbial ecosystem.  
As with other murine studies, high fat feeding significantly increased levels of 
Firmicutes while populations of Bacteroidaceae family and Bacteroides genus were 
significantly decreased compared to those animals in receipt of a LFD (Ley et al. 
2005, Turnbaugh et al. 2006, Turnbaugh et al. 2008, Murphy et al. 2010, Daniel et 
al. 2014). Interestingly, substitution of casein with either Lf or BSA reversed several 
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of the HFD associated taxonomic shifts and enriched bacteria previously associated 
with the lean phenotype.  Consistent with phylum level differences observed 
between the low and high fat diet groups, animals which consumed the HF-Lf and 
HF-BSA diets also had significantly lower populations of Firmicutes than the HFD 
group and significantly higher Bacteroidetes populations, in the case of the HF-Lf 
group. Notably, the inversion in the Firmictutes:Bacteroidetes ratio achieved by both 
LF and BSA compared to casein may in turn have beneficial implications in terms of 
weight gain and obesity (Ley et al. 2006). Mice consuming the HF-Lf or HF-BSA 
diets had significantly increased proportions of the Alcaligenaceae family and the 
Parasuterella genus compared to those consuming the HFD. An increase in 
populations of Alcaligenaceae  was previously reported by Clarke et al. and Murphy 
et al. in lean mice compared to their diet-induced obese (DIO) counterparts, and 
Alcaligenaceae proportions within the DIO cohort were significantly increased after 
vancomycin treatment which was accompanied with improved metabolic function 
and reduced weight gain (Murphy et al. 2010, Clarke et al. 2013). A further study by 
Zhang et al. showed a significant increase in Parasuterella upon switching DIO 
C57BL/6 mice to a normal chow diet after 12 weeks of high fat diet feeding, a 
switch which restored overall structure, composition and bacterial diversity (Zhang 
et al. 2012).  
In the context of alterations to the host phenotype reported by McManus et 
al.(McManus et al. 2015, McManus et al. 2015), the authors reported a significant 
decrease in body weight in the HF-BSA fed animals compared to that of the HFD 
fed animals which was associated with increased lean mass and reduced 
subcutaneous fat mass. Given the negligible effect of BSA on microbial populations 
observed in the ex vivo study, changes to microbial taxonomies observed presently 
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between the HFD and HF-BSA may result from the significant reduction in weight 
which has been shown in other studies to alter gut microbiota composition (Ley et 
al. 2006, Ravussin et al. 2012). Conversely, animals consuming the HF-Lf diet 
showed no difference in either body weight or body composition when compared to 
the animals consuming the HFD.  High throughput sequence data generated 
presently therefore suggests that dietary Lf invokes changes to the gut HFD 
associated microbiota by a mechanism which is independent of host physiological 
state and therefore suggests a use for Lf as a beneficial modulator of the gut 
microbiota.   
Mice in receipt of the HF-Lf diet displayed significantly higher levels of the 
Roseburia genus than mice on any of the other diet groups. Bacterial species 
contained within the Roseburia genus and other related genera, such as Roseburia 
inulinivorans and Eubacterium rectale, have been shown to be amongst the most 
dominant butyrate producers within the colonic ecosystem and thus are thought to be 
beneficial to the host (Aminov et al. 2006, Duncan et al. 2006, Louis and Flint 
2009). Butyrate confers several health benefits to the host such as providing energy 
to colonocytes, reducing inflammation, exerting anti-carcinogenic effects and 
improving gut barrier function (Kruh 1981, Pryde et al. 2002, Flint et al. 2007, Peng 
et al. 2007). A reduced abundance of Roseburia has previously been linked with 
gastrointestinal (GI) inflammatory diseases such as Crohn’s disease and ulcerative 
colitis (UC) which was associated with reduced butyrate levels.  This data suggests 
that dietary Lf (or Lf associated bioactive peptides) may benefit host health by 
enriching growth of Roseburia either as a direct growth factor, or more likely as 
Roseburia depend on carbohydrates for growth (Duncan et al. 2007), by inhibition of 
competing bacterial species.  
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In line with observed taxonomic alterations to the gut microbiota, the PICRUSt-
based metabolic function analysis of in vivo data predicted several metabolic 
pathways to be significantly different between the HF-Lf and HF-BSA groups and 
the HFD group. Indeed, of the 251 predicted metabolic functions examined, the 
abundance of 44 pathways were significantly different in the HFD group compared 
to the HF-Lf group, while the abundance of 23 pathways were significantly different 
in the HFD group compared to the HF-BSA group. In contrast, the abundance of 
only 7 pathways were significantly different in the LFD group compared to the HF-
Lf group and no differences were observed between the LFD group and the HF-BSA 
group. Within the microbiome of the HFD group, gluconeogenesis was predicted to 
be significantly higher than all other diet groups and have significantly higher 
fructose and mannose metabolism than that of the HF-Lf group. Notably, Turnbaugh 
et al. previously reported enrichment in both of these pathways in animals in receipt 
of a western diet suggesting that Lf and BSA may reduce the energy harvest of the 
gut microbiota on a high fat diet. Other significant differences were predicted 
between the LFD, HF-Lf and HF-BSA group compared to HFD group in that 
pathways associated with valine/leucine/isoleucine degradation and tyrosine 
metabolism were predicted to be decreased and increased, respectively, within the 
HFD microbiome. Valine, leucine and isoleucine can be oxidised by gut bacteria to 
form branched chain fatty acids (BCFAs) whose levels were reduced in patients with 
irritable bowel syndrome (IBS) and UC with respect to controls (Le Gall et al. 
2011), while bacterial  metabolism of tyrosine may result in the formation of cresols 
which are associated with a wide range of pathological conditions including those of 
the gut such as inflammatory bowel disease (IBD) (Nicholson et al. 2012). This data 
suggests that Lf and BSA may alter the functional potential of the gut microbiota to 
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reduce energy harvest from a high fat diet and may contribute to improved gut 
health.   
The present study provides the first insight into the impact of the whey proteins 
bovine serum albumin and lactoferrin on the composition of the enteric microbial 
composition. The results, particularly those observed in C57BL/6 mice, suggest a 
use for these bovine whey proteins in the modulation of the gut microbiota to 
improve gut health which may reverse obesity and high fat feeding associated 
changes to microbial populations. 
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Table 1. Statistically altered PICRUSt predicted metabolic pathways between C57BL/6 mice in receipt of a HFD, LFD, HF-Lf diet or HF-BSA 
diet. 
Metabolic pathway LFD HFD HF-Lf HF-BSA 
Processing;Membrane Transport;Bacterial secretion system 0.574* 0.540 0.564* 0.578* 
Processing;Membrane Transport;Transporters 6.894 7.488¥†∆ 6.721 6.745 
Processing;Signaling Molecules and Interaction;Bacterial toxins 0.140 0.147† 0.132 0.138 
Folding, Sorting and Degradation;Chaperones and folding catalysts 0.964* 0.918 0.981* 0.977* 
Folding, Sorting and Degradation;Protein processing in endoplasmic reticulum 0.073* 0.062 0.073* 0.074* 
Processing;Folding, Sorting and Degradation;RNA degradation 0.451* 0.431 0.464* 0.459* 
Processing;Transcription;Transcription factors 1.464  1.609¥∆ 1.501 1.446 
Amino Acid Metabolism;Phenylalanine, tyrosine and tryptophan biosynthesis 0.790* 0.756 0.826* 0.800* 
Amino Acid Metabolism;Tyrosine metabolism 0.315 0.335¥†∆ 0.308 0.318 
Amino Acid Metabolism;Valine, leucine and isoleucine degradation 0.263* 0.253 0.270* 0.263* 
Carbohydrate Metabolism;Citrate cycle (TCA cycle) 0.503 0.423 0.540* 0.510 
Carbohydrate Metabolism;Fructose and mannose metabolism 1.237 1.339† 1.094 1.239 
Carbohydrate Metabolism;Glycolysis / Gluconeogenesis 1.060 1.096¥†∆ 1.049 1.067 
Carbohydrate Metabolism;Pentose phosphate pathway 0.900 0.949† 0.870 0.909 
Energy Metabolism;Carbon fixation pathways in prokaryotes 0.905 0.816 0.952* 0.912 
Energy Metabolism;Nitrogen metabolism 0.652* 0.632 0.656* 0.661* 
PICRUSt analysis of 16s rRNA sequence data of metabolic profiles where a significant difference was observed between dietary groups. Data is expressed as the relative 
abundance of the metabolic pathway and where * indicates a significantly higher abundance than the HFD group, ¥ indicates a significantly higher abundance than the LFD 
group, † indicates a significantly higher abundance than the HF-Lf group and ∆ indicates a significantly higher abundance than the HF-BSA group. Statistical significance 
determined using the Kruskal-Wallis test where significance was taken as p≤0.05.
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Table 1. (Continued) 
Metabolic pathway LFD HFD HF-Lf HF-BSA 
Glycan Biosynthesis and Metabolism;Glycosyltransferases 0.306* 0.290 0.309* 0.302 
Glycan Biosynthesis and Metabolism;Lipopolysaccharide biosynthesis 0.225* 0.151 0.224* 0.229* 
Glycan Biosynthesis and Metabolism;Lipopolysaccharide biosynthesis proteins 0.312* 0.232 0.311* 0.319* 
Glycan Biosynthesis and Metabolism;N-Glycan biosynthesis 0.022 0.014 0.023* 0.020 
Lipid Metabolism;Glycerolipid metabolism 0.399 0.417†∆ 0.394 0.390 
Lipid Metabolism;Linoleic acid metabolism 0.078† 0.083† 0.068 0.076† 
Metabolism of Cofactors and Vitamins;Biotin metabolism 0.115 0.096 0.126* 0.117 
Metabolism of Cofactors and Vitamins;Folate biosynthesis 0.350* 0.323 0.353* 0.356 
Metabolism of Cofactors and Vitamins;Pantothenate and CoA biosynthesis 0.507 0.475 0.562* 0.513 
Metabolism of Other Amino Acids;beta-Alanine metabolism 0.165 0.150 0.184* 0.169 
Metabolism of Terpenoids and Polyketides;Geraniol degradation 0.024 0.015 0.036* 0.024 
Biodegradation and Metabolism;Benzoate degradation 0.211 0.229¥ 0.225¥∆ 0.210* 
Biodegradation and Metabolism;Bisphenol degradation 0.088 0.093†∆ 0.079 0.086 
Biodegradation and Metabolism;Caprolactam degradation 0.011 0.007 0.016*∆ 0.008 
Biodegradation and Metabolism;Chloroalkane and chloroalkene degradation 0.162† 0.172¥† 0.151 0.158 
Biodegradation and Metabolism;Styrene degradation 0.008 0.009∆ 0.014¥∆ 0.007 
PICRUSt analysis of 16s rRNA sequence data of metabolic profiles where a significant difference was observed between dietary groups. Data is expressed as the relative 
abundance of the metabolic pathway and where * indicates a significantly higher abundance than the HFD group, ¥ indicates a significantly higher abundance than the LFD 
group, † indicates a significantly higher abundance than the HF-Lf group and ∆ indicates a significantly higher abundance than the HF-BSA group. Statistical significance 
determined using the Kruskal-Wallis test where significance was taken as p≤0.05.
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Table 1. (Continued) 
Metabolic pathway LFD HFD HF-Lf HF-BSA 
Biodegradation and Metabolism;Toluene degradation 0.063* 0.042 0.074* 0.071* 
Endocrine System;Adipocytokine signaling pathway 0.047 0.035 0.049* 0.051 
Cellular Processes and Signaling;Cell motility and secretion 0.159 0.141 0.159* 0.164* 
Cellular Processes and Signaling;Germination 0.013 0.012 0.023*¥∆ 0.011 
Cellular Processes and Signaling;Membrane and intracellular structural 
molecules 0.477* 0.406 0.479* 0.485* 
Cellular Processes and Signaling;Other transporters 0.245 0.255¥† 0.243 0.252 
Cellular Processes and Signaling;Pores ion channels 0.270 0.228 0.291* 0.291 
Genetic Information Processing;Protein folding and associated processing 0.708*† 0.685 0.680 0.699 
Metabolism;Amino acid metabolism 0.230 0.230† 0.221 0.234 
Unclassified;Metabolism;Others 1.017 1.080¥†∆ 0.970 0.999 
 
PICRUSt analysis of 16s rRNA sequence data of metabolic profiles where a significant difference was observed between dietary groups. Data is expressed as the relative 
abundance of the metabolic pathway and where * indicates a significantly higher abundance than the HFD group, ¥ indicates a significantly higher abundance than the LFD 
group, † indicates a significantly higher abundance than the HF-Lf group and ∆ indicates a significantly higher abundance than the HF-BSA group. Statistical significance 
determined using the Kruskal-Wallis test where significance was taken as p≤0.05.
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Figure 1. Bar charts representing the relative abundance of the Prevotella genus in 
the control, 2.5% BSA and 5% BSA containing vessels at the 0 and 24h time points. 
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Figure 2. Comparison of peptide breakdown profiles of Lf digesta samples based on 
SDS-PAGE, where A) represents nLf, B) hLf and C) mLf. 
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Figure 3. Principal Coordinate analysis (PCoA) of unweighted Unifrac distances of generated 16s rRNA sequences highlighting the 
change in microbial composition along the 24h batch fermentation in response to addition of 1% FOS, nLf, hLf or mLf. 
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Figure 4.  Doughnut charts representing the relative abundance of detected microbial 
taxonomies at genus level at 0, 4, 8 and 24h of a simulated colonic fermentation in response 
to the addition of 1% (w/v) FOS, nLf, hLf or mLf. 
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Figure 5. Comparison of alpha diversity indices across the HFD, LFD, HF-LF and 
HF-BSA consuming cohorts. Data shown are means ± SEM (n=8). 
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Figure 6. Principal Coordinate analysis (PCoA) of unweighted Unifrac distances of 
generated 16s rRNA sequences demonstrating a clustering according to diet group, 
where • represents sequence data generated from LFD cohort, • represents sequence 
data generated from the HFD cohort, • represents sequence data generated from the 
HF-Lf diet cohort and • represents sequence data generated from the HF-BSA diet 
cohort. 
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Figure 7. Stacked bar charts representing the significantly altered microbiota taxonomies at A) phylum, B) family and C) genus level within the 
gut microbiotas of C57BL/6 mice after 12 weeks of consuming either a HFD, LFD, HF-Lf diet or HF-BSA diet, with the corresponding p-
values, as determined by the Kruskal-Wallis statistical test (p≤0.05). 
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3.7 SUPPORTING INFORMATION 
Table S1. Microbial taxonomies detected, by high-throughput pyrosequencing, within the gut microbiota of C57BL/6 mice consuming set diets 
for 12 weeks 
 
LF HF HF-Lf HF-BSA 
Phylum 
    Proteobacteria  0.62 0.36 0.88*¥ 1.20* 
Bacteroidetes  27.33 17.78 31.09* 34.47 
Firmicutes 67.59 79.63¥†∆ 63.46 61.01 
Deferribacteres  2.26* 0.32 2.32* 1.53 
Tenericutes 0.34 0.37 0.32 0.60 
Verrucomicrobia 0.38 0.16 0.27 0.24 
Actinobacteria  1.48 1.38 1.65 0.95 
Family 
    Alcaligenaceae  0.12* 0.00 0.33* 0.62*¥ 
Bacteroidaceae 1.42* 0.74 1.96∆ 1.04 
Desulfovibrionaceae  0.48 0.35 0.49 0.54 
Rikenellaceae  8.22 6.83 9.38 12.26 
Porphyromonadaceae  2.91 3.50 5.20¥ 7.76¥ 
Microbial taxonomies detected within the microbiotas of C57BL/6   mice after 12 weeks consuming either a HF, LF, HF-Lf diet or HF-BSA diet. Data is expressed as the 
total percentage of bacteria present within the data set and where * indicates a value significantly higher than the HFD group, ¥ indicates a value significantly higher than the 
LFD group, † indicates a value significantly higher than the HF-Lf group and ∆ indicates a value significantly higher than the HF-BSA group, where significance was taken 
as p≤0.05 as determined by the non-parametric Kruskal-Wallis test. 
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Table S1. (Continued) 
 
LF HF HF-Lf HF-BSA 
Bifidobacteriaceae  1.43 1.32 1.55 0.84 
Lactobacillaceae  4.85 6.78 5.48 3.16 
Erysipelotrichaceae  44.80 49.68 31.75 37.04 
Lachnospiraceae  9.78 13.00 15.91∆ 9.10 
Ruminococcaceae  6.62 5.93 7.65 7.94 
Peptococcaceae  0.38 0.45 0.66∆ 0.30 
Anaeroplasmataceae  0.05 0.45† 0.00 0.03 
Deferribacteraceae  2.26 0.32 2.29* 1.53 
Coriobacteriaceae 0.05 0.04 0.09 0.10 
Streptococcaceae 0.06†∆ 0.11†∆ 0.00 0.00 
Rhodospirillaceae 0.01 0.00 0.02 0.02 
Akkermansiaceae 0.38 0.16 0.27 0.24 
Enterobacteriaceae 0.00 0.01 0.00 0.00 
Clostridiaceae 0.00 0.34 0.06 0.00 
 
Microbial taxonomies detected within the microbiotas of C57BL/6   mice after 12 weeks consuming either a HF, LF, HF-Lf diet or HF-BSA diet. Data is expressed as the 
total percentage of bacteria present within the data set and where * indicates a value significantly higher than the HFD group, ¥ indicates a value significantly higher than the 
LFD group, † indicates a value significantly higher than the HF-Lf group and ∆ indicates a value significantly higher than the HF-BSA group, where significance was taken 
as p≤0.05 as determined by the non-parametric Kruskal-Wallis test. 
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Table S1. (Continued) 
 
LF HF HF-Lf HF-BSA 
Genus 
    Parasutterella  0.12* 0.00 0.32* 0.62*∆ 
Desulfovibrio  0.38 0.25 0.35 0.45 
Bilophila  0.09 0.09 0.14 0.09 
Bacteroides  1.42* 0.74 1.96∆ 1.04 
RC9 gut group  2.40 1.69 2.04 2.07 
Alistipes  5.21 4.25 6.12 8.05 
Rikenella  0.60 0.88 1.21¥ 2.11 
Odoribacter  2.73 3.41 4.94¥ 7.58¥ 
Parabacteroides 0.17 0.39 0.25 0.18 
Bifidobacterium  1.43 1.00 1.55 0.84 
Lactobacillus  4.85 5.37 5.46 3.15 
Allobaculum  44.79 49.58 31.66 37.03 
Lachnospiraceae IS 0.72*∆ 0.39 0.57 0.39 
Roseburia  0.30 0.12 2.19*¥∆ 0.21 
 
Microbial taxonomies detected within the microbiotas of C57BL/6   mice after 12 weeks consuming either a HF, LF, HF-Lf diet or HF-BSA diet. Data is expressed as the 
total percentage of bacteria present within the data set and where * indicates a value significantly higher than the HFD group, ¥ indicates a value significantly higher than the 
LFD group, † indicates a value significantly higher than the HF-Lf group and ∆ indicates a value significantly higher than the HF-BSA group, where significance was taken 
as p≤0.05 as determined by the non-parametric Kruskal-Wallis test. 
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Table S1. (Continued) 
 
LF HF HF-Lf HF-BSA 
Coprococcus  0.14 0.10 0.89 0.27 
Catabacter  0.05* 0.02 0.08 0.02 
Ruminococcaceae IS 3.67 3.24 3.74 4.92 
Anaerotruncus  0.90* 0.45 0.54 0.78 
Oscillibacter  0.13 0.17 0.19 0.46*¥† 
Peptococcus  0.24 0.36 0.35 0.24 
Anaeroplasma  0.43 0.05 0.08 0.03 
RF9  0.29 0.32 0.26 0.57 
Mucispirillum  2.26* 0.32 2.36* 1.53 
Coriobacteriaceae 0.01 0.03 0.02 0.01 
Lactococcus 0.06†∆ 0.09†∆ 0.00 0.00 
Peptostreptococcaceae IS 0.16 2.13¥ 0.37 1.96 
Thalassospira 0.00 0.00 0.02 0.02 
Enterorhabdus 0.01 0.02 0.07 0.05 
Akkermansia 0.00 0.16¥ 0.24 0.24 
Turicibacter 0.00 0.08 0.02 0.00 
Blautia 0.00 0.00 0.00 0.02 
Ruminococcus 0.00 0.00 0.00 0.01 
Uncultured bacteria 0.54 1.95 0.97 0.66 
Microbial taxonomies detected within the microbiotas of C57BL/6   mice after 12 weeks consuming either a HF, LF, HF-Lf diet or HF-BSA diet. Data is expressed as the 
total percentage of bacteria present within the data set and where * indicates a value significantly higher than the HFD group, ¥ indicates a value significantly higher than the 
LFD group, † indicates a value significantly higher than the HF-Lf group and ∆ indicates a value significantly higher than the HF-BSA group, where significance was taken 
as p≤0.05 as determined by the non-parametric Kruskal-Wallis test.
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Table S2. Total 16s rRNA sequence reads generated by sequencing processes 
 
Experiment Sequencing platform 
16s rRNA 
gene region 
Total reads 
generated 
Reads per 
sample 
Impact of 2.5% and 
5% BSA on the adult 
human gut microbiota 
in a distal colon 
model. 
Roche 454 high-throughput 
pyrosequencing 
V4-V5 182,890 
 
10,161 
 
     
Impact of nLf, hLf and 
mLf on the adult gut 
microbiota in a distal 
colon model. 
Illumina MiSeq 16s rRNA 
amplicon sequencing 
V3-V4 1,396,892 29,102 
     
Investigation of the 
substitution of casein 
with either Lf or BSA 
in a high fat murine 
diet on the gut 
microbiota of C57BL/6 
mice. 
Roche 454 high-throughput 
pyrosequencing 
V4-V5 371,333 11,604 
 1 
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Figure S1. Principal Coordinate analysis (PCoA) of unweighted Unifrac distances 
of generated 16S rRNA sequences across 3 runs of an ex vivo simulated adult human 
microbiota fermentation containing 2.5% BSA, 5% BSA or no additional BSA 
(control). Where, • represents Control (0h), • represents control (24h), • represents 
2.5% BSA (0h), • represents 2.5% BSA (24h), • represents 5% BSA (0h) and • 
represents 5% BSA (24h).  
 
 
216 
 
Figure S2. Scatter plot analysis representing the assigned score for each examined 
alpha diversity measure (Chao1, Simpson index, Shannon index, PD Whole Tree 
and observed species) at 0, 4, 8 and 24h of an ex vivo fermentation with an adult 
human gut microbiota with the addition of 1% (w/v) FOS, nLf, hLf or mLf.   
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Figure S3a. Doughnut charts representing the relative abundance of detected microbial taxonomies at phylum level at 0, 4, 8 and 24h of a 
simulated colonic fermentation in response to the addition of 1% (w/v) FOS, nLf, hLf or mLf. 
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Figure S3b. Doughnut charts representing the relative abundance of detected microbial 
taxonomies at family level at 0, 4, 8 and 24h of a simulated colonic fermentation in response 
to the addition of 1% (w/v) FOS, nLf, hLf or mLf. 
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Chapter 4 
Voluntary exercise alters energy balance and the gut microbiota in a 
time dependent manner in C57BL/6 mice fed a low fat diet. 
 
 
 
 
 
 
 
 
 
 
 
Manuscript in review 
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4.1 ABSTRACT 
Here, we investigated the effect of voluntary exercise on energy balance and related 
parameters, including the composition of the gut microbiota, in male C57BL/6 mice. 
Mice consumed a 10% energy (low) fat diet (LFD), with (RW+) or without (RW-) 
access to running wheels for eight weeks. The RW+ group had similar body weight 
trajectory and body composition to RW- animals, but consumed significantly more 
food by week three of the trial (p<0.05), as a result of higher intake during the dark 
phase. Metabolic activity was increased in the RW+, both in the light and dark 
phases, compared to RW- group and respiratory exchange ratio was significantly 
increased in the dark phase in the RW+ compared to RW- group, indicating 
increased tissue carbohydrate metabolism (p<0.05). This was supported by 
unchanged levels of plasma insulin and glucose and by a trend towards an increased 
expression of  hypothalamic insulin receptor (INSR) (p=0.085), glucose transporter 
1 (Glut1) (p=0.085), insulin receptor substrate 1 (IRS1) (p=0.065), fatty acid 
synthase (FASN) (p=0.071) and peroxisome proliferator activated receptor alpha 
(PPAR (p=0.052), all at the trial’s week 8 end point.High throughput DNA 
sequencing revealed subtle changes in the microbiota of the RW+ group relative to 
the RW- group. More specifically, at week 4 the RW+ cohort contained significantly 
higher proportions of Bacteroidaceae/Bacteroides and significantly lower levels of 
Clostridiaceae/Clostridium compared to the RW- cohort. When week 4 taxonomic 
data was coupled with PICRUSt-based predicted metabolic functional data, 
differences in the functional potential of the microbiota, with propionate metabolism 
and fatty acid biosynthesis were predicted to be significantly higher in the RW+ 
cohort at week 4, but not week 8. Thus, initial changes to the gut microbiota 
observed after four weeks of voluntary exercise preceded changes in host expression 
of genes involved in energy intake. This study suggests a time dependent, link 
between physical exercise, the gut microbiome and energy balance.  
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4.2 INTRODUCTION 
Physical exercise has been shown to reduce systemic inflammation and is an 
excellent therapeutic intervention for obesity and type-2-diabetes (T2D), with effects 
often shown to be as beneficial (in terms of efficacy) as pharmaceutical interventions 
(Booth et al. 2002, Group 2002, Gleeson 2007). Using the diet-induced obesity 
(DIO) mouse model, it has been shown that physical exercise reverses obesity 
associated hyperglycaemia, body fat, body weight, and alters the gut microbiota (see 
below) as well as markers of inflammation (Bradley et al. 2008, Huang et al. 2010). 
Furthermore, exercise has been associated with the improvement of several non-
obesity related conditions such as osteoporosis and lowering the risk of developing 
several GI diseases such as colon cancer and inflammatory bowel diseases (IBDs) 
(Booth et al. 2002, Martin 2011, Sanchez et al. 2012, Khalili et al. 2013).  Thus, 
there has been a growing interest in understanding the related mechanisms 
associated with physical exercise.  
Similarly, there have been ever greater efforts to determine if the gut microbiota 
plays a role in exercise-induced alterations in the balance between energy intake and 
expenditure that determines body weight, as this knowledge could be used to 
optimise the effects of exercise and in the general population and provide better 
health outcomes for patients with a wide range of conditions including obesity and 
associated T2D and inflammatory bowel diseases such as Crohn’s disease and 
ulcerative colitis (UC) (Booth et al. 2002, Group 2002, Gleeson 2007, Dicksved et 
al. 2008, Machiels et al. 2013) . Notably, it is increasingly appreciated that humans 
may now be thought of as “superorganisms” owing to the metabolic potential not 
only encoded by our own genomes but also that encoded within our associated 
microbial metagenome. It has been estimated that the human microbiota contains 
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more than 1000 bacterial species each possessing a genome encoding an average of 
5000 genes resulting in a microbial genetic repertoire far larger than that of the 
human host (Xu et al. 2003, Eckburg et al. 2005) and  therefore capable of 
performing metabolic functions not encoded by the host genome. The vast majority 
of these microbial inhabitants (~1.5kg or 100 trillion cells) reside within the gut 
leading to the gut microbiota being heralded as the body’s “forgotten organ” (O'Hara 
and Shanahan 2006, Consortium 2012). These bacterial gut residents have been 
shown to play a key role in dietary energy harvest through the action of microbial 
enzymes. Bäckhed et al. showed germ-free mice develop less body fat than their 
conventionally raised counterparts, however when germ-free mice were 
conventionalized, a dramatic increase in body fat was observed in spite of decreased 
energy intake (Bäckhed et al. 2004).  
While several studies have examined the effect of obesity and high fat feeding on the 
composition of the gut microbiota, to date relatively few studies have examined the 
impact of exercise on the gut microbiota and, in turn, energy balance. In a recent 
study by Clarke et al., the bacterial diversity of professional athletes was shown to 
be significantly higher than that of both high and low BMI controls (Karlsson et al. 
2012, Everard et al. 2013, Clarke et al. 2014). With respect to murine studies, Evans 
et al. assessed how a diet consisting of 60% energy (high) fat, 20% energy protein 
and 20% energy carbohydrate (high fat diet; HFD) affects the gut microbiota in mice 
that had access to running wheels (RW+) for 14 weeks. Voluntary exercise was 
shown to reduce weight gain and alter the composition of the gut microbiota 
compared to sedentary (RW-) controls. By feeding a 10% energy (low) fat, 20% 
energy protein and 70% energy carbohydrate enriched diet (LFD) to RW+ mice, the 
same study demonstrated that physical exercise does not significantly change body 
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weight but still altered the composition of gut microbial profiles at week 12 along 
with food intake at week 13, albeit to a lesser degree than observed in the HFD fed 
animals (Evans et al. 2014).   
While these studies provide an insight into the effect of exercise on gut microbial 
composition, variation in (1) diet, (2) species differences and (3) alteration in body 
weight make drawing direct conclusions between exercise, gut microbiota 
composition and energy balance difficult. Using the previously described LFD fed 
C57BL/6 RW+ mouse model (Evans et al. 2014) here we gained an insight into a 
time dependent effect linking physical activity, gut microbiota, and energy balance, 
without the confounding effects of high fat intake or exercise induced alteration in 
body weight. 
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4.3 MATERIALS AND METHODS 
4.3.1 Ethics 
All research procedures involving mice were licenced under the Cruelty to Animals 
Act 1976 and ethical approval was obtained via the University College Cork (UCC) 
Animal Ethical Review Committee (#2011/005). 
4.3.2 Animals 
Three week old male C57BL/6J mice (Harlan, Oxon, UK) were individually caged 
upon arrival and acclimatised for 2 weeks in individually ventilated cages. Animals 
were housed in the following controlled environment: light (06.00-18.00), 
temperature (21±1˚C) and humidity (45-65%) and allowed free access to drinking 
water and a LFD (10% kJ fat and 20% kJ casein; #D12450, Research diets, New 
Brunswick, NJ, USA). 
4.3.3 Experimental protocol 
Following the 2 week acclimatisation period, weight matched mice were housed 
individually with (RW+) or without (RW-) access to running wheels 
(n=8/group)(Figure 1). Mice were given the LFD with free access to drinking water 
and food. Body weights and food consumption were measured weekly with the 
exception of week 5 where food consumption could not be measured due to 
technical issues. During weeks 6-7, both food intake and metabolic activity were 
measured during light and dark phases using TSE PhenoMaster cages (TSE systems, 
Bad Homburg, Germany)(Figure 1). Fecal pellets were taken from all cages at weeks 
0, 4 and 8 to allow for the examination of gut microbial population via Illumina 
MiSeq DNA sequencing. At the end of the trial period, animals were fasted for 6 
hours and their body composition analysed using the Bruker minispec LF50H 
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(Bruker optics, Ettlingen, Germany). Mice were then anesthetised with a co-
administration of Ketamine (65 mg/kg bodyweight) and Xylazine (13 mg/kg 
bodyweight). Blood was taken from anesthetised mice into EDTA treated tubes (BD, 
USA) and treated with both Aprotinin and Diprotin A at a final concentration of 
500,000 KIU/L and 0.1mM respectively (Sigma, Ireland) to protect from proteolytic 
digestion. Plasma was separated from blood by centrifugation at 2000rpm at 4˚C for 
15 minutes. Mice were then sacrificed by cervical dislocation and tissues of interest 
dissected, weighted and either snap frozen in liquid nitrogen (subcutaneous, 
epididymal, stomach, intestine, colon, cecum, liver) or on dry ice (brain). Plasma 
and tissues were then stored at -80˚C prior to analysis.  
4.3.4 Analysis of metabolic activity  
The experimental protocol described by McAllan et al. (McAllan et al. 2013, 
McAllan et al. 2014) was used to analyse food intake, metabolic activity (VO2; 
oxygen consumption) at 9 minute intervals over the study period, with the exception 
that running wheels (used in the home cages) were introduced into the TSE 
PhenoMaster cages upon housing the RW+ mice. Mice had ad libitum access to LFD 
and water during the ~3 day housing period in the PhenoMaster cages. After the 
initial 17h acclimatisation period, wheel rotations were automatically recorded on 
day 1 (Figure 1). Although the RW+ mice had access to RW in day 2, the RW 
sensor was disconnected on this day in order to measure metabolic activity. Food 
intake was measured over day 1 and 2, averaged. Respiratory exchanged ration 
(RER) was determined using VCO2 and VO2 data recorded on day 2.  
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4.3.5 Microbial DNA extraction, 16s rRNA amplification and Illumina MiSeq 
sequencing 
Fecal pellets were collected form each animal on the trial at weeks 1, 4 and 8. Total 
metagenomic DNA was extracted from these fresh pellets with the QIamp DNA 
Stool Mini Kit (Qiagen, Hilden, Germany) where, an additional bead beating step 
was incorporated into the protocol (Yu and Morrison 2004). Extracted DNA was 
quantified using the Nanodrop 1000 spectrophotometer (Thermo Scientific, Ireland). 
The V3-V4 variable region of the 16s rRNA gene was amplified from each extracted 
DNA sample according to the 16S metagenomic sequencing library protocol 
(Illumina). Initially the template DNA was amplified using primers specific to the 
V3-V4 region of the 16s rRNA gene which also allowed for the Illumina overhang 
adaptor, where, the forward primer 
(5’TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWG
CAG) and reverse primer 
(5’GTCTCGTGGGCTCGGAGATGTGTATAAGAGACA 
GGACTACHVGGGTATCTAATCC) were used. Each PCR reaction contained 
2.5µl DNA template, 5 µl forward primer (1µM), 5 µl reverse primer (1µM) (Sigma, 
Ireland) and 12.5 µl Kapa HiFi Hotstart Readmix (2X) (KAPA Bioscystems Inc, 
USA). The template DNA was amplified under the following PCR conditions for a 
total of 25 cycles: 95˚C for 3 minutes and 30 seconds respectively (initialization and 
denaturation), 55˚C for 30 seconds (annealing), 72˚C for 30 seconds (elongation) 
followed by a final elongation period of 5 minutes. A negative control reaction 
whereby the template DNA was replaced with PCR grade water was employed to 
confirm lack of contamination and PCR products were visualised using gel 
electrophoresis (1X TAE buffer, 1.5% agarose gel, 100v) post PCR reaction. 
227 
 
Successful amplicons were then cleaned using the AMpure XP purification system 
(Beckman and Coulter, Takeley, UK). A second PCR reaction was then completed 
using the previously amplified and purified DNA as the template. Two indexing 
primers (Illumina Nextera XT indexing primers, Illumina, Sweden) were used per 
sample to allow all samples to be pooled, sequenced on one flow cell and 
subsequently identified bioinformatically. Each reaction contained 25 µl Kapa HiFi 
HotStart ReadyMix (2X), 5 µl template DNA, 5 µl index 1 primer (N7xx), 5 µl 
index 2 primer (S5xx) and 10 µl PCR grade water. PCR conditions were the same as 
previously described with the samples undergoing just 8 cycles instead of 25. PCR 
products then underwent the same electrophoresis and cleaning protocols as 
described above. Samples were then quantified using the Qubit 2.0 fluorometer 
(Invitrogen, Carlsbad, CA, USA) in conjunction with the broad range DNA 
quantification assay kit (Life technologies, Carlsbad, CA, USA)). All samples were 
then pooled to an eqimolar concentration and the pool underwent a final cleaning 
step. Quality of the pool was determined using the Agilent Bioanalyser prior to 
sequencing. The sample pool was then denatured with 0.2M NaOH, diluted to 4pM 
and combined with 10% (v/v) denatured 4pM PhiX. Samples were then sequenced 
in house on the MiSeq sequencing platform at the Teagasc Next Generation 
sequencing platform centre (Teagasc Food Research Centre, Moorepark) using a 
2x300 cycle V3 Kit following protocols outlined by Illumina (Fouhy et al. 2015).   
4.3.6 Bioinformatic analysis 
Three hundred base pair paired-end reads were assembled using FLASH (fast length 
adjustment of short reads to improve genome assemblies). Paired-end reads were 
further processed with the inclusion of quality filtering based on a quality score of > 
25 followed by subsequent removal of mismatched barcodes and sequences below 
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length threshold using QIIME. USEARCH v7 (64-bit) was then used for denoising 
and chimera detection ad well as clustering into operational taxonomic units 
(OTUs). PyNAST was used to align OTUs and taxonomy was assigned by using 
BLAST against the SILVA SSURef database release 111. QIIME was used to 
generate Alpha and Beta diversities, calculated based on Bray Curtis, Weighted and 
UnWeighted Unifrac distance matrices. Principal coordinate analysis (PCoA) plots 
were then visualised using EMPeror v0.9.3-dev. Predictive functional profiling was 
performed using the  PICRUSt (phylogenetic investigation of communities by 
reconstruction of unobserved states) tool (Langille et al. 2013). 
4.3.7 RNA extraction and Real-Time (RT) PCR analysis 
Total RNA was extracted from hypothalamic blocks using the RNeasy lipid mini kit 
(Qiagen) according to manufacturer’s protocols. Potential DNA contamination was 
eliminated by the incorporation of DNase (Qiagen) treatment during the RNA 
extraction process. Reverse transcription of 1µg of RNA was achieved using 
2.5ng/µl random hexamer primers (Bioline, London, UK), 2 U/µl RNase inhibitor 
(Promega, Madison, USA), 0.5 mM dNTP (Promega) and the Superscript II first 
stand system (Invitrogen) in accordance with manufacturer’s instructions. Gene 
expression was measured using the Roche Lightcycler 480 system (Roche, Rotkreuz, 
Switzerland) by the amplification of 1µl complementary DNA using the Lightcycler 
SYBR Green I Mastermix kit (Roche, Penzberg, Germany) with 2.5µM gene 
specific primers (Table 1). Complimentary DNA was amplified under the following 
PCR conditions for a total of 50 cycles: 95˚C for 10 minutes (initial denaturation), 
95˚C for 10 seconds (denaturation), 58-65 ˚C for 5 seconds (annealing) and 72˚C for 
5 seconds (elongation). The authenticity of PCR products was determined by 
melting curve analysis and using automated sequencing.  Data corresponding to 
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crossing point (Cp) values were normalised to the expression of the housekeeping 
genes -actin. (∆∆Cp = ∆ Cp target gene - ∆ housekeeping gene).  
4.3.8 Plasma analysis 
ELISA were used to quantify plasma levels of Insulin (Crystal Chem, Downers 
Grove, IL,  USA), glucagon-like peptide 1 (GLP-1) (Millipore, St. Charles, MO, 
USA), Peptide YY (PYY) (Phoenix Pharmaceuticals), Ghrelin (EMD Millipore), 
and glucose (Calibochem, Darmstadt, Germany). 
4.3.9 Statistical analysis 
Data were analysed by Two-Sample T-Test. ANCOVA was used to assess the effect 
of RW on VO2, with body weight as the co-varite. Non-parametric Kruskall-Wallis 
analysis was carried out to determine statically significant taxonomic differences 
between the RW+ and RW- groups where statistical significance was accepted as 
p<0.05. Spearman correlations were used to examine relationships between the 
measured parameters where again significance was accepted as p<0.05. Statistics 
were performed using Graphpad prisim (ver. 6.04; San Diego, CA, USA) and 
Minitab statistical software package (ver. 15; State College, PA, USA) 
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4.4 RESULTS 
4.4.1 Voluntary exercise altered energy balance. 
Body weights of the RW+ mice did not significantly differ from RW- mice at any 
point during the 8 week trial period (Figure 2A), which was reflected by unchanged 
% fat and lean mass (Figure 2C) and by tissues weights (Table 2). In contrast, in the 
home cages, voluntary exercise increased food intake, becoming significant at weeks 
3 and 4 in the RW+ compared to the RW- control group (P<0.05)(Figure 2B), and in 
weeks 6 and 7 when the feeding behaviour was further characterised using TSE 
Phenomaster cages. The metabolic cage analysis further revealed that mice in RW+ 
group had significantly increased dark phase food consumption compared to RW- 
counterparts (p<0.05) (Figure 3A) along with significantly increased use of the 
running wheels during dark phase compared to light phase, as measured by running 
wheel rotations (left and right)(p<0.05) (Figure 3B). Energy expenditure, as 
determined by VO2, was significantly increased in the RW+ compared to RW- 
(p<0.05) during both light and dark phases (Figure 3C). 
To understand the mechanisms underlying the increased food intake in RW+ group, 
plasma levels of several gastrointestinal derived hormones and associated 
hypothalamic neuropeptide gene expression were examined. Plasma levels of GLP-
1, PYY and ghrelin showed no significant difference between the two groups. 
Hypothalamic expression of orexigenic neuropeptide Y (NPY) and anorexigenic 
pro-opiomelanocortin (POMC) was unaltered in RW+ group while gene expression 
of fatty acid synthase (FASN) and peroxisome proliferator activated receptor alpha 
(PPAR both showed a notable trend towards an increase in the RW+ cohort 
compared to the RW- cohort (P=0.071 and 0.052, respectively) (Figure 4).  
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4.4.2 Voluntary exercise and carbohydrate metabolism 
The RER calculated based on metabolic data generated at week 6 and 7 using TSE 
PhenoMaster cages revealed an increased metabolism of carbohydrate (RER close to 
1) in the dark phase in the RW+ group compared to RW- (Figure 3D) and yet plasma 
insulin and glucose of both groups were not significantly different. This was 
accompanied by a notable trend towards significantly higher expression of genes 
involved in cellular glucose uptake in the hypothalamus, namely insulin receptor 
(INSR) (p=0.085), glucose transporter 1 (Glut1) (p=0.085) and insulin receptor 
substrate 1 (IRS1) (p=0.065)(Figure 4). 
4.4.3 Voluntary exercise  does not alter microbial diversity and invokes only 
minor changes to gut microbial taxonomies. 
A total of 11,513,829 V3-V4 16s rRNA paired end sequence reads were generated 
during the sequencing process, corresponding to an average of 239,871 reads per 
animal per time point. Alpha diversity values were calculated (Figure 5) for species 
richness (Chao1), biodiversity (Shannon index), observed species and species 
number relative to abundance within the sample (Simpson diversity index). At week 
0 (i.e. before any exercise took place), values for both Chao1 and observed species 
were statistically higher the in RW+ cohort compared to the RW- cohort, a trend 
which continued at weeks 4 and 8. No other significant differences were observed in 
-diversity. Principal coordinate analysis (built upon the unweighted unifrac 
algorithm) (Figure 6) did not reveal any distinct clustering between the two groups 
within the trial at any of the examined time points.  
Phylogenetic analysis (examined at phylum, family and genus level) detected minor 
changes in microbial taxonomy between RW+ and RW- animals (Table 3). At week 
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0, significantly higher relative proportions of the families Veillonellaceae and 
Moraxellaceae (p=0.046 and 0.002, respectively) and the genera Acidominococcus 
and Morella (p=0.027 and 0.002, respectively) were detected in the animals that 
were subsequently assigned as the RW+ cohort compared to the RW- animals. By 
week 4 of the experiment, the RW+ cohort showed significantly lower relative 
abundances of Cyanobacteria (p=0.016) at phylum level, significantly higher 
proportions of Bacteroidaceae and Rhodospirillaceae (p=0.046 and 0.046, 
respectively) at family level and Bacteroides and Mogibacterium (p=0.046 and 
0.043, respectively) at genus level compared to the RW- group. Conversely, the 
RW- sequence data showed significantly higher proportions of Clostridaceae 
(p=0.035) at family level and Clostridium and Blautia (p=0.019 and 0.028, 
respectively) at genus level when compared to that of the RW+ animals. At the 
trial’s end point (week 8), exercising animals showed significantly lower 
populations within the Cyanobacteria (p=0.002) phylum but significantly higher 
proportions within the Coriobacteriaceae and Alcaligenaceae (p=0.016 and 0.025, 
respectively) families and the Enterorhabdus and Parasutterella (p=0.036 and 
0.025, respectively) genera when compared to those populations within the RW- 
group.  
4.4.4 Voluntary exercise-induced food intake positively correlates with gut 
microbial diversity. 
Correlations between metabolic parameters and both microbiota composition and 
diversity were examined using Spearman correlations. In the RW+ cohort, 
significant negative correlations were observed between Deferribacteres (phylum), 
Deferribacteraceae (family), Mucispirillum (genus) (p=0.007, r=-0.929) and 
Coprococcus (genus) (p=0.024, r=-0.857) and voluntary exercise while conversely, 
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Clostridium proportions were significantly positively correlated with exercise 
(p=0.048, r=0.802). Spearman correlations also revealed a significant positive 
correlation between VO2 and the taxonomic family Rikenellaceae while a strong 
positive correlation was observed between total food consumed and the Simpson and 
Shannon alpha diversity indices (p=0.034, r=0.821). 
4.4.5 PICRUSt analysis revealed alterations to metabolic pathways due to 
voluntary exercise. 
A PICRUSt analysis was carried out on both week 4 and week 8 sequence data. 
PICRUSt analysis of week 4 sequences predicted significantly altered metabolic 
pathways between the gut bacteria of the RW+ and RW- cohorts, where, 
carbohydrate metabolism, specifically propanoate  metabolism (p=0.036) and lipid 
metabolism, specifically fatty acid biosynthesis (p=0.027) were significantly higher 
in the RW+ cohort. In contrast, PICRUSt analysis of week 8 data did not suggest 
any significant differences between the two groups in terms of carbohydrate 
metabolism or fatty acid biosynthesis pathways.   
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4.5 DISCUSSION 
This study aimed to determine the effect of voluntary exercise on host metabolic 
parameters and the composition and diversity of the gut microbiota in C57BL/6 mice 
fed a LFD. Results from this study suggest that voluntary exercise alters energy 
balance and invokes subtle changes to gut microbial communities in a time 
dependent manner.  
Voluntary exercise has been shown to increase food intake in rodents (Garland et al. 
2011, Evans et al. 2014). We extend these findings by showing that degree of 
exercise dictates changes in energy balance, as mice in the RW+ group did not 
change food intake in weeks 1 and 2, but increased consumption only after 3 weeks 
of running wheel activity. Mice in the RW+ group exercise more in the dark phase 
and consumed more food compared to RW- controls. The increased food intake was 
not related to plasma ghrelin, PYY or GLP-1 or associated hypothalamic POMC and 
NPY gene expression, suggesting an alternative mechanism by which RW activity 
increased food intake in the animals. Notably, both hypothalamic FASN and 
PPARexpression have been shown to play important roles in food intake, as 
inhibition of FASN resulted in dramatic weight loss in BALB/c mice which was 
attributed to the inhibition of feeding. Moreover, mice with pancreatic and 
hypothalamic inactivated FASN show reduced food intake, which was normalised 
upon administration of a PPAR antagonist into the hypothalamus (Chakravarthy et 
al. 2007). These data indicate an important role for hypothalamic FASN/PPAR 
pathway in the control of food intake. It remains to be determined if this 
hypothalamic pathway plays a role in exercise induced food intake, given that in the 
current study, their gene expression showed a trend towards an increase in the RW+ 
group compared with that of the RW- group. It is also noteworthy that metabolic 
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activity (as determined by VO2 measurements) was highest in the dark phase in 
RW+ compared to RW- (either phase), as was food consumption, when running 
wheel rotations were highest. This further supports the above suggestion that degree 
of voluntary exercise impacts on energy intake and expenditure. In the current study, 
the LFD consisted mainly of carbohydrate (70% energy). This along with the 
increased food intake recorded during the dark phase in the RW+ group in 
comparison to the control group, are consistent with the high RER value (1.04±0.01) 
obtained in the RW+ group in the dark phase, indicating carbohydrate metabolism. 
Notably RER values exceeding 1.0 have previously been associated with intense 
physical activity (Jondeau et al. 1992). However, plasma insulin and glucose levels 
were not significantly different between groups. 
With respect to the mouse microbiota, alpha diversity differences originated from 
before separation of the RW+ and RW- groups and did not change significantly 
thereafter. These differences likely arose from either or litter or cage variations, 
which have been shown to have the ability to invoke considerable changes to the 
murine gut microbiota in terms of both composition and diversity (Whittaker 1972, 
Benson et al. 2010, Hildebrand et al. 2013). Beta diversity measured by the 
unweighted unifrac distances matrix (Figure 6) showed no clear separation between 
the two groups. This close clustering is consistent with results reported by Allen et 
al. in a recent study, who reported a similarly proximal clustering between 
exercising RW+ and RW- C57BL/6 mice both consuming a LFD after a 6 week trial 
period. Another comparable study conducted by Evans et al. showed a larger 
separation between control and voluntarily exercising mice after a 12 week period, 
and thus exercise may invoke more substantial changes to gut microbial profiles if 
sustained over a longer period of time (Evans et al. 2014, Allen et al. 2015).  
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The aforementioned increased energy intake and nutrient uptake observed within the 
RW+ cohort may, in some part, be modulated by the gut microbiota. High 
throughput DNA sequencing of fecal pellets taken at week 4 showed significantly 
higher proportions of the Bacteroidetes genus in the RW+ group compared to the 
RW- group.  Studies have shown that the Bacteroides genus harbour a wide amount 
of carbohydrate utilisation enzymes and therefore considerable saccharolytic 
potential is associated within this genus (Salyers et al. 1977, Salyers et al. 1977, Xu 
et al. 2003). Bäckhed et al. showed a 23% increase in body total body fat in germ 
free mice when colonised with Bacteroides thetaiotaomicron.  This increased total 
body fat  was accompanied by increased hepatic expression of FASN to facilitate the 
uptake of monosaccharaides (produced by the processing of dietary polysaccharides 
by microbial glycosylhydrolases) and their subsequent conversion in the liver to 
fatty acids (Bäckhed et al. 2004). Hooper et al. showed that B. thetaiotaomicron 
modulates the expression of several important intestinal functions including glucose 
uptake (Hooper et al. 2001). In this context it is interesting to note our 
hypothalamus-related observation that expression of FASN trended towards an 
increase, and was accompanied by similar changes in the insulin signalling pathway 
involved in glucose uptake, specifically a trend towards an increased expression of 
INSR, Glut1 and IRS1 compared to RW-. Interestingly, PICRUSt analysis of week 4 
sequence data predicted higher numbers of metabolic pathways for fatty acid 
biosynthesis among the RW+ group.  
As well as potentially playing a role in increased expression of FASN and glucose 
uptake, exercise may also drive changes in the gut microbiota that improve gut 
health by the production of short chain fatty acids (SCFAs). SCFAs are produced by 
the microbial fermentation of dietary macronutrients (primarily carbohydrates). The 
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major SCFAs found within the gut ecosystem are acetate, propionate and butyrate 
and are thought to influence host health by a variety of different mechanisms which 
include, providing energy for host tissues, exerting anti-inflammatory effects and 
maintaining microbial balance within the gut and members of the Bacteroidetes 
genus have been shown to produce these SCFAs indeed, fecal propionate levels have 
been significantly correlated to their relative abundance (Cummings 1981, Topping 
and Clifton 2001, Salonen et al. 2014, Flint et al. 2015). PICRUSt analysis further 
supported the production of SCFAs where it predicted the RW+ cohort had 
significantly higher proponoate production metabolic pathways resulting in the 
formation of propionate.  Conversely, significantly lower proportions of the SCFA 
producing genus Blautia were observed within the RW+ cohort at the same time 
point.  
Taxonomic analysis of sequence data generated at week 8 showed significant 
increases in proportions of Coriobacteriaceae and Alcaligenaceae at family level 
which corresponded to Enterorhabdus and Parasutterella, respectively, at genus 
level, in RW+ animals. Notably, both of these genera have been associated with the 
microbiota of lean mice compared with their obese and diabetic counterparts.  A 
2011 study by Geurts et al. showed Enterorhabdus to be present within the gut 
microbiota of lean mice but was not detected in the microbiota of either obese or 
diabetic animals. The authors suggested a relationship between specific gut bacteria 
and the regulation of certain important physiological systems such as the 
endocannabinoid (eCB) and apelin systems which play important roles in several 
physiological functions. This significant increase in the proportions of 
Enterorhabdus observed within the RW+ group may provide a mechanism through 
which sustained voluntary exercise can invoke microbially-mediated regulation of 
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important host genes. Zhang et al. showed a significant increase in Parasuterella 
upon switching DIO C57BL/6 mice to a normal chow diet after 12 weeks of high fat 
diet feeding, a switch which restored overall structure, composition and bacterial 
diversity (Geurts et al. 2011, Zhang et al. 2012).  
Finally, Spearman correlation analysis highlighted some potential links between 
voluntary exercise, energy intake and microbial taxonomies. A negative correlation 
was observed between voluntary exercise and Coprococcus. This is unexpected as 
Coprococcus has come to be regarded as a desirable component of the microbiota, as 
a producer of SCFAs and genus that is present in higher populations in elderly 
populations living in the community relative to those in in long time care (Claesson 
et al. 2012, Louis et al. 2014, Reichardt et al. 2014). The strong significant negative 
correlation between running activity and Mucispirillum was noteworthy given the 
previous association with this genus and ulcerative colitis (Robertson et al. 2005, 
Cook et al. 2013).  Strong positive correlations were also observed between total 
food consumed and both the Shannon and Simpson diversity indices. Given the 
significant increase in food consumption observed within the RW+ cohort, this 
correlation suggests that over a longer trial period, exercise driven increased food 
consumption may lead to increased bacterial diversity, a key marker of gut health 
(Shanahan 2003Shanahan 2003, Moran and Shanahan 2014). It is important, 
however, to remember that Spearman correlations are a direct parameter to 
parameter numerical comparison and do not take into account the complex interplay 
which exists within the gut microbiota. Therefore while these correlations suggest 
links to potential roles which parameters such as running wheel rotations may have 
on particular taxonomic populations, conclusions relating to the effect which 
voluntary exercise invokes on the gut microbiota are better drawn from the 
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differences observed between the RW+ and RW- groups (as determined by the 
Kruskal-Wallis test).  
In summary, the present data demonstrates that voluntary exercise increases energy 
intake, metabolic activity, and carbohydrate utilisation and are associated with subtle 
changes in the gut microbiota in C57BL/6 mice, with initial changes to the gut 
microbiota (observed at week 4) potentially contributing to subsequent changes in 
hypothalamic gene expression and associated increased energy intake.  
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Table 1. Primers used for RT-PCR to determine hypothalamic gene expression. 
 
RT_PCR primer sequences for examination of the hypothalamic expression of 
POMC, Pro-opiomelancortin; NPY, Neuropeptide Y; IRS-1, Insulin receptor 
substrate 1; PPAR,Peroxisome proliferator activated receptor alpha; FASN, Fatty 
acid synthase; IR, Insulin resistance and -actin.
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Table 2. Harvested tissues/organ weights. 
Tissue/Organ (g) RW- RW+ 
Sub Cutaneous (as % of BW) 1.49 ± 0.13 1.35 ± 0.18 
Epididymal fat (as % of BW) 2.03 ± 0.19 1.78 ± 0.16 
Stomach 0.41 ± 0.06 0.43 ± 0.03 
Intestine 0.91 ± 0.03 0.91 ± 0.03 
Colon 0.23 ± 0.02 0.24 ± 0.03 
Cecum 0.27 ± 0.01 0.28 ± 0.02 
Liver 1.01 ± 0.04 0.93 ± 0.05 
 
Animal tissues and organs weights (g) harvested post sacrifice. Data are means ± 
SEM.  
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Table 3. Significant taxonomic differences between RW + and RW – groups. 
Taxonomy P-value RW+ Group 
v RW- 
Group 
Week  0  Group in which 
proportions are 
significantly 
higher 
Family   
Veillonellaceae 0.046 RW+ 
Moraxellaceae 0.002 RW+ 
Genus   
Acidaminococcus 0.027 RW+ 
Moraxella 0.002 RW+ 
Week  4   
Phylum   
Cyanobacteria 0.016 RW- 
Family   
Bacteroidaceae 0.046 RW+ 
Clostridiaceae 0.035 RW- 
Rhodospirillaceae 0.046 RW+ 
Genus   
Bacteroides 0.046 RW+ 
Clostridium 0.019 RW- 
Mogibacterium 0.043 RW+ 
Blautia 0.028 RW- 
Week  8   
Phylum   
Cyanobacteria 0.002 RW- 
Family   
Coriobacteriaceae 0.016 RW+ 
Alcaligenaceae 0.025 RW+ 
Genus   
Enterorhabdus 0.036 RW+ 
Parasutterella 0.025 RW+ 
 
Statistically significant taxonomic differences between the RW+ and RW- groups 
observed at week 0, 4 and 8 where significance was taken at p<0.05 as determined 
by the Kruskal-Wallis non parametric test.   
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Figure 1. Experimental overview. Experimental overview showing timeline of the 
trial where; * indicates weekly bodyweight/food consumption measurements,  
indicates fecal pellet collection from individual mice for 16s rRNA compositional 
sequencing,  indicates point at which animal’s body composition was analysed 
using the Bruker minispec LF50H and  indicates point at which animal tissues were 
isolated (post sacrifice). 
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Figure 2. Impact of voluntary exercise on body weight, food consumption and 
body composition. (A) Body weight trajectories of mice during the 8 week 
experiment, (B) food consumption (up to week 5) and (C) body composition. Data 
represented are mean values ± SEM and where * determines significant differences 
between the two groups (p<0.05). 
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Figure 3. Impact of voluntary exercise on metabolic activity. Metabolic activity 
was measured using TSE Phenomaster cages at weeks 6-7 for mice with and without 
access to running wheels. Experimental data for; (A) total food consumption, (B) 
running wheel rotations (RW+ group), (C) oxygen consumption (Vo2) and (D) 
respiratory exchange ratio (RER) were collected from individual mice at 12 minute 
intervals during the 65 hour experimental period and are shown as mean values ± 
SEM for light and dark phases. Statistical significance was determined using 
ANCOVA for Vo2 and a Two-sample T-Test for all other parameters where 
significance was taken as p<0.05. 
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Figure 4. Hypothalamic gene expression. Hypothalamic gene expression was 
investigated in mice after 8 weeks of voluntary exercise on a standard low fat diet. 
Relative mRNA expression is shown here for fatty acid synthase (FASN), 
peroxisome proliferator activated receptor alpha (PPAR), Insulin receptor (INSR), 
glucose transporter 1 (Glut1), insulin receptor substrate 1 (IRS-1), pro-
opiomelancortin (POMC) and neuropeptide (NPY). Data represent mean values 
±SEM (n=8 per group). Gene expression shown is relative to -actin and statistical 
significance was determined where p<0.05. 
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Figure 5. Alpha diversity values. Alpha diversity measurements of  bacterial 
communities represented as means ± SEM, where, Choa1 and observed species 
show significantly higher values within the RW+ group as determined using the 
Kruskal-Wallis algorithm (p<0.05). 
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Figure 6. Impact of voluntary exercise on gut microbial composition. Principal Coordinate analysis (PCoA) of unweighted Unifrac 
distances of generated 16s rRNA sequences demonstrating no clear separation between the RW+ and RW- groups at weeks 0, 4 or 8, 
where, • points represent data generated from animals within the RW+ group and • represent points generated from animals within the 
RW- group.  
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4.7 SUPPORTING INFORMATION 
Table S1. PICRUSt predicted metabolic pathway activity. 
Week 4 data- Higher in RW+ Cohort P-Value 
Cellular.Processes.Cell.Growth.and.Death.Meiosis...yeast 0.093* 
Cellular.Processes.Cell.Growth.and.Death.p53.signaling.pathway 0.093* 
Environmental.Information.Processing.Signal.Transduction.Phosphatidylinositol.signaling.system 0.093* 
Genetic.Information.Processing.Folding..Sorting.and.Degradation.Sulfur.relay.system 0.036** 
Genetic.Information.Processing.Replication.and.Repair.Non.homologous.end.joining 0.093* 
Genetic.Information.Processing.Transcription.Transcription.machinery 0.059* 
Human.Diseases.Cancers.Colorectal.cancer 0.093* 
Human.Diseases.Cancers.Small.cell.lung.cancer 0.093* 
Human.Diseases.Cardiovascular.Diseases.Viral.myocarditis 0.093* 
Human.Diseases.Immune.System.Diseases.Systemic.lupus.erythematosus 0.059* 
Human.Diseases.Infectious.Diseases.Influenza.A 0.093* 
Human.Diseases.Infectious.Diseases.Toxoplasmosis 0.093* 
Metabolism.Amino.Acid.Metabolism.Phenylalanine.metabolism 0.036** 
Metabolism.Amino.Acid.Metabolism.Tyrosine.metabolism 0.036** 
Metabolism.Biosynthesis.of.Other.Secondary.Metabolites.Caffeine.metabolism 0.059* 
Metabolism.Carbohydrate.Metabolism.Glyoxylate.and.dicarboxylate.metabolism 0.074* 
Metabolism.Carbohydrate.Metabolism.Propanoate.metabolism 0.036** 
Metabolism.Carbohydrate.Metabolism.Pyruvate.metabolism 0.074* 
Metabolism.Energy.Metabolism.Sulfur.metabolism 0.059* 
Metabolism.Glycan.Biosynthesis.and.Metabolism.Glycosyltransferases 0.046** 
Metabolism.Lipid.Metabolism.Biosynthesis.of.unsaturated.fatty.acids 0.027** 
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Table S1. (Continued)  
Week 4 data- Higher in RW+ Cohort P-Value 
Metabolism.Lipid.Metabolism.Fatty.acid.elongation.in.mitochondria 0.059* 
Metabolism.Lipid.Metabolism.Linoleic.acid.metabolism 0.003** 
Metabolism.Lipid.Metabolism.Steroid.biosynthesis 0.059* 
Metabolism.Lipid.Metabolism.Steroid.hormone.biosynthesis 0.059* 
Metabolism.Metabolism.of.Cofactors.and.Vitamins.Retinol.metabolism 0.027** 
Metabolism.Metabolism.of.Terpenoids.and.Polyketides.Carotenoid.biosynthesis 0.059* 
Metabolism.Metabolism.of.Terpenoids.and.Polyketides.Limonene.and.pinene.degradation 0.074* 
Metabolism.Metabolism.of.Terpenoids.and.Polyketides.Tetracycline.biosynthesis 0.074* 
Metabolism.Xenobiotics.Biodegradation.and.Metabolism.Aminobenzoate.degradation 0.021** 
Metabolism.Xenobiotics.Biodegradation.and.Metabolism.Atrazine.degradation 0.046** 
Metabolism.Xenobiotics.Biodegradation.and.Metabolism.Bisphenol.degradation 0.009** 
Metabolism.Xenobiotics.Biodegradation.and.Metabolism.Caprolactam.degradation 0.036** 
Metabolism.Xenobiotics.Biodegradation.and.Metabolism.Chlorocyclohexane.and.chlorobenzene.degradation 0.074* 
Metabolism.Xenobiotics.Biodegradation.and.Metabolism.Drug.metabolism...cytochrome.P450 0.059* 
Metabolism.Xenobiotics.Biodegradation.and.Metabolism.Fluorobenzoate.degradation 0.059* 
Metabolism.Xenobiotics.Biodegradation.and.Metabolism.Metabolism.of.xenobiotics.by.cytochrome.P450 0.059* 
Metabolism.Xenobiotics.Biodegradation.and.Metabolism.Naphthalene.degradation 0.093* 
Metabolism.Xenobiotics.Biodegradation.and.Metabolism.Styrene.degradation 0.059* 
Organismal.Systems.Circulatory.System.Cardiac.muscle.contraction 0.093* 
Organismal.Systems.Endocrine.System.Insulin.signaling.pathway 0.046** 
Organismal.Systems.Environmental.Adaptation.Circadian.rhythm...plant 0.059* 
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Table S1. (Continued)  
Week 4 data- Higher in RW+ Cohort P-Value 
Unclassified.Cellular.Processes.and.Signaling.Inorganic.ion.transport.and.metabolism 0.059* 
Unclassified.Cellular.Processes.and.Signaling.Other.ion.coupled.transporters 0.009** 
Unclassified.Cellular.Processes.and.Signaling.Signal.transduction.mechanisms 0.059* 
Unclassified.Genetic.Information.Processing.Transcription.related.proteins 0.059* 
Unclassified.Metabolism.Metabolism.of.cofactors.and.vitamins 0.046** 
Unclassified.Metabolism.Others 0.046** 
Unclassified.Poorly.Characterized.Function.unknown 0.046** 
Week 4 data- higher in RW- Cohort 
 
Human.Diseases.Infectious.Diseases.Epithelial.cell.signaling.in.Helicobacter.pylori.infection 0.046** 
Metabolism.Metabolism.of.Cofactors.and.Vitamins.Nicotinate.and.nicotinamide.metabolism 0.074* 
Metabolism.Metabolism.of.Cofactors.and.Vitamins.One.carbon.pool.by.folate 0.093* 
Metabolism.Nucleotide.Metabolism.Pyrimidine.metabolism 0.093* 
Metabolism.Xenobiotics.Biodegradation.and.Metabolism.Drug.metabolism...other.enzymes 0.093* 
Unclassified.Metabolism.Glycan.biosynthesis.and.metabolism 0.074* 
Unclassified.Cellular.Processes.and.Signaling.Cell.division 0.036** 
Metabolism.Metabolism.of.Cofactors.and.Vitamins.Vitamin.B6.metabolism 0.059* 
Metabolism.Metabolism.of.Other.Amino.Acids.D.Glutamine.and.D.glutamate.metabolism 0.093* 
Metabolism.Energy.Metabolism.Methane.metabolism 0.059* 
Metabolism.Biosynthesis.of.Other.Secondary.Metabolites.Novobiocin.biosynthesis 0.074* 
Metabolism.Amino.Acid.Metabolism.Phenylalanine..tyrosine.and.tryptophan.biosynthesis 0.074* 
Human.Diseases.Metabolic.Diseases.Type.I.diabetes.mellitus 0.093* 
Human.Diseases.Metabolic.Diseases.Type.II.diabetes.mellitus 0.093* 
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Table S1. (Continued)  
Week 4 data- higher in RW- Cohort P-Value 
Human.Diseases.Neurodegenerative.Diseases.Amyotrophic.lateral.sclerosis..ALS. 0.046** 
Metabolism.Amino.Acid.Metabolism.Lysine.biosynthesis 0.046** 
Genetic.Information.Processing.Translation.Translation.factors 0.074* 
Genetic.Information.Processing.Transcription.Basal.transcription.factors 0.009** 
Genetic.Information.Processing.Replication.and.Repair.DNA.replication.proteins 0.093* 
Genetic.Information.Processing.Replication.and.Repair.Homologous.recombination 0.093* 
Genetic.Information.Processing.Folding..Sorting.and.Degradation.Protein.export 0.093* 
Cellular.Processes.Transport.and.Catabolism.Peroxisome 0.036** 
Cellular.Processes.Cell.Growth.and.Death.Cell.cycle...Caulobacter 0.093* 
Week 8 data- Higher in RW+ Cohort 
 
Environmental.Information.Processing.Signaling.Molecules.and.Interaction.Ion.channels 0.074* 
Human.Diseases.Infectious.Diseases.African.trypanosomiasis 0.074* 
Metabolism.Amino.Acid.Metabolism.Tyrosine.metabolism 0.059* 
Metabolism.Lipid.Metabolism.Linoleic.acid.metabolism 0.021** 
Metabolism.Metabolism.of.Cofactors.and.Vitamins.Retinol.metabolism 0.093* 
Metabolism.Metabolism.of.Other.Amino.Acids.Glutathione.metabolism 0.074* 
Metabolism.Xenobiotics.Biodegradation.and.Metabolism.Chlorocyclohexane.and.chlorobenzene.degradation 0.093* 
Organismal.Systems.Immune.System.RIG.I.like.receptor.signaling.pathway 0.093* 
Week 8 data- Higher in RW- Cohort 
 
Genetic.Information.Processing.Transcription.Basal.transcription.factors 0.021** 
Human.Diseases.Infectious.Diseases.Vibrio.cholerae.pathogenic.cycle 0.074* 
Human.Diseases.Neurodegenerative.Diseases.Parkinson.s.disease 0.074* 
Metabolism.Energy.Metabolism.Methane.metabolism 0.046** 
Unclassified.Metabolism.Glycan.biosynthesis.and.metabolism 0.027** 
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Figure S1. Plasma hormone levels 
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Chapter 5 
Short term exercise and/or dietary protein supplementation do not 
introduce elite athlete-like gut microbial diversity in previously 
inactive individuals.  
 
 
 
 
 
 
 
Peter Skuse Chapter Contributions 
Experimental: 
 Designed and performed all experiments relating all fecal sample DNA 
extraction, PCR amplification and DNA sequencing 
Results interpretation: 
 Analysis of all data pertaining to 16S rRNA gene sequencing. 
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5.1 ABSTRACT 
The gut microbiota of professional rugby players was recently shown to be 
significantly more diverse than that of controls. This increased diversity correlated 
with creatine kinase levels, a marker of extreme exercise, and dietary protein intake. 
To investigate the possibility of a link between exercise, protein consumption and 
the gut microbiota, the current study employed a three arm strategy to evaluate the 
impact of 1) an eight week exercise program (Ex), 2) the same exercise program in 
combination with daily whey protein supplementation (Ex+WPS) and 3) eight weeks 
of daily whey protein supplementation without exercise (WPS) on the composition 
and diversity of the gut microbiota of physically inactive subjects. Over the eight 
week intervention period, exercise increased the general fitness of the volunteers but 
did not significantly alter the composition or diversity of the gut microbiota. Within 
the Ex+WPS and WPS cohorts, a significant increase in Lactococcus populations 
was apparent, which is assumed to be as a consequence of daily whey protein 
supplementation. These results establish that eight week exercise regimes or dietary 
whey protein supplementation have negligible to subtle impacts on the gut 
microbiota and, thus, longer term intervention studies are required to determine if 
more considerable changes can be induced by these interventions.  
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5.2 INTRODUCTION 
The human gut microbiota has been the subject of intensive investigation over the 
last decade, largely due to increasing number of studies linking its composition and 
function with health and disease. A ‘normal/healthy-functioning’ gut microbiota has 
been shown to confer several health benefits to the host, such as protection against 
opportunistic pathogens and modulation of the host immune system (Sekirov et al. 
2010, Joyce and Gahan 2014). Conversely, perturbations in the composition of the 
normal gut microbiota have been implicated in the pathogenesis of several disease 
states, including type-2-diabetes, obesity and inflammatory bowel disease (Qin et al. 
2012, Moran and Shanahan 2014, Marchesi et al. 2015). Therefore the gut 
microbiota may be thought of as an environmental factor which may confer risk or 
resistance to a wide range of inflammatory and metabolic disorders.  
Changes in human behaviour have, in turn, been shown to invoke changes to the 
composition of the gut microbiota (Shanahan 2012). Several studies have shown that 
changes in dietary habits can result in alterations in the composition of the gut 
microbiota. Walker et al. reported a change in the fecal bacterial populations in 
obese men within four days after the subjects had been switched to a diet 
supplemented with resistant starch (Walker et al. 2011). Furthermore, Claesson et al. 
reported  that community dwelling elderly subjects which consumed a healthier and 
more diverse diet, harboured a more diverse gut microbiota than individuals residing 
in long term care facilities which consumed a less diverse diet (Claesson et al. 2011). 
Although exercise is also an environmental factor that influences a wide range of 
physiological processes, its impact on the gut microbiota has received relatively little 
attention. This is despite data showing that the type and degree of exercise 
undertaken by an individual invokes differential impacts on intestinal function. 
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Moderate exercise is associated with an improvement in intestinal barrier function 
and reduced bacterial translocation (Luo et al. 2014). In mice, forced aggressive 
treadmill training has been shown to aggravate inflammatory indices and outcomes 
in colitis-induced mice, while conversely, voluntary running wheel exercise 
produced a protective effect (Cook et al. 2013). Given the capacity for exercise to 
influence intestinal conditions, it is a reasonable supposition that physical activity 
also influences commensal enteric microbial populations. It is also notable that 
exercise has been increasingly recognised as an excellent alternative to 
pharmaceutical treatments for several disease states that have been linked with the 
gut microbiota, such as type-2-diabetes (Schwingshackl et al. 2014), irritable bowel 
syndrome (IBS) (Johannesson et al. 2011) and colorectal cancer (CRC) (Robsahm et 
al. 2013). To date, the majority of the relatively few studies that have investigated 
the influence of physical activity on the enteric microbiota have utilised rodent 
models, and have tended to explore the impact of physical activity on the intestinal 
microbiota in combination with dietary interventions such as low or high fat diets 
(Evans et al. 2014, Allen et al. 2015). In one recent human study, Clarke et al. 
reported that professional rugby players harboured a gut microbiota which was 
significantly more diverse, and had a significantly lower inflammatory tone, than 
that of high or low BMI control subjects. Moreover, this increased biodiversity 
significantly and positively correlated with increased dietary protein intake and 
creatine kinase (serving as a proxy for the degree of exercise), raising the question; 
are exercise and increased protein intake drivers of microbial diversity within the gut 
(Clarke et al. 2014)? 
To address this topic, this study aimed, through the use of high-throughput DNA 
sequencing, to determine if an eight week exercise intervention and/or whey protein 
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supplementation would influence the gut microbiota of previously physically 
inactive individuals whilst maintaining habitual dietary habits.  
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5.3 MATERIALS AND METHODS 
5.3.1 Ethical Approval and informed consent 
Prior to commencement of the study, ethical approval was sought and granted by the 
Clinical Research Ethics Committee (CREC) of the Cork Teaching Hospitals, Cork 
City, Ireland, in accordance with guidelines outlined in the declaration of Helsinki. 
All volunteers provided informed consent prior to their participation in the study and 
were informed of their right to withdraw consent at any stage. 
5.3.2 Subject recruitment 
Healthy males and females between the ages of 18 and 40 years with a body mass 
index (BMI) of 22-35 were recruited subject to meeting the inclusion/exclusion 
criteria outlined in table 1. At the time of recruitment, individuals were required to 
be physically inactive as determined using the short form of the International 
Physical Activity Questionnaire. Volunteers with significant medical histories that 
posed a potential harm to the patient by participating in an exercise program were 
excluded. All participants were screened for potential risks using an adapted version 
of the American College of Sports Medicine’s safe participation guidelines 
(Pescatello 2014). 
5.3.3 Withdrawal and exclusion from the study 
Less than 90% compliance with WPS led to exclusion from the study. Likewise, 
participants who missed over one week of the study period due to any reason were 
excluded from the study. Adverse events experienced by the subjects during the 
study were recorded and discussed with the principal investigators as to whether it 
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was safe for the participant to continue. Any subjects experiencing a serious adverse 
event during the study period was to be withdrawn.  
5.3.4 Experimental Design 
This study comprised a prospective, randomized, three armed, diet-controlled trial 
based in a single centre at Cork University Hospital, Cork, Ireland. Volunteers 
assigned to arm 1 of the study (Ex) participated in a defined exercise program 
throughout the 8 week intervention period (n=26). Volunteers assigned to arm 2 of 
the study (Ex+WPS) undertook the same 8-week exercise program in combination 
with a once daily whey protein supplement (WPS) for the duration of the study 
period (n=22). Finally participants assigned to arm 3 of the study (WPS) only 
consumed the daily WPS and did not participate in the exercise program (n=27).  
Baseline (week 0) and post intervention (week 8) anthropometric characteristics 
were recorded for each subject recruited into the study (Table 2). Resting blood 
pressure and body composition were also recorded at the same time points. Blood 
pressure was measured in the seated position using a calibrated electronic 
sphygmomanometer (Welch-Allyn, 300 Series, Beaverton, OR, USA). Dual Energy 
X-ray absorptiometry (DEXA) was used to assess body composition using a GE 
Healthcare Lunar iDXA (GE-Healthcare.). Total body scans of the participants were 
performed using the same apparatus providing whole body and segmental analyses 
(trunk, arms and legs). The enCORE software (version 13.4, 2010) was used for 
scan analysis and uses a 3-compartment model to estimate body fat percentage %BF. 
Total body fat values were derived using the region %BF value calculated from the 
GE Lunar iDXA machine (Region %BF = Fat mass/(Fat + Lean + Bone mass)). 
Apparatus calibration was performed before the commencement of the study period 
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and quality control assessment was performed before each scanning session.   
5.3.5 Blood and stool sampling 
Approximately 10 – 15mls of venous blood was drawn per participant at the same 
previously mentioned time points. Blood was filled into standard EDTA and serum 
blood tubes extensive blood profile testing was carried out at the Mercy University 
Hospital Haematology and Biochemistry laboratories (Table 3). Commercial 
multiplex microplates (Meso Scale Diagnostics, Rockville, Maryland, USA) were 
used to measure volunteers resting cytokine profiles. All participants provided a 
fresh stool sample at the week 0 and week 8 time points for total genomic DNA 
extraction and subsequent Illumina Miseq compositional sequencing.  
5.3.6 Whey protein supplementation 
Subjects randomized to the Ex+WPS or WPS groups were required to take a once 
daily whey protein supplement (WPS) (30g) (Carbery foods, Ballineen, Co. Cork). 
Throughout the study period, participants were asked to maintain their normal 
dietary patterns and asked to refrain from taking unspecified dietary, multivitamin or 
herbal. Subjects already consuming dietary supplements prior to recruitment 
underwent a 14 day washout period before participating in the study.  
5.3.7 Structured exercise program 
All subjects undertook an 8-week mixed aerobic and resistance training program 
having first undergone a 90 minute induction session with a qualified gym 
instructor. Subjects were required to train 3 times per week aiming for a total of 24 
sessions during the 8-week study period. All sessions took place in the Mardyke 
Arena gymnasium at University College Cork, Cork, Ireland.  
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Aerobic exercise was standardized and progressive, suitable for inactive and 
exercise naïve individuals. The program required similar levels of energy 
expenditure to couch to 5km training regimes. Subjects were allowed to select from 
a number of cardiovascular machines (treadmill, upright stationary bike, cross-
trainer and stepper machine). Duration of activity was altered to ensure that similar 
levels of energy expenditure occurred regardless of choice of machine. Aerobic 
activity was of moderate to vigorous intensity (5 to 7/10 on the Borg scale of 
perceived exertion).  
At resistance each training session, participants were required to complete 7 out of 
10 resistance exercises including 3 upper body, 3 lower body and 1 core muscle 
exercise. Starting weights were 70% of the individual’s one repetition maximum 
valued calculated using the Bryzicki formula (Brzycki 1998). Free weight use was 
not permitted in the study. Progress, attendance and compliance to the subject’s 
training programs recorded using the FitLinxx system installed in all machines in the 
Mardyke arena.   
5.3.8 Cardio-respiratory fitness testing 
Baseline and post intervention cardio-respiratory fitness levels among subjects were 
measured using the 1-mile walk test (Rockport test) as described by Kline (Kline et 
al. 1987). This validated measure is a sub-maximal aerobic fitness test that predicts 
VO2 maximum values based on subject’s weight, age, sex, time to complete a brisk 
one mile walk and heart rate upon completion of the walk. A sub-maximal fitness 
test was chosen for participant safety. Each participant was allowed a 3 to 5 minute 
warm up before commencement of the test. The test was performed at a temperature 
controlled indoor track at the Mardyke Arena.  
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5.3.9 DNA extraction 
Total genomic DNA was extracted from fresh (within 2 hours after excretion) stool 
samples using the QIAmp DNA Stool Mini Kit (Qiagen, Crawley, West Sussex, 
UK) which was combined with an additional bead beading step (30s x 3). Extracted 
DNA was quantified using the Nanodrop 1000 spectrophotometer and stored at -
20˚C.  
5.3.10 Illumina MiSeq 16S rRNA amplicon sequencing 
The V3-V4 variable region of the 16S rRNA gene was amplified from each 
extracted DNA sample according to the 16S metagenomic sequencing library 
protocol (Illumina, San Diego CA, USA). Initially the template DNA was amplified 
using primers specific to the V3-V4 region of the 16S rRNA gene which also 
allowed for the Illumina overhang adaptor, where, the forward primer 
(5’TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCAG) and 
reverse primer (5’GTCTCGTGGGCTCGGAGATGTGTATAAGAGACA 
GGACTACHVGGGTATCTAATCC) were used. Each PCR reaction contained 2.5µl 
DNA template, 5 µl forward primer (1µM), 5 µl reverse primer (1µM) (Sigma, 
Ireland) and 12.5 µl Kapa HiFi Hotstart Readmix (2X) (KAPA Biosystems Inc, 
USA). The template DNA was amplified under the following PCR conditions for a 
total of 25 cycles: 95˚C for 3 minutes and 30 seconds respectively (initialization and 
denaturation), 55˚C for 30 seconds (annealing), 72˚C for 30 seconds (elongation) 
followed by a final elongation period of 5 minutes. A negative control reaction 
whereby the template DNA was replaced with PCR grade water was employed to 
confirm lack of contamination and PCR products were visualised using gel 
electrophoresis (1X TAE buffer, 1.5% agarose gel, 100v) post PCR reaction. 
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Successful amplicons were then cleaned using the AMpure XP purification system 
(Labplan, Dublin, Ireland). A second PCR reaction was then completed using the 
previously amplified and purified DNA as the template. Two indexing primers 
(Illumina Nextera XT indexing primers, Illumina, CA, USA) were used per sample 
to allow all samples to be pooled, sequenced on one flow cell and subsequently 
identified bioinformatically. Each reaction contained 25 µl Kapa HiFI HotStart 
ReadyMix (2X), 5 µl template DNA, 5 µl index 1 primer (N7xx), 5 µl index 2 
primer (S5xx) and 10 µl PCR grade water. PCR conditions were the same as 
previously described with the samples undergoing just 8 cycles instead of 25. PCR 
products then underwent the same electrophoresis and cleaning protocols as 
described above. Samples were then quantified using the Qubit 2.0 fluorometer 
(Invitrogen) in conjunction with the broad range DNA quantification assay kit (Life 
technologies, Carlsbad, CA, USA). All samples were then pooled to an eqimolar 
concentration and the pool underwent a final cleaning step. Quality of the pool was 
determined using the Agilent Bioanalyser prior to sequencing. The sample pool was 
then denatured with 0.2M NaOH, diluted to 4pM and combined with 10% (v/v) 
denatured 4pM PhiX. Samples were then sequenced in house on the MiSeq 
sequencing platform using a 2.300 cycle V3 Kit following protocols outlined by 
Illumina. 
5.3.11 Bioinformatic analysis 
Three hundred base pair paired-end reads were assembled using FLASH (fast length 
adjustment of short reads to improve genome assemblies). Paired-end reads were 
further processed with the inclusion of quality filtering based on a quality score of > 
25 followed by subsequent removal of mismatched barcodes and sequences below 
length threshold using QIIME. USEARCH v7 (64-bit) was then used for denoising 
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and chimera detection as well as clustering into operational taxonomic units (OTUs). 
PyNAST was used to align OTUs and taxonomy was assigned by using BLAST 
against the SILVA SSURef database release 111. QIIME was used to generate 
Alpha and Beta diversities, calculated based on Bray Curtis, weighted and 
unweighted Unifrac distance matrices. Principal coordinate analysis (PCoA) plots 
were then visualised using EMPeror v0.9.3-dev. Predictive functional profiling was 
performed using the PICRUSt (phylogenetic investigation of communities by 
reconstruction of unobserved states) tool (Langille et al. 2013). 
5.3.12 Statistical analysis 
All statistical analysis was carried out using the R statistical package (V.2.13.1). A 
paired t-test was employed to compare baseline (week 0) and post intervention 
(week 8) blood cytokine levels and anthropometric measurements, where statistical 
significance was taken as p≤0.05. The non-parametric Wilcoxon test was used to 
determine significant differences in microbial taxonomies, -diversity indices and 
PICRUSt predicted metabolic pathways between baseline and post intervention 
sequence data where statistical significance was again taken as p≤0.05. Spearman 
correlations were used to examine relationships between the measured parameters 
where significance was accepted as p<0.05   
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5.4 RESULTS 
5.4.1 An eight week structured exercise programme improves subject’s fitness 
and blood pressure profile 
Subject’s anthropometric characteristics are summarised in table 2. When subject’s 
post intervention (week 8) anthropometric measurements were compared to their 
baseline (week 0) measurements, VO2 max was determined to be significantly 
higher in individuals assigned to the Ex (p=0.001) and Ex+WPS (p=0.006) groups. 
Diastolic pressure was significantly reduced in the Ex (p=0.016), Ex+WPS 
(p=0.040) and WPS (p=0.024) groups, with a significant reduction in systolic 
pressure also noted in the Ex+WPS (p=0.005) and WPS (p=0.039) groups (Figure 
2). No other significant differences in anthropometric characteristics were observed.  
5.4.2 A combination of exercise and whey protein supplementation improves 
inflammatory tone 
There were no significant differences between the baseline and post intervention 
blood profiles of either the Ex or WPS cohorts. However, when compared to 
baseline measurements, subjects within the Ex+WPS cohort displayed significantly 
lower levels of IL-8 (p=0.039) after the intervention period (Figure 3).  
5.4.3 Exercise, whey protein supplemetation or a combination of both does not 
alter the diversity of the gut microbiota 
Faecal samples were collected before and after the intervention period. After DNA 
extraction and amplicon generation, a total of 15,161,178 16S rRNA post-quality 
paired end sequence reads were generated during the sequencing process, 
corresponding to an average of 101,075 reads per individual time point. Baseline and 
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post intervention alpha diversity values were calculated for species richness 
(Chao1), biodiversity (Shannon index), observed species and species number 
relative to abundance within the sample (Simpson diversity index) in each case. 
Comparison of the baseline and post intervention values for each of the calculated 
indices revealed no significant differences in alpha diversity among any of the three 
test cohorts (Figure 4).  
Spearman correlations were used to examine the relationships between week 8 
assigned alpha diversity values and post intervention clinical data (Figure 5). In the 
Ex cohort, alkaline phosphatase was noted to negatively correlate with Shannon 
index (r
2
 = -0.638, p<0.001), Chao1 (r
2
=-0.530, p=0.005), Simpson index (r
2
=-0.573, 
p=0.002) and observed species (r
2
=-0.557, p=0.003, while lean mass was positively 
correlated with Chao1 (r
2
=0.418, p=0.034). In the Ex+WPS cohort, Shannon index 
was negatively correlated with % change in body fat (r
2
=-0.460, p=0.031) and 
positively correlated with % increase in lean mass (r
2
=0.429, p=0.046). Finally, in 
the WPS cohort, negative correlations were observed between alkaline phosphatase 
and Chao1 (r
2
=-0.471, p=0.013), PD whole tree (r
2
=-0.495, p=0.009) and observed 
species (r
2
=0.473, p=0.021). 
Principal coordinate analysis (PCoA), based upon unweighted Unifrac distances, 
revealed proximal clustering, i.e. no clear separation, between the baseline and post 
intervention time points for each of the three test groups within the study (Figure 6). 
Similarly, Procrustes imaging of unweighted Unifrac distances matrices revealed no 
uniform change in beta diversity between baseline and post intervention samples 
(Figure 7).  
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5.4.4 A short period of exercise, whey protein supplementation or a 
combination of both does not invoke major changes to gut microbiota 
taxonomy  
Phylogenetic analysis was examined at phylum, family and genus level for each of 
the study’s three cohorts to determine if changes in microbial taxonomy occurred 
during the intervention period (Figure 8). No significant phylogenetic differences 
were determined within the gut microbiotas of individuals assigned to the Ex group 
from week 0 to week 8. Lactococcus proportions were determined to be significantly 
increased from week 0 to week 8 in the Ex+WPS (p=0.014) and WPS (p=0.002) 
cohorts, while proportions of the Veillonellaceae (p=0.024) family and 
Marvinbryantia (p=0.035) genus significantly increased and decreased, respectively, 
from week 0 to week 8 in the WPS cohort. Similarly PICRUSt analysis of predicted 
functional pathways revealed no significant differences between baseline and post 
intervention data for any of the three groups of the study.  
5.4.5 High compliance with exercise program may differentially alter microbial 
taxonomies within the gut microbiota 
To determine if the amount and type of exercise completed by the subjects within 
the Ex and Ex+WPS groups correlated with changes in the diversity or composition 
of the gut microbiota, phylogenetic comparative analysis of baseline and post 
intervention sequence data of eight individuals which completed the most or least 
amount of either cardiovascular (as determined by total minutes of cardiovascular 
training) or resistance training (as determined by total repetitions completed) in each 
group (Figure 9). Throughout the study period, individuals within the Ex group 
which completed the most cardiovascular training were noted to have increased 
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proportions of Gordonibacter (p=0.032), while those completing the most resistance 
training had increased proportions of Succinivibrionaceae/Succinivibrio (p=0.035) 
from week 0 to week 8. No significant differences were observed between week 0 
and week 8 data for individuals within the Ex+WPS group which completed the 
most cardiovascular training. However those which completed the most resistance 
training showed significantly lower proportions of Actinomycetaceae/Actinomyces 
(p=0.05) and significantly increased Eggerthella proportions (p=0.032).  
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5.5 DISCUSSION 
The gut microbiota of professional athletes has previously been shown to be 
significantly more diverse than that of control subjects. This increased diversity was 
positively correlated with exercise and protein intake levels (Clarke et al. 2014), 
suggesting that further studies to investigate the possibility of a link between diet 
and/or exercise with gut microbial diversity were merited. Therefore this study, 
through a three armed approach, aimed to evaluate the impact of exercise, increased 
dietary protein and the combined effect of both on the composition and diversity of 
the gut microbiota in physically inactive individuals over a short-term intervention 
period.   
An improvement in aerobic fitness was observed in individuals assigned to the Ex 
and Ex+WPS groups, as determined by a significant increase from baseline to post 
intervention in VO2 measurements. Regular exercise is well known to reduce blood 
pressure and, consistent with this, subjects assigned to both Ex and Ex+WPS groups 
displayed a significantly lower resting blood pressure after the intervention period.  
Notably, a significant reduction between baseline and post intervention resting blood 
pressure was also observed in the WPS cohort. This reduction is likely due to the 
anti-hypertensive properties which several whey derived peptides have been shown 
to exert via angiotensin-converting enzyme (ACE) inhibition (Pihlanto-Leppälä 
2000, Pal and Ellis 2010).  
In their study of profession athletes, Clarke et al. showed that, when compared to 
control cohorts, the athlete cohort had a significantly higher dietary protein intake 
and a significantly lower inflammatory tone (Clarke et al. 2014). In the present 
study, circulating levels of the pro-inflammatory cytokine IL-8 were significantly 
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reduced throughout the intervention period in those individuals assigned to the 
Ex+WPS group. This reduction in IL-8 levels suggests that even a short term 
combination of exercise and whey protein supplementation lowers individuals 
inflammatory tone which in turn could have beneficial implications for 
inflammatory disease states such as type-2-diabetes, obesity and IBD (Murata et al. 
1995, Kim et al. 2006). 
With respect to the subjects’ gut microbiota, no significant change in alpha diversity 
was observed throughout the intervention period for any of the three groups (Figure 
4). The intervention period employed may have been too short to induce a 
substantial change to the biodiversity of the gut microbiota. Population studies have 
shown that enteric microbial diversity may be greatly influenced by long term 
dietary habits, for example children from a rural African village, which consume a 
diet high in polysaccharides, were observed to harbour a significantly more diverse 
microbiota than that of European children consuming a typical ‘western’ diet (De 
Filippo et al. 2010). While, with respect to whey protein supplementation, we have 
previously shown that even over a long intervention period (21 weeks), whey protein 
supplementation did not increase the microbial biodiversity of the murine gut 
microbiota (McAllan et al. 2014). Consistently, murine studies which investigated 
the effect of exercise on the gut microbiota over a comparable intervention period 
have also reported that exercise does not invoke increases in alpha diversity 
measures (Chapter 4) (Allen et al. 2015).  Furthermore, human exercise intervention 
studies have shown that a longer period of regular exercise (> 6 months) is required 
to invoke changes to host physiology which in turn may result in alterations to the 
diversity of the gut microbiota (Balducci et al. 2010, Ho et al. 2013).  Similarly, beta 
diversity based upon unweighted Unifrac distances (Figure 5) showed no clear 
280 
 
separation between baseline and post intervention data for each of the three groups 
within the study. The lack of separation observed between  pre and post intervention 
data points for individuals consuming a daily WPI supplement might be unexpected 
as we have previously shown, in murine models, that whey protein consumption 
resulted in distinct beta diversity clustering patterns, even over a short intervention 
period ((McAllan et al. 2014); Chapter 3). The lack of separation seen presently 
likely arises from the short intervention period combined with the large inter-
individual dietary variations, the latter being an issue not encountered when dealing 
with laboratory animals (Nguyen et al. 2015). The proximal clustering observed 
within the Ex cohort  is consistent with rodent studies examining the effect of 
voluntary exercise on the gut microbiota over a comparable period, further 
suggesting that exercise does not invoke substantial changes to the gut microbiota 
over a short intervention period (Chapter 4)(Allen et al. 2015).  
With respect to phylogenetic analysis, no significant differences were observed 
throughout the intervention period in individuals assigned to the Ex groups, once 
again highlighting that while exercise may increase physical fitness over a short 
period, a longer intervention period may be required to invoke changes to gut 
microbial populations. When compared to the trial’s start point, Lactococcus 
proportions were significantly increased post intervention in both Ex+WPS and 
WPS cohorts. Members of the Lactococcus genera are naturally found in dairy 
products, in addition to their use as dairy starter cultures, and have been shown to 
possess potent proteolytic activity (Korhonen and Pihlanto 2006). Thus the 
significant increase in Lactococcus observed in the Ex+WPS and WPS groups 
presumably arises directly from the consumption of lactococci within the WPS with 
lactococci acquired from other dietary sources also potentially benefiting from the 
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ability of members of this bacterial genus to utilise the proteins within whey as a 
growth source. While it would appear that whey protein intake increases the 
proportions of lactococci, further investigation is required examining the viability of 
lactococci cells present in whey and in turn wither this increase in lactococci impacts 
the host. Veillonellaceae were also significantly increased in the WPS cohort 
throughout the intervention period. Members of the Veillonellaceae family have 
been shown to preferentially ferment amino acids (Scott et al. 2013). Furthermore, 
we have previously shown (Chapter 3) that the whey protein lactoferrin enriched 
populations of Veillonellaceae whose increased proportions may contribute to health 
via their conversion of lactate to the short chain fatty acid propionate (Flint et al. 
2012, Smith et al. 2013).  
Spearman correlations between anthropometric measurements and alpha diversity 
indices revealed a positive correlation between lean mass and % change in lean mass 
in the Ex (Chao1) and Ex+WPS (Shannon) groups, respectively. Given that the gut 
microbiota of obese individuals has been reported to exhibit reduced biodiversity 
(Turnbaugh et al. 2008), these present results suggest that exercise may drive 
changes in body composition which in turn increases the diversity of the gut 
microbiota.. 
Finally, to assess if the amount and type of exercise completed by subjects correlated 
with specific changes in enteric microbial populations, baseline and post 
intervention sequence data was compared for individuals which completed the most 
and least amount of exercise throughout the eight week period. Within the Ex 
cohort, subjects which completed the most resistance training displayed a significant 
increase in the proportions of Succinivibronaceae/Succinivibrio were noted. Higher 
proportions of  Succinivibronaceae/Succinivibrio were also evident when the elite 
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rugby athletes microbiota was compared to either high or low BMI controls (Clarke 
et al. 2014). Similarly, subjects assigned to the EX+WPS group, which completed 
the most resistance training, showed a significant reduction from week 0 to week 8 
in the proportions of Actinomycetaceae/Actinomyces, which have previously been 
associated with inflammatory disease states such as obesity and IBD (Frank et al. 
2007, Mandal et al. 2015). Results from these subsets within the groups of our study 
suggest that more intensive exercise, particularly resistance training, may influence 
the gut microbiota.  
Results from the present study therefore are consistent with both our own previous 
work and that of other studies and further suggests that, while exercise and dietary 
protein supplementation can improve individual’s fitness over a short period, a 
longer intervention period is required to determine if considerable alterations to the 
gut microbiota can be brought about.   
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Table 1. Subject recruitment inclusion/exclusion critera 
Inclusion/exclusion criteria  
Personal history of coronary artery disease, congenital heart disease or any cardio-vascular disease 
Family history of known coronary artery disease before 45 years of age 
Uncontrolled hypertension (>140/90mmHg) 
Known renal or hepatic impairment 
Type 1 or type 2 diabetes mellitus 
Significant pulmonary disease – not including well-controlled, mild asthma 
Primary or secondary immunodeficiency or autoimmune disorder 
Current smoker or ex-smoker of less than 3 months duration.  
Psychiatric disorders including previous history of depression 
A history of substance abuse 
Current or recent involvement in another clinical research study 
Known or suspected hypersensitivity to the dietary supplementation 
Gastro-intestinal disease e.g. coeliac disease, inflammatory bowel disease, irritable bowel syndrome or significant gastro-intestinal surgery 
Previous significant gastro-intestinal surgery e.g. colectomy 
Any other medical condition deemed exclusionary by the investigators including suspected or confirmed pregnancy 
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Table 2. Anthropometric characteristics 
 Ex (W0) Ex (W8) Ex+WPS (W0) Ex+WPS (W8) WPS (W0) WPS (W8) 
BMI 27.98 ± 0.68 27.58 ± 0.64 27.90 ± 0.74 27.61 ± 0.77 27.35 ± 0.63 27.27 ± 068 
Waist/Hip Ratio 0.86 ± 0.01 0.85 ± 0.01 0.85 ± 0.02 0.84 ± 0.02 0.83 ± 0.01 0.84 ± 0.01 
Systolic  Pressure 126.46 ± 2.43 121.54 ± 1.88 126.86 ± 2.35 118.18 ± 1.73 124.33 ± 1.68 118.67 ± 2.08 
Diastolic Pressure 80.27 ± 1.69 74.65 ± 1.50 79.95 ± 2.12 71.73 ± 1.25 79.00 ± 1.15 74.67 ± 1.46 
Heart Rate 72.88 ± 1.95 68.19 ± 1.85 69.00 ± 2.34 65.14 ± 1.91 72.59 ± 1.81 75.96 ± 1.79 
Total % Body Fat 33.32 ± 1.25 31.99 ± 1.23 33.93 ± 1.35 32.96 ± 1.37 34.78 ± 1.44 35.20 ± 1.47 
Fat Mass (Kg) 28.47 ± 1.74 27.40 ± 1.79 28.46 ± 1.86 27.65 ± 1.86 27.31 ± 1.51 27.63 ± 1.57 
Total % Lean Mass 63.15 ± 1.20 64.46 ± 1.18 62.62 ± 1.29 63.50 ± 1.32 61.73 ± 1.38 61.39 ± 1.41 
Lean Muscle Mass (Kg) 52.42 ± 2.22 53.20 ± 2.22 1.97 ± 2.69 52.37 ± 2.61 47.91 ± 1.52 47.64 ± 1.50 
VO2 Max 41.82 ± 1.12 46.88 ± 0.085 42.42 ± 0.98 47.11 ± 1.31 N/A N/A 
Rockport HR 129.27 ± 4.58 128.00 ± 3.76 132.32 ± 4.06 128.27 ± 3.64 N/A N/A 
Data shown as mean ± SEM where statistically significant differences between baseline and post intervention data are highlighted in bold and 
italics (p ≤ 0.05) 
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Table 3. Blood profile analysis  
 Ex (W0) Ex (W8) Ex+WPS (W0) Ex+WPS (W8) WPS (W0) WPS (W8) 
Hgb 14.57 ± 0.25 14.36 ± 0.26 14.69 ± 0.32 14.24 ± 0.34 13.93 ± 0.26 13.66 ± 0.27 
RBC 5.04  ±0.1 4.94 ± 0.11 5.02 ± 0.11 4.83 ± 0.11 4.83 ± 0.09 4.69 ± 0.09 
Hct 0.44 ± 0.01 0.43 ± 0.01 0.44 ± 0.01 0.42 ± 0.01 0.42 ± 0.01 0.41 ± 0.01 
Platelets 270.2 ± 10.71 260.66 ± 10.47 264.78 ± 14.57 246.1 ± 12.45 276.49 ± 11.67 247.78 ± 10.67 
WBC 6.48 ± 0.31 6.47 ± 0.4 6.33 ± 0.26 5.84 ± 0.3 6.21 ± 0.23 6.58 ± 0.31 
Neuts 3.44 ± 0.21 3.51 ± 0.27 3.55 ± 0.18 3.05 ± 0.22 3.55 ± 0.18 3.95 ± 0.29 
Lymph 2.25 ± 0.14 2.19 ± 0.16 2.07 ± 0.09 2.1 ± 0.12 1.87 ± 0.09 1.86 ± 0.08 
Monocytes 0.44 ± 0.04 0.43 ± 0.04 0.39 ± 0.02 0.4 ± 0.03 0.42 ± 0.03 0.42 ± 0.03 
Eosinophils 0.22 ± 0.04 0.23 ± 0.04 0.18 ± 0.03 0.18 ± 0.03 0.24 ± 0.03 0.22 ± 0.03 
Basophils 0.03 ± 0.01 0.03 ± 0.01 0.05 ± 0.02 0.03 ± 0.01 0.04 ± 0.01 0.03 ± 0.01 
Na 140.16 ± 0.43 139.54 ± 0.31 140.19 ± 0.44 139.46 ± 0.36 139.88 ± 0.38 139.82 ± 0.32 
K 4.55 ± 0.06 4.49 ± 0.07 4.57 ± 0.09 4.54 ± 0.07 4.7 ± 0.13 4.56 ± 0.07 
Urea 5.39 ± 0.25 5.32 ± 0.29 5.05 ± 0.28 5.03 ± 0.31 4.89 ± 0.17 5.42 ± 0.25 
Creatinine 80.43 ± 2.94 81.77 ± 2.73 76.1 ± 2.68 76.96 ± 2.97 73.56 ± 1.7 72.00 ± 1.65 
AST 19.97 ± 1.1 20.39 ± 1.24 21.87 ± 1.73 18.6 ± 0.76 20.8 ± 2.07 21.75 ± 1.83 
GGT 26.47 ± 3.27 26.43 ± 5.43 28.78 ± 4.18 23.32 ± 3.13 24.3 ± 2.42 22.34 ± 1.89 
CK 110.97 ± 11.45 124.81 ± 19.02 172.41 ± 64.23 126.19 ± 20.31 103.23 ± 8.5 110.75 ± 10.59 
Alk Phos 63.31 ± 3.86 64.00 ± 3.89 56.19 ± 2.83 56.96 ± 2.52 61.67 ± 2.87 60.38 ± 2.5 
Calcium 2.39 ± 0.02 2.37 ± 0.02 2.38 ± 0.02 2.37 ± 0.02 2.42 ± 0.02 2.39 ± 0.02 
Phosphate 1.11 ± 0.04 1.08 ± 0.04 1.08 ± 0.04 1.07 ± 0.04 1.25 ± 0.05 1.15 ± 0.04 
CRP 2.93 ± 0.74 2.54 ± 0.57 2.28 ± 0.57 3.6 ± 1.38 1.67 ± 0.26 2.19 ± 0.63 
IFN 13.47 ± 2.65 12.34 ± 3.17 7.4 ± 0.63 11.45 ± 3.02 6.74 ± 0.74 8.11 ± 1.63 
IL-10  0.39 ± 0.05 0.74 ± 0.45 0.46 ± 0.07 1.22 ± 0.79 0.34 ± 0.09 0.41 ± 0.1 
IL-12 p70  0.9 ± 0.45 1.83 ± 1.6 0.74 ± 0.26 3.00 ± 2.07 0.5 ± 0.16 0.7 ± 0.31 
IL-1beta  0.25 ± 0.11 0.2 ± 0.14 0.14 ± 0.06 0.56 ± 0.46 0.04 ± 0.02 0.13 ± 0.07 
IL-6 0.83 ± 0.24 0.95 ± 0.42 0.75 ± 0.17 1.38 ± 0.77 0.56 ± 0.09 0.78 ± 0.18 
IL-8 33.48 ± 8.05 80.4 ± 49.49 82.16 ± 23.5 28.21 ± 9.27 10.73 ± 0.84 82.27 ± 41.82 
TNF 2.96 ± 0.27 3.1 ± 0.61 3.61 ± 0.63 3.41 ± 0.58 2.16 ± 0.1 2.43 ± 0.17 
Data shown as mean ± SEM where statistically significant differences between baseline and post intervention data are highlighted in bold and 
italics (p ≤ 0.05) 
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Figure 1. Experimental overview 
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Figure 2. An eight week exercise improves general fitness, while exercise, whey 
protein supplementation and a combination of both decreases resting blood 
pressure. Statistically significant differences determined between baseline and post 
intervention anthropometric measurements determined by paired t-test where 
significance was taken as p≤0.05. 
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Figure 3. Eight weeks of exercise combined with daily whey protein 
supplementation reduces circulating levels of the pro-inflammatory cytokine 
IL-8.  Scatter plot analysis of pre and post intervention circulating IL-8 levels of all 
subjects assigned to the Ex+WPS group. 
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Figure 4. Alpha diversity is unchanged by 8 weeks of exercise, whey protein supplementation or a combination of both. Comparison of 
pre and post intervention assigned alpha diversity scores for each group within the study. Data is represented as mean ± SEM. 
296 
 
 
Figure 5. Statistically significant Spearman correlations determined between 
post intervention anthropometric measurements, blood profile data and alpha 
diversity indices 
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Figure 6. Principal Coordinate analysis (PCoA) based upon unweighted Unifrac distances shows no separation between pre and post 
intervention sequence data. PCoA analysis of each of the enrolled subjects’ pre and post intervention 16S rRNA sequence data where • 
represents baseline (week 0) data and • represents post intervention (week 8) data. 
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Figure 7. Procrustes imaging of unweighted Unifrac distances matrices derived from pre and post intervention data from each subject 
within the study, reveal no uniform clustering pattern. Individuals pre and post intervention data, where • represents baseline (week 0) data 
and • represents post intervention (week 8) data with flux in diversity illustrated by the connecting line. 
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Figure 8. Whey protein supplementation increases Lactococcus populations. 
Statistically significant differences in microbial taxonomies between individuals 
assigned to all three groups within the study’s pre and post intervention sequence 
data. Data is represented as a % of total bacteria ± SEM where significance was 
taken at p≤0.05. 
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Figure 9. The amount of exercise completed differentially alters enteric 
microbial taxonomies. Statistically significant differences in microbial taxonomies 
determined between pre and post intervention period of the eight individuals 
assigned to the Ex and Ex+WPS groups which completed the most exercise both in 
terms resistance and cardiovascular training.  Data is represented as a % of total 
bacteria ± SEM where significance was taken at p≤0.05. 
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General Discussion 
The composition, diversity and functionality of the gut microbiota play a critical role 
in maintaining human health, with our microbial inhabitants and associated 
metagenome influencing several important physiological process including energy 
absorption, regulation of fat storage and modulation of the host immune system 
(Sekirov, Russell et al. 2010). Conversely, perturbations to the composition or 
function of the gut microbiota have frequently been associated in the pathogenesis of 
a host of inflammatory GI diseases such as obesity and IBD (Marchesi, Adams et al. 
2015). It is logical that selective manipulation of the gut microbiota can yield novel 
treatments for many such diseases (Walsh, Guinane et al. 2014). Diet is an 
environmental factor which has repeatedly been shown to be a major factor in 
driving the composition and metabolism of the gut microbiota (De Filippo, Cavalieri 
et al. 2010, Claesson, Jeffery et al. 2012, Scott, Gratz et al. 2013) and, therefore, diet 
represents one such tool by which gut microbial communities may be beneficially 
modulated. With respect to such dietary modulation, the vast majority of research to 
date has focused on the use of complex carbohydrates (prebiotics) such as 
fructooligosaccharides, whose fermentation by members of the gut microbiota 
primarily results in the formation of SCFAs (e.g. butyrate) which confer several 
health benefits to the host (Macfarlane, Steed et al. 2008, Flint, Scott et al. 2012, 
Dehghan, Gargari et al. 2014). However, the effect of other dietary components, 
such as protein, on the gut microbiota have received considerably less attention. 
Indeed dietary protein has been associated with the formation of putrefactive 
metabolites such as amines and N-nitroso compounds which may be detrimental to 
gut health (Windey, De Preter et al. 2012, Louis, Hold et al. 2014). Whey is the milk 
serum which remains after the casein curd has been removed during cheese 
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manufacture and accounts for ~20% of the total protein content of bovine milk. 
Whey is comprised of several component proteins such as -lactoglobulin, -
lactalbumin, serum albumin, lactoperoxidase, and lactoferrin whose properties have 
been shown to beneficially influence several physiological processes such as energy 
balance and glucose metabolism (Pal, Ellis et al. 2010, Shertzer, Woods et al. 2011). 
While the consumption of whey protein(s) has/have been shown to have beneficial 
outcomes in disease states in which perturbations of the gut microbiota have been 
noted, such as obesity and T2D, their effect on the composition of gut microbial 
communities remains largely unknown.  
Like diet, exercise is another environmental factor which influences a wide range of 
physiological processes and has become increasingly recognised as an effective 
alternative to pharmaceutical treatments for several disease states (Schwingshackl, 
Missbach et al. 2014). Given the capacity for exercise to influence intestinal 
conditions, it seems likely that exercise also influences the gut microbiota. However, 
as has been the case for whey protein, the impact of exercise on the gut microbiota is 
currently poorly understood. Notably, a recent study by Clarke et al. showed that 
professional rugby players harbour a significantly more diverse gut microbiota 
(indicator of gut health) than high or low BMI controls and it was also noted that a 
correlation existed between each of exercise and protein intake with this greater 
diversity (Clarke, Murphy et al. 2014). The aim of this thesis was, through in vitro 
and in vivo experimentation, to employ next generation sequencing technologies to 
investigate the effects of dietary whey protein (and its component proteins) and 
exercise on the composition and diversity of the gut microbiota.  
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As previously stated, the impact of dietary whey protein on the gut microbiota is 
poorly understood. Prior to the commencement of this study, it had been shown by 
Sprong et al. that dietary whey protein protected rats against induced colitis in that 
dietary whey was observed to increase mucin production and improve markers of 
inflammation (associated with GI disorders such as obesity and IBD). Furthermore, 
the same study reported that dietary whey protein increased fecal lactobacilli and 
bifidobacteria counts (Sprong, Schonewille et al. 2010).  Unlike this previous study, 
which used qPCR to quantify fecal bacterial counts,  our initial study (Chapter 2) 
employed high-throughput sequencing to more comprehensively assess the impact 
on the gut microbiota of C57BL/6J mice fed a high fat diet, with either WPI or 
casein as a protein source, for 21 weeks. Results from this study revealed that ,when 
compared to mice consuming a high fat diet where casein was the protein source, the 
gut microbiota of WPI-fed animals contained significantly higher proportions of 
Lactobacillus and Bifidobacterium. With respect to obesity and other GI conditions 
characterised by inflammation, our results suggest that dietary WPI can confer 
health benefits to the host by enriching populations which exhibit anti-inflammatory 
properties (Imaoka, Shima et al. 2008, Liu, Fatheree et al. 2010). It was also notable 
that the body weights of mice in receipt of the high fat/whey protein diet were 
significantly lower than those of the high fat/casein diet and thus changes to 
microbial taxonomies may result from this significant reduction in body weight, 
which has been shown in other studies to alter the gut microbiota (Duncan, Lobley et 
al. 2008, Ravussin, Koren et al. 2012). Ultimately, while the question of cause 
verses effect remains, this study provides a valuable initial insight into the impact of 
dietary WPI consumption on the composition of the gut microbiota.  
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While results from our initial study delivered promising insights/findings relating to 
the impact of whey protein on weight gain and, potentially, the gut microbiota, it is 
not possible to determine the individual contributions of the large array of proteins 
and associated bioactive peptides contained within whey (Pihlanto-Leppälä 2000). 
Therefore the subsequent chapter (Chapter 3) represents a logical extension of 
Chapter in that it describes an investigation of the impact some of the component 
proteins of whey on body weight and the gut microbiota. More specifically, this 
study employed a two armed approach to investigate the effect of two component 
proteins of whey, namely BSA and Lf, on the composition and diversity of 1) the 
human gut microbiota by means of an ex vivo anaerobic fermentation system and 2) 
the gut microbiota of C57BL/6J mice in receipt of a high fat diet. In each case high-
throughput DNA sequencing was employed to determine microbial composition. 
Our study, which was the first to use 16s rRNA gene sequencing to evaluate the 
effect of component proteins of whey on the murine enteric microbiota, revealed that 
replacement of casein as the protein source of a high fat murine diet with either Lf or 
BSA reversed several of the high fat associated taxonomic changes to the gut 
microbiota. Interestingly, with respect to Lf, these taxonomic changes were 
independent of a significant decrease in the animals’ body weight. Furthermore, 
replacement of casein with Lf in a high fat murine diet was shown to significantly 
increase the proportions of the Roseburia genus, representatives of which, such as 
Roseburia intestinalis, have recently been proposed as new targets for prebiotic 
treatments owing to their butyrate producing capabilities (Duncan, Hold et al. 2002, 
Conlon and Bird 2014). To predict the effects that this altered microbiota might have 
with respect to gut microbiota functionality, we employed the PICRUSt 
pipeline/application to predict the metabolic pathways that are encoded therein. This 
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approach revealed that the functional potential of the microbiome of both Lf and 
BSA fed animals was more akin to that of animals consuming a low fat diet than 
those consuming a high fat diet where casein was the protein source. This result 
suggests that as well as invoking taxonomic alterations, both Lf and BSA 
beneficially alter the functionality of the microbiota, which is regarded by many as 
being even more important with respect to its influence on health than microbiota 
composition (Turnbaugh, Hamady et al. 2009). The possibility that Lf and BSA can 
improve gut health, and reverse high fat diet associated changes to the to the 
composition and function of the gut microbiota, in the presence of a high fat diet is 
particularly relevant given that weight regain remains the most common long term 
outcome of weight loss programs (Bray and Wadden 2015). While these results 
suggest a use for bovine whey proteins (particularly Lf) in the beneficial modulation 
of the gut microbiota, further investigation into the mechanisms by which these 
dairy proteins bring about alterations to microbial taxonomies and the identification 
of the bacterial metabolites produced as a consequence of their fermentation is 
required.  
As previously stated, exercise is an environmental factor which has been shown to 
influence several physiological processes. However its effects on the gut microbiota 
remain unclear (O’Sullivan, Cronin et al. 2015). Our study (Chapter 4) aimed to 
determine the effect of voluntary exercise on energy balance, metabolic activity and 
the composition of the gut microbiota through the use of a C57BL/6J murine model. 
To negate diet induced variability, such as high fat diet associated inflammation 
(Todoric, Löffler et al. 2006, Cani, Bibiloni et al. 2008), and to better assess the 
direct impact of exercise on bodily process and the gut microbiota, both control and 
exercising animals were fed the same low fat chow for the eight week study period. 
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Our results showed that, over the eight week intervention period, voluntary exercise 
significantly increased the animals’ energy intake and metabolic activity while 
invoking subtle changes to the gut microbiota. Notably at the study’s week four mid-
point, Illumina MiSeq 16s rRNA gene sequencing of the murine fecal microbiota 
revealed that the gut microbiota of exercising animals harboured significantly higher 
proportions of the Bacteroides genus and showed significantly higher number of 
metabolic pathways for fatty acid biosynthesis (as determined by PICRUSt). At the 
trial’s end point, hypothalamic gene expression analysis revealed that exercising 
animals showed a trend towards increased expression of genes involved in fatty acid 
biosynthesis and subsequent glucose uptake. Therefore, it may be that exercise 
invokes initial changes to the gut microbiota which in turn influence host gene 
expression profiles. Our findings support those from previous short term trials that 
have shown a similar subtle effect of exercise. (Allen, Miller et al. 2015). 
Furthermore, while the results of this study suggest subtle changes to the gut 
microbiota induced by exercise, as this was a short term study (eight weeks duration) 
perhaps a longer intervention period could result in more substantial exercise-driven 
changes to the gut microbiota. Indeed, a previous study in which a 12 week 
intervention period was employed showed, using PCoA analysis of 16s rRNA gene 
sequence data, a clear separation in the microbiotas of exercising and sedentary mice 
(Evans, LePard et al. 2014). Thus further studies over a variety of intervention 
periods are required to fully elucidate the exercise induced changes on the gut 
microbiota. 
The gut microbiota of professional athletes was previously found to be significantly 
more diverse than that of control subjects and that this increased diversity was 
correlated with both exercise and protein consumption (Clarke, Murphy et al. 2014). 
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This observation, together with data from this thesis relating to both in vivo and in 
vitro experiments investigating the individual effects of whey, whey protein 
constituents and exercise on the gut microbiota and functionality, prompted a final 
study to examine the combined effects of altered diet and exercise on gut microbiota 
in a human trial. In this final study (Chapter 5), high-throughput DNA sequencing 
was employed to determine if an eight week exercise intervention and/or whey 
protein supplementation would influence the gut microbiota of previously physically 
inactive individuals whilst maintaining habitual dietary habits. Results from the 
study revealed that while completion of an eight week exercise program increased 
the general fitness of subjects, exercise did not invoke alterations to the composition 
or diversity of the gut microbiota. Similarly an eight week daily whey protein isolate 
supplementation alone or in combination with exercise did not alter the diversity of 
the subjects’ microbiota. This result suggests that the large inter-individual dietary 
variations existing between the subjects within the trial reduces the impact of WPI 
supplementation of the gut microbiota and suggests that further studies should also 
consider other components of diet within the study design.  Akin to our own 
observations from Chapter 4, the short intervention period employed presently 
appears to also seems to be a limiting factor in exercise’s ability to considerably 
influence the gut microbiota.  
Ultimately, the importance of the composition, diversity and functionality of the gut 
microbiota with respect to human health is now clearer than ever. Developments in 
culture independent technologies over the past decade have allowed for a rapid 
expansion in our understanding of these microbial communities and the 
environmental factors which influence their composition. Through the use of high-
throughput next generation sequencing technologies, this thesis provides valuable 
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and novel insights into the impact of both dairy whey proteins and exercise on the 
enteric microbial communities.   
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